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ABSTRACT 
Background 
Sickle cell disorders (SCD) are the most common inherited blood disorders in England. Without 
prompt diagnosis and proper treatment, they can be a serious source of morbidity and 
mortality. Sickle cell diseases affect mainly black minority and ethnic populations, and have so 
far received relatively low priority from a health policy perspective. Antenatal and newborn 
screening, the development of minimum standards, antibiotic prophylaxis, comprehensive 
immunisations, and preventive diagnostic tests have positively influenced SCD management.  
There remains an unclear picture as to the trends and health care utilization of patients with 
SCD in England.  
 
Aims 
This study looks at the burden of disease in England by assessing hospital admissions, 
readmissions and related costs.  It also aims to identify gaps in care and prevention which may 
identify possible contributors to avoidable admissions. 
 
Findings 
Using Hospital Episode Statistics (HES) data, trends for SCD hospital admissions in England 
showed a rise in 50% of hospital admissions over a 10 year period.  The most deprived areas 
had a higher rate of readmission and in-patient mortality among those with SCD.  Adolescents 
had a higher rate of readmission possibly identifying a gap in health care access.  Local findings 
in a high prevalence area showed that the majority of admissions were for a short length of stay 
and 74% of patients accounted for multiple admissions.  A patient focus group and 
questionnaire both identified potential gaps in care and prevention. 
 
Conclusion 
Through the use of 6 studies which showed the SCD admission rates in England, the     
readmission rates, local admissions, costs associated with admission and patient perspectives in 
both care and prevention, there is a clearer picture as to the trends and health care utilization of 
patients with SCD in England. The studies suggest that ascertaining the prevalence of at-risk 
groups in England as well as addressing inequalities in health care access among minority 
groups and areas of high disease prevalence can further aid in disease management. Shifting 
diagnostic and follow-up care from acute care facilities to primary care facilities and promoting 
preventive care measures and adherence to standards and guidelines may possibly decrease the 
cost burden, reduce avoidable hospital admissions and increase the timeliness and effectiveness 
of disease management. Investing in training and education of primary care physicians for sickle 
cell diseases may also improve quality of care. 
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1. RATIONALE FOR THESIS 
At the start of this study, what was known is that Sickle Cell Disease is the most common genetic 
disorder in England; that two national standards have been published –paediatric and adult and 
that the National Confidential Enquiry into Patient Outcomes and Death was critical of the role of 
general practitioners and primary care trusts.   
In May 2008, the National Confidential Enquiry into Patient Outcome and Death (NCEPOD) 
released a report entitled A Sickle Crisis? (Report) addressing the current challenges in Sickle 
Cell Disease (SCD) management in England. The NCEPOD investigates patient mortality and 
morbidity in the United Kingdom (UK), gathers baseline data and makes recommendations for 
practice for health care providers. The NCEPOD reviewed the lives of SCD patients and deaths 
due to SCD over two years and made recommendations on future practice. The review on deaths 
gathered information on why these deaths were occurring and whether addressing clinical care 
pathways could result in improved patient outcomes. The review on current clinical care 
practices in living patients found that the bridges linking these networks were fragile at best. 
The Report highlighted key findings and principal recommendations, including some aimed at 
health care providers and others at health policy makers. 
The NCEPOD Report gives purpose behind the investigative nature of this thesis and has 
support from the Collaboration for Leadership in Applied Health Research and Care (CLAHRC) 
programme. CLAHRC was established by the National Institute for Health Research (NIHR) to 
undertake high-quality applied health research focused on the needs of patients and to support 
the translation of research evidence into practice in the NHS. One of the areas selected for 
improvement is SCD. 
1.1. SICKLE CELL DISEASE 
This first chapter gives a concise description of SCD, its history, discovery in the West, the 
consequences of the disease, and the ways in which the disease is currently being clinically 
managed. The objective is not to paint a clinical picture of SCD or its treatment options. The 
objective is to emphasise three things for the reader: 
1. The importance of the disease from a public health perspective. 
2. That the disease has the potential of being underserved from a public policy perspective. 
3. That appropriate interventions could potentially reduce the burden of disease. 
1.1.1. DEFINITION 
Sickle cell disease, also known as sickle cell anaemia or sickle cell disorder, is an inherited blood 
disorder, also referred to as a haemoglobinopathy. The genetic disease is biochemically caused 
by a single amino acid substitution of valine for glutamic acid in the sixth position of the beta (β) 
chain of the haemoglobin tetramer (Pack-Mabien & Haynes, 2009; Pace & Zein, 2006). The 
disease damages and changes the shape of red blood cells (RBCs). The change in shape is a 
response to cell deoxygenation. When the oxygen uptake of the cell is low, cells change their 
shape from a healthy round disk to a crescent, holly leaf or other similarly distorted shape. This 
shape distortion is referred to as sickling. Hence, the disease is known as sickle cell disease. The 
sickled cells are rigid, less malleable and stickier than normal, healthy cells, so they 
consequently may stick to each other and obstruct blood vessels or are not sufficiently 
malleable and obstruct blood vessels. This obstruction causes harsh and painful complications. 
Often, these red blood cells will also break down and cause anaemia, so we also refer to the 
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disease as sickle cell anaemia. Consequent to the breakdown of red blood cells (haemolysis), cell 
survival may be reduced to as little as twenty days (Wilson, Krishnamurti & Kamat, 2003), 
whereas a normal red blood cell will last anywhere from 110-120 days (Allison, 1960). 
Haemolysis also causes jaundice, aplastic crisis (where the red blood cell does not mature so 
anaemia is worsened), and retarded growth and development in children. 
FIGURE 1: DEOXYGENATION OF THE RED BLOOD CELL 
 
Source: http://1.usa.gov/1ItZlPz 
Haemoglobinopathies, which consist of sickle cell and thalassaemia disorders, are passed to the 
next generation in an autosomal recessive manner (Pack-Mabien, Labbe, Herbert, et al., 2001a). 
Those who are heterozygous for the haemoglobinopathies are trait carriers for sickle cell and, 
aside from some cases presenting with mild anaemia, show none of the clinical manifestations 
of the disease. Individuals who are homozygous for the haemoglobinopathies (designated in 
Figure 2 as with ‘anaemia’) will present with one of the sickle cell diseases (Wilson, 
Krishnamurti & Kamat, 2003). 
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FIGURE 2: GENE COMBINATIONS FOR SICKLE CELL DISEASE 
 
AA = two normal genes ● AS = one normal gene (A) and one sickle gene (S) SS = two sickle genes 
and with disease 
Source: sickle cell society website (http://bit.ly/1KAPcOg) 
As pictured in Figure 2, if both the mother and the father are sickle cell trait carriers (‘trait’), 
there is a 1 in 4 chance (25%) of having a child born with the disease and a 2 in 4 chance (50%) 
of having a child born with the trait. If one parent has the trait and the other parent actually has 
the disease, there is a 2 in 4 chance (50%) of having a child born with the disease and a 2 in 4 
chance (50%) of having a child born with the trait. If one parent is normal (‘usual’) and the 
other parent has the trait, there is a 2 in 4 chance (50%) of having a child born with the trait. If 
one parent is usual and the other parent has the disease, there is a 4 in 4 chance (100%) of 
having a child born with the trait. 
There are several forms of SCD. The most common is haemoglobin SS (HbSS), also known as 
homozygous sickle cell anaemia. Patients with haemoglobin SS inherit one sickle cell gene from 
each parent. Other forms are heterozygous combinations of haemoglobins such as haemoglobin 
SC, haemoglobin SD, haemoglobin SO and haemoglobin S/β thalassaemia. The severity of 
sickling is proportional to the percentage of haemoglobin S present. Hence, HbSS is the most 
severe form of the disease (Standards for the Clinical Care of Adults with Sickle Cell Disease in 
the UK, 2008). 
HbSS is the most clinically significant abnormal haemoglobin condition. It results when the gene 
for sickle haemoglobin is inherited from both parents. The predominant haemoglobin is 
Haemoglobin S (HbS). The infant appears normal at birth. The reason for this ‘false normalcy’ 
amongst newborn sickle babies is due to foetal Haemoglobin (Haemoglobin F). During the last 
seven months of pregnancy, Haemoglobin F is produced by all babies and is responsible for 
transporting oxygen around the baby’s body. After birth, the baby continues for several weeks 
to produce Haemoglobin F as he/she starts to produce and build up its reservoir of adult 
Haemoglobin (Haemoglobin A). In a sickle cell baby, the baby also continues to produce 
Haemoglobin F but he/she also starts to produce the sickle Haemoglobin (Haemoglobin S). 
Hence, anaemia develops within the first few months as Haemoglobin F decreases and 
Haemoglobin S increases (Orkin & Higgs, 2010a). The anaemia is usually moderate to severe. 
There are several other potential complications that will be discussed in further detail later. The 
topic of foetal haemoglobin will also be revisited again in the therapies section with regards to 
hydroxyurea as a treatment option for SCD (Richer & Chudley, 2005). 
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1.1.2. SICKLE CELL TRAIT 
Sickle cell trait (HbAS) is a carrier state which, unlike HBSS, does not give rise to a significant 
clinical presentation. However, it has been reported that those with sickle cell trait are more 
prone to certain conditions and complications. Health care practitioner knowledge of these 
associations is critical for proper management. For example, renal medullary cancer, a rare but 
fatal form of kidney tumour, is seen almost exclusively in young individuals with sickle cell trait 
(Tsaras, Owusu-Ansah, Boateng, et al., 2009). The trait is also linked to exercise related deaths 
from overexertion, splenic infarction at high altitudes such as in airplanes and mountains 
(Embury, 1986), and hyposthenuria, which is an inability to concentrate urine that often leads 
to dehydration (Tsaras, Owusu-Ansah, Boateng, et al., 2009). There is also an increased rate of 
bacteriuria, pyelonephritis and haematuria, especially during pregnancy. Screening for these 
potential complications is essential and a positive results need to be treated with antibiotics 
promptly and rigorously (Serjeant & Serjeant, 2001). The good news about sickle trait is that 
there is a reason to believe that it came about due to genetic evolution as it offers some 
protection against contracting malaria in malarious regions of the world, which is discussed in 
more detail below. 
1.2. HISTORY 
1.2.1. GENETIC EVOLUTION OF SCD 
At first, it was thought that the sickle cell gene mutation occurred during Neolithic times (also 
referred to as the Stone Age) around 10,000 BC in the Arabian Peninsula. During these times, 
humans started living in close proximity to each other and to a range of animal species, thus the 
period is attributed to a number of epidemics and the evolution of serious diseases (Khelil, 
Perrin, Lefranc, et al., 2012). It was thought that with the migration of people, the sickle gene 
also migrated (Lehmann, 1954). However, while there is truth to the migration theory, there is 
also more scientific evidence that suggests the sickle cell mutation in fact occurred as several 
independent events giving rise to different types of the gene mutation (Desai & Dhanani, 2004). 
The HbS gene is associated with at least four different chromosome structures (haplotypes) that 
represent independent sickle cell gene mutations, including the Benin haplotype, the Senegal 
haplotype, the Bantu haplotype and the Asian haplotype. Each haplotype is named based on the 
region where the original sickle cell gene mutation occurred (Pagnier, 1984). These different 
haplotypes explain why it is more common to see chromosomal heterogeneity in the West as 
compared to the homozygous conditions more likely to be seen in Africa, Arabia or Asia (Desai 
& Dhanani, 2004). The slave trade in the United States brought the Bantu haplotype found in the 
African region, but after the arrival of this population to the United States, this gene type mixed 
with gene types arriving from the Caribbean and Brazil, creating a mixture of African ethnic 
groups (Nagel, Erlingsson, Fabry, et al., 1991). 
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FIGURE 3: ORIGINS OF THE SICKLE CELL GENE 
 
Source: www.sicklecellinfo.net (accessed 29 July, 2010) 
 
FIGURE 4: GLOBAL DISTRIBUTION OF THE SICKLE GENE 
 
Source: (Oni, 2007 – Parent’s Handbook) 
1.2.2. THE ROLE OF MALARIA IN PERPETUATING THE SICKLE GENE 
Plasmodium falciparum malaria is the most dangerous of the four species of human malaria and 
considered to be a killer. In places where P. falciparum malaria is endemic, populations have 
been wiped out. Studies have shown that malaria could have contributed to the fall of the 
Roman Empire by killing children and adults in villages during a time when the parasite made 
its way to parts of Europe. Much later, mosquito eradication programmes were carried out in 
Europe and the United States (Sallares, Bouwman & Anderung, 2004). 
When the falciparum malaria parasite attacks an HbAS erythrocyte (Sickle Cell Trait), the cell 
sickles at a much higher rate than a non-parasitised cell. Once a parasitised cell is sickled, it is 
removed from circulation by phagocytosis, which is the main mechanism whereby a person 
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with sickle cell trait has a selective advantage against malaria (Luzzatto, Nwachuku-Jarrett & 
Reddy, 1970). Those who survive malaria are able to pass on their genes. Hence, it has acted as a 
selective factor by increasing the prevalence of the gene in areas where malaria exists. Over the 
generations, the sickle cell trait has therefore reached high frequencies in countries with 
endemic malaria. The factor in common to the distribution of the sickle cell gene is therefore 
malaria (Serjeant, 1997). 
Although the sickle cell trait may protect against malaria, inheritance of two abnormal genes 
leading to SCD offers no such protection, and malaria is a major cause of ill-health and death in 
people with SCD (WHO Secretariat, 2006). This is thought to be partially due to the spleen, as 
the spleen plays an important role in malaria immunity. Therefore, increased morbidity and 
mortality from malaria in people with SCD increases as spleen function deteriorates with age in 
patients with SCD. A second reason is that SCD patients, even without malaria, are already 
anaemic. Malaria can cause anaemia, and a sudden decline in haemoglobin from an already low 
baseline value could be disastrous for a patient suffering from both SCD and malaria (McAuley, 
Webb, Makani, et al., 2010). 
FIGURE 5: MAP OF THE DISTRIBUTION OF MALARIA AND THE SICKLE CELL ALLELE 
 
 
 
 
 
Map 1: Distribution of malaria in southern Europe, southwest Asia, and Africa around the year 1920 (green), 
prior to mosquito eradication programmes. 
Map 2: Distribution of the sickle cell allele within the same area. The darker the blue, the greater the 
percentage of people carrying the allele. 
Note the correlation between these maps. 
Source: Understanding Evolution. 2010. University of California Museum of Paleontology. 22 August 2008 
http://bit.ly/1KXpkg8  
1.2.3. DISCOVERY IN THE WEST 
The first record in the western world of a sickle cell disease blood sample was made by Chicago 
physician James Herrick in 1910. Herrick describes the patient’s red blood cells as ‘very 
irregular, but what especially attracted attention was the large number of thin, elongated, sickle 
shaped and crescent-shaped forms.’ At the time, Herrick could not diagnose the patient, but 
rather just gave an account of his case (Herrick, 2001; Savitt & Goldberg, 1989). While this was 
the first published case in the west, there is evidence that suggests that many families in Africa 
were able to trace the disease through their family genealogy and gave the disease tribal names 
based on the symptoms of sickle cell disease. In the south of Nigeria, sickle cell disease was 
called ‘arun romolegungun’ which means ‘disease that aches the child’s bones’ which is in 
essence a description of sickle cell crisis pain (Brent Sickle Cell & Thalassaemia Centre, 
http://bit.ly/1J5Hz46). 
The next one hundred years (1910-2010) showed a vast improvement in the understanding and 
treatment of the disease with the discovery of the deoxygenation of the cells, gene mutations, 
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 1910-Herrick provides the first formal description of sickle cell anaemia when he 
reports that the blood smear of a dental student at the Chicago College of Dental 
Surgery contains ‘pear-shaped and elongated forms.’ 
 1927-Hahn and Gillespie associate the sickling of red blood cells with low oxygen 
conditions. 
 1940-Sherman reports that the sickling of red blood cells in the absence of oxygen is 
caused by a change in the haemoglobin molecular structure. 
 1948-Watson suggests that the presence of foetal haemoglobin in the red blood cells of 
sickle cell newborns is the reason they do not show disease symptoms. 
 1949-Noted physical chemist Linus Pauling and associates publish ‘Sickle Cell Anaemia, 
a Molecular Disease’ in Science. This paper explains how protein electrophoresis was 
used to show that sickle cell haemoglobin differed in structure from normal 
haemoglobin. This was the first time that the cause of a disease was linked to a change 
in protein structure. 
 1956-Vernon Ingram and J.A. Hunt sequence haemoglobin and discover that the change 
of a single amino acid in the protein sequence is the cause of sickle cell anaemia. 
 1978-Flavell prepares maps of the human beta and delta globin genes. 
 1995-Upon the completion of the Multicentre Study of Hydroxyurea in Sickle Cell 
Anaemia, Charache reports that the anticancer drug hydroxyurea is the first to 
reduce the frequent, painful complications that characterise sickle cell disease. 
Source: 
Online Mendelian Inheritance in Man, OMIM (TM). Johns Hopkins University, Baltimore, MD. MIM No. 141900 (6 
November, 2001). <http://goo.gl/qdoVoj> 
A Brief History of Sickle Cell Disease. Joint Center for Sickle Cell and Thalassemic Disorders (25 February, 2001). 
<http://goo.gl/2AD9xH> 
Timeline taken from: http://goo.gl/U15GH6 
the protective nature of foetal haemoglobin, and the discovery of the chemotherapy drug 
hydroxyurea in the treatment of painful crisis. 
FIGURE 6: SCD TIMELINE 1910-2010 
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1.3. INCIDENCE AND PREVALENCE 
1.3.1. GLOBAL INCIDENCE 
There are an estimated 3 to 5 million people globally affected by SCD (Vichinsky, Neumayr, 
Gold, et al., 2010; Steenhuysen, 2010), and there are 300,000 births per year of babies with SCD, 
with up to 70% of these births taking place in Africa (Makani, Komba, Cox, et al., 2010). SCD is 
most common in people originating from Africa, the Mediterranean, the Middle East, India, 
Caribbean and Central and South America. All people of non-Northern European origin are 
therefore considered to be at greater risk of inheriting sickle cell disorders, but it is not 
exclusive to these populations and can affect people of any race, colour, or ethnic origin 
(Lehmann, 1954). 
In the Unites States of America, SCD affects around 72,000 people, most of whose ancestors 
come from Africa. The disease occurs in about 1 in every 500 African-American births and 1 in 
every 1000 to 1400 Hispanic-American births (Genomic resource centre, http://bit.ly/1ItZJ0j). 
1.3.2. TRENDS IN THE INCIDENCE AND PREVALENCE OF SCD IN ENGLAND 
SCD is the most common genetic condition in England. It is estimated that there are around 
12,500 people with SCD living in England; 9,000 (3/4) of them live in London, and one baby in 
every 2,000 is born with the condition (http://bit.ly/1cpGpDM, Streetly, Latinovic, Hall, et al., 
2009). In London, SCD is now one of the most common reasons for admission to hospital 
(Streetly et al., 2008, McColl Karen Pickworth & Raymond, 2006). 
The significant migration of people from the West Indies, Africa and Asia during the 1950s and 
onwards may partially account for the high incidence of SCD in England. Figures also suggest 
that 6% of the population and approximately 10% of all births are at risk for 
haemoglobinopathy disorders (Anionwu & Atkin, 2001). With current trends in population 
migration into the country, these conditions are likely to become even more common over the 
next decade (Streetly, Clarke, Downing, et al., 2008). 
1.3.3. INCIDENCE OF SICKLE CELL TRAIT 
It is estimated that 300 million people worldwide carry the sickle cell trait, with the highest 
concentration in Africa and the Mediterranean region. Approximately 1 in 3 persons in West 
Africa (33%) and 1 in 5 persons (20%) in the eastern province of Saudi Arabia are carriers 
(Tsaras, Owusu-Ansah, Boateng, et al., 2009). Approximately 1 in 100 Greeks carry the sickle 
cell trait (Brent Sickle Cell & Thalassaemia Centre, http://bit.ly/1J5Hz46). In the United States, 
about 2 million people carry the trait (Genomic resource centre, http://bit.ly/1ItZJ0j) and in 
England, around 9,723 carriers are born each year (NHS sickle and Thalassaemia Screening 
Programme, 2011/12). 
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1.3.4. PUBLIC HEALTH IMPLICATIONS OF GROWING PREVALENCE 
There is a growing global public health concern regarding SCD due to a marked increase in 
prevalence over the past decade. The increase in sickle numbers is likely due to a number of 
factors including a rise in screening programmes, a move towards incorporating various 
haemoglobinopathy diagnosis codes, and population migration (WHO Secretariat, 2006). The 
increase is also due to an increase in life expectancy of patients living with sickle cell through 
improved secondary and tertiary prevention, including improving managing risk factors 
associated with haemoglobinopathies and earlier detection and management of disease-related 
complications. 
The public health implications of SCD are great, particularly when health impact is measured by 
under-five mortality. With medical science advancements, an increasing proportion of affected 
children now survive past five years of age but still remain at risk of premature death. When 
health impact is measured by under-five mortality, SCD contributes the equivalent of 5% of 
under five deaths on the African continent, more than 9% of such deaths in West Africa, and up 
to 16% of under-five deaths in individual West African countries (WHO Secretariat, 2006). 
In the USA, median survival was estimated in 1994 to be 42 years for men and 48 years for 
women, whereas comparable figures for Jamaica published in 2001 suggested 53 years for men 
and 58.5 years for women. In Jamaica, the greatest mortality occurs between 6 and 12 months 
of age when 10% of patients die despite considerable experience in the diagnosis and therapy of 
the condition and the absence of malaria. There are, however, no firm data on the survival of 
patients with sickle cell anaemia on the African continent. In sub-Saharan Africa mortality will 
be much higher than in Jamaica, and in some areas estimates derived from the age structure of 
populations attending clinics suggest that half of those with sickle cell anaemia have died by the 
age of five years, usually from infections including malaria, pneumococcal sepsis, and anaemia 
itself (WHO Secretariat, 2006). 
Sickle cell disease can be detected from birth by a blood test. With health care practitioners and 
policy makers recognising that management of SCD can be achieved by early diagnosis, 
newborn screening programmes have rapidly developed internationally (Serjeant, 2000). 
1.4. THE CONSEQUENCES OF SICKLE CELL DISEASE 
1.4.1. MORTALITY AND LIFE EXPECTANCY 
Mortality rates have been published in the USA and the Caribbean, showing a decrease in 
mortality rates due to SCD in recent years. Sickle related deaths among African American 
children less than four years of age was shown to have fallen by 42% between 1999 and 2002 
(Yanni, Grosse, Yang, et al., 2009). As recent as the 1970s, people with SCD were not expected to 
survive into adulthood (A., J., A., et al., 2009). These drops in mortality are attributed to timely 
diagnostic testing, educating patients, and advances in medical care, including neonatal 
screening, which allows for prophylactic treatment with antibiotics starting at two months of 
age up until the age of five years, thereby reducing premature deaths due to infection 
(Steinberg, 2002). Aside from two recorded studies, one from Brent and the other covering 
sickle centres from France and England that discuss mortality due to SCD, there is little 
information originating from the UK and the rest of Europe. Despite the increasing number of 
people in England with SCD or with the trait, England lacks a properly updated survey of how 
many people in England are dying from SCD or its complications (Lucas, Mason, Mason, et al., 
2008). 
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1.4.2. PATHOPHYSIOLOGY 
The clinical features of SCD do not follow a single pattern; some patients have mild symptoms, 
and some have very severe symptoms. There are two pathological processes – vaso-occlusion 
and haemolysis. When sickled cells stick together and block blood vessels or get stuck in narrow 
blood vessels, blocking the flow of blood, this event is called vaso-occlusion. This can happen 
anywhere in the body, resulting in a vaso-occlusive crisis, or what is often referred to as painful 
crisis. Vaso-occlusion prevents blood flow into the surrounding tissues and organs, depriving 
them of oxygen and potentially resulting in localised tissue death and permanent organ damage 
(Serjeant & Serjeant, 2001; Frenette, 2002). Haemolysis results in anaemia and a functional 
deficiency of nitric oxide, which results in vascular endothelial damage and can be responsible 
for complications such as pulmonary hypertension and stroke (Stuart & Nagel, 2004). Some 
more common complications of the disease are discussed below (National Heart Lung and Blood 
Institute, 1996). 
FIGURE 7: VASO-OCCLUSION 
 
Source: Sickle Cell Society at www.sicklecellsociety.org 
Hand-foot syndrome. This disease is also referred to as sickle cell dactylitis. Small blood 
vessels in hands or feet are blocked usually during a vaso-occlusive (pain) crisis and swelling 
can result, along with fever. This often results in a radiological change where small bones end 
up looking ‘moth eaten’ (Babhulkar, Pande & Babhulkar, 1995). 
Anaemia. Symptoms of fatigue, paleness, and shortness of breath are present. These are all 
typical symptoms of a shortage of red blood cells (Anon, 2004). 
Painful crisis. This is also referred to as a vaso-occlusive crisis. Pain occurs unpredictably in 
any body organ or joint wherever there is a block of oxygen flow due to sickled cells sticking 
together. Some patients have these episodes infrequently and some have them very frequently. 
The pain can last anywhere from a couple of hours to several weeks. Most hospitalisations for 
SCD patients are due to painful crisis. Pain is the principal symptom of SCD in both children and 
adults. Frequent painful episodes are associated with shorter lifespans (Castro, Brambilla, 
Thorington, et al., 1994). 
Sickle cell eye disease. The retina, i.e. the layer of cells at the back of the eye that receives and 
processes visual images, can deteriorate when it does not get enough nourishment from 
circulating red blood cells. Damage to the retina can be serious enough to cause blindness 
(Anon, n.d.). Clinically detectable retinal disease in sickle cell patients is found most commonly 
between 15 and 30 years of age (Condon & Serjeant, 1980). 
Jaundice. Jaundice creates a yellowing of skin and eyes which are manifestations of the rapid 
breakdown of the red blood cells (Anon, n.d.). 
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Growth retardation. A shortage of red blood cells also gives rise to physical growth delays and 
a late onset of puberty (Anon, n.d.). 
Infections. The most common cause of death for SCD is infection. In one study, 33-48% of all 
deaths with SCD as a diagnosis were reported due to infection (Manci, Culberson, Yang, et al., 
2003). In general, both children and adults with sickle cell anaemia are more vulnerable to 
infections and have a harder time fighting them off. A major contributor to this vulnerability is 
the result of spleen damage from sickled red cells, which prevents the spleen from destroying 
bacteria in the blood, also putting patients with SCD at higher risk for septicaemia (Magnus, 
Hambleton, Moosdeen, et al., 1999). Infants and young children in particular are susceptible to 
bacterial infections that can kill them in as little as 9 hours from the onset of fever. 
Pneumococcal infections used to be the principal cause of death in children with sickle cell 
anaemia until physicians began routinely giving penicillin on a preventive basis to those who 
were diagnosed at birth or in early infancy (National Heart Lung and Blood Institute, 1996). 
Stroke. In stroke, the sickled red blood cells stick to the blood vessel walls in the brain and 
result in narrow or blocked vessels that can lead to strokes, primarily in children (National 
Heart Lung and Blood Institute, 1996). About 10% of children with SCD suffer from stroke 
(Steinberg, 1999). Recurrence is common (Anionwu & Atkin, 2001). Another factor is anaemia. 
Anaemia increases the velocity of cerebral blood flow, and a high velocity of cerebral blood flow 
is strongly associated with stroke (Adams, McKie, Nichols, et al., 1992). 
Acute chest syndrome (ACS). ACS is similar to pneumonia and can be a life-threatening 
complication caused by infection or trapped sickled cells in the lung. It can show symptoms of 
chest pain, fever, and an abnormal chest X-ray (National Heart, Lung, and Blood Institute 
[NHLBI], 2002). After painful crisis, it is the most common reason for hospitalisation, morbidity, 
and mortality in SCD patients. It is most common in the winter months, and adults usually 
succumb to complications more frequently than children (Vichinsky, Styles, Colangelo, et al., 
1997). 
Spleen complications. Acute splenic sequestration is a relatively common and potentially life-
threatening event in young children with SCD (Aquino, Norvell & Buchanan, 1997). It is a 
condition that causes the spleen to fill with blood and become large and tender. This happens 
when the sickled red blood cells get trapped in the small blood vessels of the spleen, and the 
blood that normally flows through the spleen gets trapped and causes the spleen to enlarge. 
With more blood trapped in the spleen, there is less blood to flow through the rest of the body, 
which can cause the haemoglobin in the rest of the body to drop to a critically low level 
(Children’s Mercy Hospitals and Clinics, 2010). Complications with the spleen are managed 
through red blood cell transfusions. Chronic hypersplenism (splenomegaly), also referred to as 
enlarged spleen, is often treated by removing the spleen either fully or partially (splenectomy) 
(NHLBI, 2002). 
Leg ulcers. Leg ulcers occur in about 10-20% of persons with SCD (NIH, 2002). They increase in 
incidence after the second decade of life and are more commonly seen in men (Bonds, 2005). 
While the aetiology of leg ulcers is not entirely understood, decreased blood flow to a healed 
ulcer results in a higher chance of recurrence (Koshy, Entsuah, Koranda, et al., 1989). 
Priapism. Sickling in the blood vessels of the penis can cause painful erections and result in 
impotence. This occurs in 30-45% of males with SCD. Little is known about the pathological 
processes and genetic risk factors that contribute to the occurrence of priapism (Elliott, Ashley- 
Koch, De Castro, et al., 2007; Elliott, Ashley-Koch, De Castro, et al., 2007; Hakim, Hashmat & 
Macchia, 1994). Treatment includes fluid delivery, surgery, drugs, transfusions, and 
hydroxyurea (Serjeant & Serjeant, 2001). 
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Pregnancy. It is only in the last half of the 20th century that women with SCD have survived to 
reproduce, and even with all the advances in modern medicine, pregnancy in sickle cell patients 
is regarded as high risk. Morbidity and mortality rates for pregnant women with SCD and their 
unborn babies are higher than that of the overall population. Maternal complications include an 
increased risk of all complications due to SCD such as painful crises and all those due to 
pregnancy such as pre-eclampsia. Risks to the unborn child are also increased with a 19% risk 
of spontaneous abortion, 21% risk of stillbirth, 32% risk of premature delivery and 42% risk of 
intrauterine growth restriction (Oteng-Ntim, Chase, Howard, et al., 2008). A recent study at the 
Department of Obstetrics and Gynaecology and the Department of Haematology at King’s 
College Hospital in London showed that a combined obstetric and haematology clinic allows for 
a multidisciplinary team approach for pregnant women with SCD, and was found to be 
beneficial in the management of patients who are at risk for multiple complications (Yu, 
Stasiowska, Stephens, et al., 2009). 
1.5. CLINICAL MANAGEMENT AND HEALTH IMPROVEMENT IN SICKLE 
CELL DISEASE 
A combination of secondary and tertiary prevention programmes are required to reduce 
morbidity and mortality and improve health outcomes in sickle cell disease (Olney, 1999). 
There exists an evidence base for secondary and tertiary prevention measures to reduce 
complications of sickle cell disease, reduce hospital stays and decrease morbidity and mortality 
(Olney, 1999). Key secondary interventions include early detection, preclinical interventions 
and education; tertiary interventions include prophylactic transfusions to prevent the 
recurrence of stroke, folic acid supplementation, analgesics, hydration, and hydroxyurea 
therapy (Olney, 1999). 
1.5.1. SECONDARY PREVENTION MEASURES 
EARLY DETECTION 
Newborn screening is important as a method of early disease detection and as a trigger for 
initiating prompt secondary preventive measures such as penicillin prophylaxis and targeted 
immunisations (Olney, 1999). In the United States, screening programmes are initiated through 
a programme enabling laws in each state. The lack of a national programme gives rise to 
programme differences in each state, but it also allows for a quicker response to necessary 
changes (Therrell & Hannon, 2006). In England, national newborn screening for sickle cell 
disease was implemented in 2004 (Streetly, Clarke, Downing, et al., 2008). National 
implementation of newborn screening in England has increased the number of people identified 
with sickle cell disease, and according to a study by Streetly et al., the national approach has 
allowed for the development of national materials and training programmes that make much 
more efficient use of resources, ensures consistency of information and drive further 
developments in screening methods (Streetly, Latinovic, Hall, et al., 2009). Screening 
programmes in Sub-Saharan Africa are now being designed after American and European 
models (Tshilolo, Kafando, Sawadogo, et al., 2008). 
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PRECLINICAL INTERVENTIONS 
PROPHYLACTIC ANTIBIOTICS 
Infection is a leading cause of death among patients with SCD with mortality rates due to 
infection reported as being 20-50%. Administering oral prophylactic penicillin in sickle patients 
reduces the risk of infection by 84% for patients under the age of three (Booth, Inusa & Obaro, 
2010). This inexpensive and extremely effective intervention is a perfect example of how a 
simple intervention can create marked improvements in morbidity and mortality for SCD 
patients. 
IMMUNISATIONS 
It is well-known how important immunisations are for protecting against preventable life 
threatening diseases. This is particularly true for high risk groups such as those with SCD. That 
being said, immunisation uptake for those with SCD is not as one would hope or expect. An 
immunisation audit carried out against UK National Guidance (Salisbury, Ramsay & Noakes, 
2006) of sickle cell patients living in Coventry revealed that only 56% of children age 16 and 
under and 12% of adults had complete immunisations, and that these rates were similar to 
those found in other UK studies (Howard-Jones, Randall, Bailey-Squire, et al., 2009). 
Immunisations in some cases have reduced mortality rates for children by 68%, as was the case 
for children aged three and under after the introduction of the 23-valent pneumococcal 
polysaccharide vaccine in 1984 and the Hib vaccine in 1988 (Yanni, Grosse, Yang, et al., 2009). 
EDUCATION 
Education can be a valuable tool in health improvement. Many primary care physicians were 
found to be unprepared to manage the follow-up care of children with a positive newborn 
screen, including initial counselling, diagnosis, and subspecialty referral (Kemper, Uren, 
Moseley, et al., 2006). Knowledge and confidence can be improved with educational 
interventions (Oyeku, Feldman, Ryan, et al., 2010). Education can also mean several things, 
including re-educating practice culture.  In other words, changing the organizational culture of 
the hospital or GP practice where health care providers practice.   For example, one study 
examined the influence of nurses’ attitudes on the management of SCD and found that the 
practice culture was for nurses to believe that any patient presenting to hospital and looking for 
narcotic pain relief was a potential drug addict.  The nurses would benefit from further 
education with a focus on attitudes towards pain and drug addiction in SCD (Pack-Mabien, 
Labbe, Herbert, et al., 2001b).  Not only can health care providers be educated, but the patients, 
caregivers, and key members of the community can be educated to optimise health outcomes. 
1.5.2. TERTIARY PREVENTION MEASURES 
Doctors can do a great deal to help patients with SCD, and treatment is constantly being 
improved. The most common tertiary preventive measures for sickle cell patients are blood 
transfusions and hydroxyurea therapy. 
Blood transfusions. Transfusions correct anaemia by increasing the number of normal red 
blood cells in the circulation. They can also be used to treat spleen enlargement in children 
before the condition becomes life-threatening. Regular transfusion therapy can help prevent 
recurring strokes in children at high risk (SCD Guidelines Adults). 
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Hydroxyurea. Basic treatment of painful crises relies heavily on painkilling drugs and oral and 
intravenous fluids to reduce pain and prevent complications. Painful crises account for 90% of 
all hospital episodes (Anon, 2008). Generally speaking, there is an enormous amount of 
sympathy for patients with cancer pain, postoperative pain, or pain due to trauma, but little 
sympathy or understanding for the pain of SCD (Pack-Mabien, Labbe, Herbert, et al., 2001b). 
Hydroxyurea is the first effective drug treatment for adults with severe sickle cell disease. It was 
discovered in 1995, when the Multicenter Study of Hydroxyurea in Sickle Cell Anemia (MSH) 
trial showed that this cancer therapy increases total and foetal haemoglobin and reduces the 
frequency of painful crises and acute chest syndrome. The patients taking the drug needed 
fewer blood transfusions (Orkin & Higgs, 2010b). Moreover, there was improved red blood cell 
hydration among other possible benefits (Dick, 2008). A follow-up study 10 years after the MSH 
trial showed that hydroxyurea is also effective for primary stroke prevention (Verduzco & 
Nathan, 2009). 
Bone marrow transplantation. Haematopoietic transplantation, otherwise known as bone 
marrow transplantation (BMT), remains the only possible curative therapy for those with sickle 
cell disease (Mankad, 2001). BMT can change the phenotype of HbSS patients to HbAA or HbAS. 
The strongest cases for BMT are made when patients develop a more severe disease such as 
leukaemia or stroke, but the risks remain too high for this to be a common practice. Along with 
the extremely high cost of the procedure, risks include but are not limited to rejection of the 
transplant and neurological complications (Serjeant & Serjeant, 2001). BMT has recently given 
way to the developing idea of gene therapy. 
Gene therapy. Gene therapy introduces a normal gene into a patient’s cells and tissues either 
through viral vector or gene replacement in order to treat a genetic disorder such as SCD. If 
gene therapy is successful, it avoids the complications that are involved with BMT (Olowoyeye & 
Okwundu, 2010). So far, gene therapy has been used to correct SCD in mice (Frenette & Atweh, 
2007) and it holds future promise as clinical trials are initiated (Romero, Urbinati, Geiger, et al., 
2013). 
TABLE 1: SCD PREVENTIVE CARE MEASURES 
Secondary Prevention Tertiary Prevention 
Early Detection/Newborn Screening Blood Transfusions 
Antibiotic Prophylaxis Hydroxyurea 
Immunisations Bone Marrow Transplant 
Education Gene Therapy 
1.5.3. COMPLEMENTARY AND ALTERNATIVE THERAPIES 
As with several other areas in medicine, SCD is not excluded from the exploration of alternative 
therapies as a compliment to allopathic therapy. In fact, two thirds of the world’s population, 
primarily in developing countries, rely on what is referred to as traditional or herbal medicine 
as their primary form of health care (Sumner, 2000). Most developing countries have used 
medicinal plants in the treatment of painful crises associated with SCD either because they 
cannot afford the high cost of allopathic medicine or simply because herbal medicine is deeply 
rooted in the culture and traditionalists believe in its efficacy (Okpuzor, Adebesin, Ogbunugafor, 
et al., 2008). Most of the alternative therapies for SCD promote an anti-sickling effect on red 
blood cells. Extracts from dried fish (tilapia) and dried prawns (Astacus red) have been 
established to have the ability to stop the formation of HbS haemoglobin, increase foetal 
haemoglobin and reduce haemolysis in sickle cell blood (Nwaoguikpe & Uwakwe, 2005). Several 
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plants and seeds indigenous to Africa are used in the treatment and management of SCD, 
including the more commonly known aloe vera, Nigerian ‘bitter kola’ and unripened papaya 
(Okpuzor, Adebesin, Ogbunugafor, et al., 2008). 
Some studies in the USA found that complementary and alternative medicine (CAM) can be 
useful (Post-White, Fitzgerald, Hageness, et al., 2009). One study measured the uptake of CAM 
for children with SCD, and found that 54% of the sample used CAM therapies for their children, 
42% used bioenergetic therapies (prayer, spiritual and energy healing), 28% used 
lifestyle/mind–body therapies (relaxation techniques, exercise, imagery, and diet), 12% used 
biochemical therapies (herbal medicines, megavitamins, and folk remedies), and 5% used 
biomechanical therapy (massage) (Sibinga, Shindell, Casella, et al., 2006). More recently, the 
antioxidant properties of garlic and green tea have been touted as an important addition to 
sickle therapy (Ohnishi, Ohnishi & Ogunmola, 2001). 
THE ROLE OF ANTIOXIDANTS 
Some studies have shown that oxidant stress plays an important part in the pathophysiology of 
SCD (Hebbel, Eaton, Balasingam, et al., 1982; Rice-Evans, Omorphos & Baysal, 1986). Oxidative 
stress occurs when the body uses oxygen to make energy. The process creates molecules 
missing electrons, which are known as free radicals. The lack of an electron causes the molecule 
to be unstable. Oxidative stress is a normal side effect of body function; usually, nutrients from 
within the body known as antioxidants are used to control this process. 
However, when these free radicals react with other molecules in the body and cause cell 
damage, this is seen as abnormal and the cause behind many illnesses (Nur, Biemond, Otten, et 
al., 2011). In the case of SCD, the oxidative stress can contribute to the sickling process. One of 
the flavour components in garlic (Allium sativum) known as AGE has been reported to have a 
significant antioxidant effect on sickled red blood cells, which can be exacerbated by oxidative 
stress (Takasu, Uykimpang, Sunga, et al., 2006). Green tea has been found to have a similar 
effect. The use of AGE and green tea as an antioxidant supplement could be a valuable and a 
relatively harmless compliment to managing SCD (Ohnishi, Ohnishi & Ogunmola, 2001). 
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1.6. KEY POINTS FROM CHAPTER 1 
1. Sickle cell disease is an important global public health problem with a growing 
morbidity burden, and there is a need to assess what this burden is in England. 
2. History and migration patterns of SCD can help to explain origins and evolution of 
disease including areas of high prevalence.   
3. Presentation of clinical co-morbidities associated with SCD can illustrate that 
measurement of primary diagnosis for hospital admissions and readmissions of SCD will 
not capture the true burden unless we also account for the broad spectrum of associated 
complications. 
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2. AIMS AND OBJECTIVES 
We do not know the burden of disease in England as can be measured through hospital 
admission, readmission and their related costs.  The aims of this research were to: 
1. Assess the burden of SCD in England by examining trends and admissions rates due to 
SCD; and 
2. Suggest that some admissions could be preventable through better primary care. 
The objective was to accomplish this by conducting one substantial study and five supporting 
studies: 
1. Assessing trends in hospital admissions due to SCD and determining geographic 
variation using the HES national data set (chapter 3);   
2. Characterizing emergency admissions in a PCT with high prevalence of SCD (chapter 3); 
3. Measuring hospital readmission due to SCD (chapter 4); 
4. Determining hospital costs due to SCD (chapter 5);    
5. Viewing patient perspectives on disease management in primary care (chapter 6); and 
6. Collecting patient views on improving SCD management in primary care (chapter 6). 
Admission trends were surveyed both nationally and locally. We need to identify national 
trends but then be able to use a local benchmark that can recommend local policies which may 
inform or grow into national policies.  This is the first study of hospital admission trends for SCD 
using HES data. Because SCD is a disease affecting primarily BME populations, the same HES 
data set was used to determine whether there was a link between socioeconomic deprivation 
and SCD hospital readmissions and also whether there was a link between socioeconomic 
deprivation and SCD hospital mortality. My research also revealed, that unlike in the US, there is 
very little published in England when it comes to cost and the burden of cost for the NHS from 
SCD. HES data were once again used to determine the hospital costs associated with SCD.  
The research using the HES data drew a very colourful backdrop to the landscape of SCD in 
England, both nationally and by borough.  A focus group of SCD patients and carers and a 
patient satisfaction questionnaire helped to identify gaps in the delivery of care. 
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3. NATIONAL TRENDS IN HOSPITAL ADMISSIONS FOR SCD 
3.1. BACKGROUND AND AIM 
Little data exists in England about the healthcare utilization of SCD patients.  Hospital admission 
data could provide information about the impact of SCD on the NHS.  It could highlight disease 
specific trends and it could be useful to clinicians, commissioners and health planners in 
prevention as well as disease management.  
The aim of this particular study was to investigate trends in the rates of hospital admissions in 
England for SCD and to determine their geographic variations. The objective was to use data 
from the Hospital Episode Statistics (HES) database, which provides data on all NHS hospital 
admissions in England and to use the study period between April 2001 and April 2010.  This 
study provided the foundation for which all other work regarding this thesis was built. 
3.2. METHODS AND RESULTS 
Hospital Episode Statistics (HES) data was used to show trends in hospital admissions for SCD, 
which I hoped could thereafter partially inform a larger policy recommendation on SCD 
management in England. As previously stated, sparse data exists in England about the 
healthcare utilisation of SCD patients. Data on hospital admissions in England for SCD can 
provide information about the impact of SCD on the National Health Service and would also be 
of value to clinicians, commissioners, and healthcare planners. Such data could also highlight 
disease-specific trends (Aljuburi, Laverty, Green, et al., 2012a). 
Patients with a primary diagnosis of Sickle Cell Anaemia with Crisis (D57.0) or Sickle Cell 
Anaemia without Crisis (D57.1) were selected for this study. With Crisis suggests that the 
patient was admitted for an acute painful episode. Without Crisis suggests that the patient was 
admitted for something other than an acute painful episode.  The overall admission rate per 
100,000 population has risen from 21.2 per 100,000 in 2001/02 to 33.5 per 100,000 in 
2009/10. Figure 8 and Table 2 show the overall admission rates for SCD as a primary diagnosis 
from 2001/02 to 2009/10. This shows a rise of over 50% in the admission rate from 2001/02 
levels, with a consistent year-on-year rise except for 2002/03 and 2003/04 (Aljuburi, Laverty, 
Green, et al., 2012a). 
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TABLE 2: OVERALL ADMISSION RATES FOR SCD 
Year 
Age (years) 2001/
02 
2002/
03 
2003/
04 
2004/
05 
2005/
06 
2006/
07 
2007/
08 
2008/
09 
2009/
10 
Men overall 20.7 24.1 24.1 25.4 25.9 28.5 31.3 32.7 35.1 
<1 8.8 6.7 7.1 4.6 12.6 16.1 16.7 15.2 14.7 
1 to 9 18.6 21.2 21.5 24.9 22.7 27.8 37.1 41.2 45.5 
10 to 19 24.9 30.6 30.0 35.8 37.8 39.2 44.6 49.9 55.6 
20 to 29 50.0 49.7 54.8 57.1 57.4 70.5 65.0 64.7 68.6 
30 to 39 44.3 54.3 47.7 44.2 39.3 37.8 42.8 41.9 46.8 
40 to 49 7.6 13.7 16.0 17.3 23.5 24.1 28.1 29.0 26.8 
Over 50 1.6 1.4 1.6 2.3 2.3 2.1 2.7 2.8 3.2 
Women 
overall 
21.6 23.3 21.7 24.6 25.2 25.6 26.1 27.6 31.9 
<1 7.3 7.0 7.9 5.2 12.8 11.9 10.9 13.2 10.8 
1 to 9 12.6 18.5 17.7 20.3 23.0 23.5 26.1 36.5 42.2 
10 to 19 29.1 36.3 31.9 40.3 41.8 47.3 48.5 51.2 56.4 
20 to 29 32.4 35.4 38.0 44.6 51.9 50.9 52.1 52.4 57.9 
30 to 39 52.4 50.1 41.2 41.7 41.4 36.6 35.7 37.0 45.3 
40 to 49 25.4 24.5 25.9 28.0 22.1 25.7 26.0 24.7 29.2 
Over 50 3.4 4.0 3.8 4.9 4.5 4.2 3.9 4.0 5.1 
Total 21.2 23.7 22.9 25.0 25.6 27.0 28.7 30.1 33.5 
(Aljuburi, Laverty, Green, et al., 2012a) 
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FIGURE 8: OVERALL ADMISSION RATES FOR SCD IN ENGLAND 
 
 
 
 
 
 
 
 
 
 
 
(Aljuburi, Laverty, Green, et al., 2012a) 
A rise in SCD admission rates can be seen in almost every age and sex group (Table 2). The 
largest rise in admission rates was seen amongst men aged between 40 and 49 years old, where 
admission rates per 100,000 population increased from 7.6 to 26.8 over this time period (Table 
2) (Aljuburi, Laverty, Green, et al., 2012a). 
London accounts for almost three quarters of all SCD admissions in England (74.9% of all 
admissions nationally) (Aljuburi, Laverty, Green, et al., 2012b; Green, Aljuburi, Majeed, et al., 
2012a). The highest admission rates can be seen in the City and Hackney Teaching PCT at 837.4 
per 100,000 population (Figure 9). 
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FIGURE 9: ADMISSIONS PER 100,000 POPULATION 
Source: (Aljuburi, Laverty, Green, et al., 2012b) 
Table 3 shows the most common secondary and tertiary diagnoses for those admitted with SCD 
as the primary diagnosis. The most common additional diagnostic codes were for respiratory 
conditions including lower respiratory tract infection, lobar pneumonia, and asthma, followed 
by vaso-occlusive conditions such as occlusion and stenosis of the middle cerebral artery, 
Moyamoya disease, hemiplegia, and sequelae of stroke (not specified as haemorrhage or 
infarction). 
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TABLE 3: TOP SECONDARY AND TERTIARY DIAGNOSES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Source: (Aljuburi, Laverty, Green, et al., 2012a) 
Table 4 shows the breakdown of crisis and non-crisis admissions in 2009/10. Slightly over half 
of all admissions (50.3%) were for a sickle cell crisis, and those in the age group 20-29 had a 
higher proportion of crisis admissions than other groups (62.8% and 62.9% for men and 
women respectively). The lowest proportion of crisis admissions was in women aged over 50 
(30.4%). 
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TABLE 4: BREAKDOWN OF CRISIS AND NON-CRISIS ADMISSIONS 
 
Source: (Aljuburi, Laverty, Green, et al., 2012a) 
57.9% of all patients were discharged within 24 hours of being admitted to hospital, while only 
15.4% of admissions stayed for longer than one week. The largest proportion of patients 
discharged on the same day was for those aged over 50 years old, at 72.1%. 
3.3. DISCUSSION 
This is the first national study on trends for hospital admission rates for SCD using HES data.  
The data has four main findings:  
1. The number of admissions due to SCD has increased substantially over the study period 
(2001-2010); 
2. The majority of admissions are in London; 
3. Most admissions were discharged within 24 hours; and 
4. There has been an increase in the number of admissions of middle-aged men. 
The over 50% in SCD admissions, is probably due to a number of factors, the most important of 
which is likely to be an increased prevalence of SCD in England through domestic growth of the 
current at-risk population and population migration from countries where SCD is common 
(WHO Secretariat, 2006). 
A previous study on the national implementation of newborn screening in England showed an 
increased number of children identified with SCD in some areas. The authors of this study 
concluded that past under-ascertainment of cases may have led to under-estimation of the 
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needs of people with SCD. Under-ascertainment of SCD cases may also have contributed to 
increased infant mortality in urban areas because babies were at risk of dying without a 
diagnosis of SCD being made and the initiation of appropriate management (Streetly, Latinovic, 
Hall, et al., 2009). 
Aside from the reasons already mentioned in Chapter 1 regarding possible contributors to the 
increase of SCD prevalence in England, the increases in admissions for SCD may also be due to a 
drop in the threshold for admission of patients with SCD, through greater recognition of the 
importance of SCD crisis, or through patients being discharged earlier and being readmitted 
more frequently for the same episode of illness (Patel, Bell, Molokhia, et al., 2007). 
Studies from the United States have also shown readmission as an important contributor to 
rising rates of admissions in patients with SCD (Ballas & Lusardi, 2005a). This may also raise 
issues of how well hospitals are managing these patients (Maxwell, Streetly & Bevan, 1999a), 
and emphasises the importance of good discharge planning for these patients, which may 
minimise the risk of hospital readmission. Good discharge planning is a process that ensures 
strong and quality links between hospitals, primary and community care services, and patients 
and their carers. Effective discharge planning for those with SCD can support the continuity of 
health care for a patient as it links treatment received in the hospital to post-discharge care 
received in the community.  One future study could be an audit of hospital discharge forms to 
show the number of hospital discharge forms being sent to GPs and the level of follow up from 
the GP.    
The data from this study shows that SCD is a growing concern and provides a basis for further 
study.   This study highlights that the majority of patients admitted with SCD were discharged 
within 24 hours.  Further study could focus particularly on these admissions which may give a 
more precise indication of which ones could actually be addressed as preventable. Currently, 
our assumption is that the 24 hour and fewer admissions could potentially be prevented 
through better ambulatory and community care of patients, including better care in emergency 
departments. 
3.4. BRENT STUDY 
Our national finding that the majority of SCD admissions are discharged within 24 hours was 
also found in another study that we conducted in the London Borough of Brent which showed 
that 36% of SCD patient admissions in Brent resulted in a length of stay of less than 2 days and 
that 74% of total bed days are associated with patients with multiple admissions (Green, 
Aljuburi, Majeed, et al., 2012b). 
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FIGURE 10: EMERGENCY ADMISSIONS BETWEEN JANUARY 2008 AND JULY 2010 FOR SICKLE CELL 
CRISIS IN NHS BRENT BY THE FREQUENCY OF SPELLS FOR INDIVIDUAL PATIENTS ADMITTED (TOTAL 
NUMBER OF PATIENTS 77) 
 
Source: (Green, Aljuburi, Majeed, et al., 2012a) 
The objective of the local study was to characterise emergency admissions for patients with 
sickle cell crisis in NHS Brent. Brent was selected because it is considered one of the high 
prevalence areas for SCD (Hickman, Modell, Greengross, et al., 1999; Anon, 2005). This was an 
observational study and looked at emergency departments attended by residents of the London 
borough of Brent with the participants being patients with sickle cell disease registered with a 
general practitioner (GP) in the borough of Brent. We analysed admissions between January 
2008 and July 2010 that included length of stay (average and <2 days versus ≥2 days) by age 
group and registered GP practice. In addition to finding that 36% of sickle cell disease admission 
spells resulted in a length of stay of less than two days, we also observed that 74% of total bed 
days are associated with patients with more than one admission during the period of analysis, 
i.e. multiple admissions (Green, Aljuburi, Majeed, et al., 2012b). 
Both the national and local study suggested that a short length of stay and multiple admissions 
could suggest potentially avoidable hospital admissions. A 2013 Nuffield Trust observational 
study of hospital admission data showed that potentially avoidable hospital admissions make 
up one in every five emergency admissions in England (Blunt, n.d.) Potentially avoidable 
hospital admissions could benefit from better preventive and primary care interventions. 
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3.5. KEY POINTS FROM CHAPTER 3 
We conducted the first national study on trends for hospital admission rates for SCD using HES 
data in England. The data provided four main findings: 
1. The number of admissions due to SCD has increased substantially over the study period 
(2001-2010); 
2. The majority of admissions are in London; 
3. Most admissions were discharged within 24 hours; and 
4. There has been an increase in the number of admissions of middle-aged men. 
The Brent Observational study showed: 
1. Thirty-six percent of sickle cell disease admission spells resulted in a length of stay of 
less than two days; and 
2. Seventy-four percent of total bed days are associated with patients with more than one 
admission during the period of analysis, i.e. multiple admissions. 
Both studies suggest that some of these admissions may be potentially avoidable hospital 
admissions and could benefit from better preventive or primary care. 
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4. EXAMINING THE HES DATA FOR THE INFLUENCE OF 
SOCIOECONOMIC CHARACTERISTICS ON THE RISK OF SCD 
HOSPITAL READMISSION 
4.1. BACKGROUND AND AIM 
The first analysis of the HES data showed that admission rates for SCD in England are 
increasing; wide variations exist in admission rates amongst primary care trusts, especially in 
London (Aljuburi, Laverty, Green, et al., 2012a).  I noted in the previous chapter that there has 
been very little published about trends in SCD hospital admissions in England, but there has also 
been limited research which examined the influence of socioeconomic characteristics on the 
risk of SCD admission (Elandera, Beach & Haywood Jr, 2011). The aim of our next analysis was 
to investigate trends in the rates of emergency readmissions in England for patients with SCD, 
to determine inpatient mortality, and to assess whether there is an association between 
deprivation and comorbidity with risk of readmission and inpatient mortality (Aljuburi, Laverty, 
Green, et al., 2013a). 
4.2. METHODS AND RESULTS 
Data from a six-year period taken from the national HES database (April 2005 to March 2011) 
was analysed. The financial year 2005/06 was taken as the index year for this analysis, and all 
patients admitted with a primary or a secondary diagnosis of SCD in this year were identified 
and classed as SCD patients in our cohort. Secondary diagnoses are only meant to be coded if 
they are related to the reason for admission. For patients who were admitted more than once in 
the index year, their first admission was used as the index admission (Aljuburi, Laverty, Green, 
et al., 2013b). 
Pseudonimised patient identifiers were used to identify subsequent hospital admissions for the 
patients identified in the index year. Outcome variables used were emergency hospital 
admissions, in-hospital mortality, and emergency readmissions to hospital. Predictor variables 
used in this analysis were age group, sex, national deprivation group (based on Lower Super 
Output Area Index of Multiple Deprivation ranks for the whole of England) (Department for 
Communities and Local Government, 2011) from 1 (most deprived) to 4 (least deprived), 
whether the index diagnosis was a primary or secondary diagnosis for SCD, whether the index 
diagnosis was for an SCD crisis or not (among those with a primary diagnosis of SCD), and the 
Charlson comorbidity index score. The Charlson score classifies patients into groups depending 
on the number and severity of their comorbidities on admission, with higher Charlson scores 
reflecting patients having a higher risk of mortality within ten years (Charlson, Pompei, Ales, et 
al., 1987). For multivariate analysis, a combination diagnosis variable was created to compare 
those admitted with SCD as a secondary diagnosis, those admitted with a primary diagnosis of 
non- crisis, and those admitted with a primary diagnosis with crisis (Aljuburi, Laverty, Green, et 
al., 2013b). 
Descriptive statistics for the number of admissions and deaths in the index year were first 
produced and then summarised for study years individually. Cox proportional hazards models 
were used to examine the association between patient demographic variables and the likelihood 
of emergency admission over the time period as well as in-hospital mortality. For patients 
admitted more than once during the study period, only the first readmission was used. All of the 
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variables mentioned previously were used in these models. All statistical analyses were 
performed using the programme STATA® version 12. (Aljuburi, Laverty, Green, et al., 2013b) 
The characteristics of the patients admitted for SCD in 2005/06 (the index year) can be seen in 
Table 5 (n=7679). The majority (58.1%) live in the most deprived quartile of Lower Super 
Output Areas nationally, with only 9.5% of admissions coming from patients living in the least 
deprived quartile. The majority (65%) involved SCD as a secondary diagnosis, and among those 
admitted with SCD as a primary diagnosis, the majority were for an SCD crisis (73%). Overall, 
the percentage of deaths in the index year was low at 0.4%. Deaths were higher among those 
with SCD as a secondary diagnosis compared to primary diagnosis (0.6% vs. 0.1%), and among 
those with a Charlson comorbidity score of two or more than a Charlson score of zero (2.7% vs. 
0.1%) (Aljuburi, Laverty, Green, et al., 2013a). 
Figure 1 shows the unadjusted cumulative time to readmission curves by national deprivation 
group among those with a primary admission for an SCD crisis (n = 1,964). Patients in the least 
deprived group were less likely to be readmitted over the whole time period compared to all 
other levels of deprivation. For example, 39.6% of the patients in the most deprived group were 
admitted at least once within two years, compared to 20.2% for the least deprived group (data 
not shown). 
TABLE 5: CHARACTERISTICS OF PATIENTS ADMITTED AND INPATIENT MORTALITY WITH A PRIMARY 
OR SECONDARY DIAGNOSIS OF SICKLE CELL ANAEMIA WITH CRISIS OR SICKLE CELL ANAEMIA 
WITHOUT CRISIS IN THE INDEX YEAR (2005/06) 
  Number % Deaths % 
Age group 
Less than 1 142 1.8 0 0.0 
1 to 9 931 12.1 1 0.1 
10 to 19 1,122 14.6 1 0.1 
20 to 29 1,736 22.6 6 0.3 
30 to 39 1,739 22.6 6 0.3 
40 to 49 1,073 14.0 9 0.8 
50 plus 936 12.2 31 3.3 
Sex 
Male 3,049 39.7 32 1.0 
Female 4,630 60.3 22 0.5 
National deprivation 
group 
1 (Most deprived) 4,454 58.0 30 0.7 
2 (Second most deprived) 1,791 23.3 16 0.9 
3 (Second least deprived) 708 9.2 2 0.3 
4 (Least Deprived) 726 9.5 6 0.8 
Initial diagnosis 
Primary 2,681 34.9 9 0.3 
Secondary 4,998 65.1 45 0.9 
Index admission for 
crisis* 
Yes 1,955 25.5 6 0.3 
No 726 9.5 3 0.4 
Charlson comorbidity 
index 
0 6,265 81.6 10 0.2 
1 819 10.7 11 1.3 
>=2 595 7.7 33 5.5 
Total 7679  54 0.7 
*This includes only patients who had an initial primary diagnosis of SCD. 
Source: (Aljuburi, Laverty, Green, et al., 2013a) 
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National deprivation group 
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Time to first emergency readmission among crisis patients 
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Years since index admission 
FIGURE 11: TIME TO FIRST EMERGENCY RE-ADMISSION ACROSS NATIONAL DEPRIVATION GROUPS, 
AMONG PATIENTS WITH AN INDEX ADMISSION FOR AN SCD CRISIS 
 
Source: (Aljuburi, Laverty, Green, et al., 2013a) 
Table 6 shows the annual percentages of readmissions (n=7679) by the demographic variables. 
Over the whole period, those patients aged 10-19 years had the highest risk of readmission 
(65.5%), as did those with SCD as a primary diagnosis (74%) and those with an index admission 
for an SCD crisis (77.5%). Those in the national deprivation group 1 (most deprived) were more 
likely to have a readmission over the whole period than those in national deprivation group 4, 
the least deprived group (54.2% vs. 28.0%) (Aljuburi, Laverty, Green, et al., 2013a). 
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TABLE 6: PERCENTAGE OF PATIENTS WITH EMERGENCY READMISSION AFTER ADMISSION IN INDEX 
YEAR (2005/6) BY PATIENT CHARACTERISTICS, (N=7679) 
   2006/07 
 
2007/08 
 
2008/09 
 
2009/10 
 
2010/11 
 
Any year 
Age group 
Less than 1 35.9 26.9 28.3 24.1 21.4 55.9 
1 to 9 53.0 46.4 45.9 44.9 43.5 65.2 
10 to 19 33.8 27.7 27.6 26.7 25.5 65.5 
20 to 29 12.4 10.7 12.0 11.3 12.8 49.3 
30 to 39 11.9 8.5 8.7 7.3 7.0 42.8 
40 to 49 30.7 27.7 26.1 27.8 25.5 45.3 
50 plus 42.8 41.9 43.9 42.6 45.8 45.3 
Sex 
Male 31.1 27.2 26.3 25.8 25.4 54.6 
Female 24.4 21.1 22.1 21.3 21.4 49.0 
National 
deprivation 
group 
1 Most 
deprived 28.9 25.1 25.2 24.5 24.9 54.2 
2 Second 
most 
deprived 
 
28.3 
 
25.3 
 
24.7 
 
24.2 
 
24.2 
 
54.0 
3 Second 
least 
deprived 
 
25.0 
 
20.3 
 
23.2 
 
22.5 
 
18.2 
 
49.0 
4 Least 
deprived 14.6 12.7 13.5 12.3 13.3 28.0 
Initial 
diagnosis 
Primary 24.3 22.1 22.8 21.9 22.2 73.8 
Secondary 32.0 26.0 25.6 25.2 24.4 38.9 
Index 
admission 
for crisis 
Yes 49.1 44.7 46.0 43.6 44.4 77.5 
No 33.0 29.9 30.9 31.1 31.4 63.7 
Charlson 
comorbidity 
index 
0 26.8 23.7 24.3 23.8 23.7 50.7 
1 26.5 23.7 21.6 21.0 21.9 53.5 
>=2 30.8 21.3 21.3 17.8 17.0 52.9 
N 
admissions 
 2,076 1,805 1,826 1,772 1,767 3,932 
Source: (Aljuburi, Laverty, Green, et al., 2012a) 
Table 7 shows the annual in-hospital mortality by the demographic variables. Patients in the 
national deprivation group 1 were more likely to die in hospital over the whole period than 
those in national deprivation group 4 (2.7% vs 1.4%). Those with an index admission not for an 
SCD crisis were more likely to die than those with an index admission for a crisis (2.9% vs 
1.9%), and those with a Charlson score of two or more were most likely to die in hospital over 
the whole period (12.6% vs 1.1 for those with a score of zero) (Aljuburi, Laverty, Green, et al., 
2013a). 
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TABLE 7: PERCENTAGE OF PATIENTS WITH INPATIENT DEATH AFTER ADMISSION IN THE INDEX YEAR 
(2005/6) BY PATIENT CHARACTERISTICS, (N=7679) 
 
 
 2006/07 2007/08 2008/09 2009/10 2010/11 Any 
year 
Age group 
Less than 1 0 0 0 0 0 0 
1 to 9 0 0.1 0.1 0.1 0.1 0.4 
10 to 19 0.2 0.2 0 0.1 0.2 0.6 
20 to 29 0.2 0.2 0.2 0.1 0.2 0.9 
30 to 39 0.2 0.3 0.3 0.3 0.2 1.4 
40 to 49 0.7 0.6 0.6 0.7 0.6 3 
50 plus 3.1 2.8 2.5 1.6 1.3 10.8 
Sex 
Male 0.8 0.6 0.5 0.5 0.5 2.9 
Female 0.5 0.5 0.5 0.3 0.3 2.1 
National deprivation 
group 
1 Most 
deprived 
0.8 0.7 0.5 0.3 0.4 2.7 
2 Second 
most 
deprived 
0.4 0.4 0.6 0.6 0.4 2.4 
3 Second 
least 
deprived 
0.3 0.3 0.1 0.7 0.1 1.6 
4 Least 
deprived 
0.1 0.3 0.4 0.3 0.3 1.4 
Initial diagnosis 
Primary 0.3 0.4 0.6 0.5 0.4 2.1 
Secondary 0.7 0.6 0.5 0.3 0.4 2.5 
Index admission for 
crisis 
Yes 0.3 0.5 0.3 0.4 0.4 1.9 
No 0.4 0.1 1.2 0.8 0.3 2.9 
Charlson comorbidity 
index 
0 0.2 0.2 0.2 0.3 0.2 1.1 
1 1.2 1.4 1.1 0.6 0.3 4.5 
>=2 3.5 3 3.4 1.3 2.1 12.6 
N deaths  46 42 38 31 27 184 
Source: (Aljuburi, Laverty, Green, et al., 2012a) 
Results from the Cox proportional hazards models are given in Table 8. These show that, over 
the time period, those in national deprivation group 1 (most deprived) were more likely to be 
readmitted than those in national deprivation group 4 (least deprived) (hazard ratio (HR) 2.97, 
95% confidence interval (CI) 2.57-3.43). Those with a Charlson comorbidity score of two or 
more were more likely to be readmitted than those with a score of zero (HR 1.71, 95% CI 1.51-
1.94).  The 30-39 year old age group was selected as the reference group because it was the 
mid-point of the age range of the patients with SCD 
Those with a primary diagnosis of an SCD crisis were more likely to be readmitted than those 
with a secondary diagnosis of SCD (SCD as a comorbidity) (2.76, 95% CI 2.49-3.05), as were 
those with a primary diagnosis of a crisis (HR 2.99, 95% CI 2.78-3.21). For in-hospital mortality, 
those in national deprivation group 1 were more likely to die in hospital than those in national 
deprivation group 4 over the time period (Hazard Ratio (HR) 2.34, 95% CI 1.41-3.90), as were 
those in national deprivation group 3 (HR 2.00, 95% CI 1.16-3.46). Those with a primary 
diagnosis of SCD non-crisis were more likely to die in hospital than those with a secondary 
diagnosis of SCD (3.58, 2.25-5.68) as were those with a primary diagnosis of crisis (HR 3.04, 
95% CI 2.11-4.39) (Aljuburi, Laverty, Green, et al., 2013a). 
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TABLE 8: MULTIVARIATE MODELS FOR RISK OF EMERGENCY RE-ADMISSION AND INPATIENT 
MORTALITY IN THE SUBSEQUENT FIVE YEARS (N=7679) 
  Hazard ratio for 
admission 
Confidence 
Interval 
Hazard ratio for 
mortality 
Confidence 
Interval 
Age group Less than 1 1.47* 1.17; 1.85 Missing - 
1 to 9 1.42* 1.28; 1.59 0.33* 0.13; 0.85 
10 to 19 1.37* 1.24; 1.52 0.36* 0.16; 0.82 
20 to 29 1.1 1.00; 1.22 0.78 0.45; 1.35 
30 to 39 1 - 1 - 
40 to 49 1.1 0.98; 1.23 1.96* 1.22; 3.14 
50 plus 1.19* 1.05; 1.35 4.77* 3.12; 7.29 
Sex Male 1 - 1 - 
Female 1.07 1.00; 1.14 0.71* 0.55; 0.92 
National 
deprivation group 
1 Most deprived 1 - 1 - 
2 Second most 
deprived 
0.96 0.89; 1.03 0.84 0.62; 1.14 
3 Second least 
deprived 
0.84* 0.75; 0.94 0.49* 0.28; 0.86 
4 Least 
deprived 
0.34* 0.29; 0.39 0.40* 0.24; 0.68 
Charlson 
comorbidity index 
0 1 - 1 - 
1 1.40* 1.26; 1.55 3.51* 2.40; 5.11 
>=2 1.72* 1.51; 1.94 8.20* 5.84; 11.51 
Initial diagnosis Secondary 1 - 1 - 
Primary - non-
crisis 
2.76* 2.49; 3.05 3.58* 2.25; 5.68 
Primary – crisis 2.99* 2.78; 3.21 3.04* 2.11; 4.39 
* Statistically significant difference from reference category at p<0.05 
4.3. DISCUSSION 
4.3.1. HIGHER FREQUENCY OF SCD READMISSIONS SEEN IN AREAS OF INCREASED 
SOCIOECONOMIC DEPRIVATION 
There is a higher frequency of SCD readmissions in areas of increased socioeconomic 
deprivation. Some of the readmissions we observed may be due to new hospital episodes, but 
we still observed lower rates in less deprived places. The majority of readmissions (over 58%) 
and highest inpatient mortality occurred in patients living in the most socioeconomically 
deprived areas; the highest risk of admission was seen in patients aged 10-19 years and the 
highest risk of death was in people aged >50. Death rates were higher in those with a Charlson 
score of 2 or more, suggesting death rates are higher in patients with increased comorbidities 
(who are also likely to be older) (Aljuburi, Laverty, Green, et al., 2013a). This is consistent with 
studies that have shown that patients who live in high poverty neighbourhoods are 24% more 
likely to be readmitted than others (Hu, Gonsahn & Nerenz, 2014). 
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4.3.2. RELATIONSHIP TO CURRENT LITERATURE 
Much remains unclear about the influence of socioeconomic status on SCD. However, the wider 
socioeconomic status (SES) and chronic disease literature indicates a number of ways in which 
those coming from the most deprived sector may experience increased hospital readmissions, 
excess in-patient mortality, and consequent inequalities in health care (Saxena, Eliahoo & 
Majeed, 2002). 
According to the 2001 United Kingdom census, 4.6 million or 7.9% of the total population of the 
UK belonged to ethnic minority groups. Indians were the largest minority group (1.8%), 
followed by Pakistanis (1.3%), those of mixed ethnic backgrounds (1.2%), Black Caribbeans 
(1.0%), Black Africans (0.8%) and people from Bangladesh (0.5%). The issue of health 
inequalities towards black, ethnic and minority (BME) populations has been recognised for 
some time, and in recent years, there has been an effort towards addressing such inequalities 
(Mackenbach, 2006). 
4.3.3. MINORITY DISEASE AND CHRONIC DISEASE 
Sickle cell disorders in England occur almost exclusively amongst BME populations, and these 
disorders have received relatively low priority from health policy makers because they are seen 
as minority diseases (Anionwu & Atkin, 2001). However, not only is SCD a minority disease, it is 
a chronic disease. Those suffering from chronic diseases such as diabetes, asthma, and 
cardiovascular disease also suffer from inequalities in health care treatment such as ineffective 
therapy and poor disease control (Wagner, 1997, 1998). Therefore, those with SCD as a chronic 
disease have the added stress of minority and socioeconomic disadvantage. Income levels for 
South Asians and African-Caribbean people working in the UK are lower than the UK average 
and their unemployment rates are about double those of white populations, which means that 
people with SCD are statistically more likely to be battling a combination of chronic disease, a 
disease that affects primarily minorities, and economic disadvantage (Anionwu & Atkin, 2001). 
The Marmot Review stated that socioeconomic inequalities affect health outcomes and 
confirmed that those who are worse off financially also do worse on health outcomes. 
Socioeconomic influencers are the factors that have the greatest impact on health, i.e. 40% of all 
influences, as compared to health behaviours (30%) and the physical environment (10%) 
(Marmot & Bell, 2012). The 2013 Nuffield Trust observational study of hospital admission data 
showed that the level of deprivation in an area is also strongly linked to rates of potentially 
avoidable hospital admissions (Blunt, n.d.). I wanted to show a similar link between the 
influence of socioeconomic characteristics and the risk of SCD hospital admissions. 
Studies have found that, in general, the causes of hospital readmission for patients with SCD 
include premature discharge, withdrawal syndrome, and the occurrence of new acute (sickle 
cell crisis) episodes (Ballas & Lusardi, 2005b). Another study found that low income is 
associated with greater emergency department use for SCD pain both in countries with and 
without universal health care coverage (Glassberg, Wang, Cohen, et al., 2012). Socioeconomic 
status may also influence the way health care providers manage chronic disease. A study by 
Struthers et al. (2000) showed an increased rate of hospital readmissions in those with lower 
socioeconomic status for congestive heart failure, independent of disease severity (Struthers, 
Anderson, Donnan, et al., 2000). The researchers suggest that this may be due to a number of 
reasons which include primary care providers in deprived areas having less time to invest in 
adequate disease management. Primary care providers working in deprived areas may also 
perceive their patients as having less capacity to understand and manage their own condition 
(Haque & Telfair, 2000), and patients living in deprived areas may perceive that their 
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community medical resources are insufficient to manage them and ‘push’ for hospital admission 
(Blair, Lloyd-Williams & Mair, 2002; Struthers, Anderson, Donnan, et al., 2000). 
Another factor that may contribute to increased SCD readmissions, particularly amongst the 
most deprived patients, is patient self-discharge. A study in England found that 14% of the 
sample of SCD patients reported having self-discharged from hospital. The most common 
reasons given by the SCD patients for self-discharging were being ‘tired of waiting for pain 
relief’, potential conflicts related to suspected analgesics abuse, and because they just simply 
wanted to go home (Elander, Lusher, Bevan, et al., 2004). Ballas and Lusardi (2005) also suggest 
that the decision by the patient to leave the hospital may be due to family pressure, childcare, or 
fear of job loss if the patient is employed (Ballas & Lusardi, 2005b). A similar study published in 
the US found a much higher rate with 46.5% of their sample of SCD patients discharging 
themselves from hospital (Haywood Jr, Lanzkron & Ratanawongsa, 2011). 
In this particular study, we were also unable to evaluate the impact of severity of SCD disease 
which may contribute to the risk of readmission and inpatient mortality, as information on this 
is not included in the HES. We also know that, in the UK, patients with SCD are a mobile 
population, especially in the young adult group who may be students temporarily resident in 
low prevalence/least deprived areas. Their readmissions may therefore be elsewhere in the UK 
(i.e. Wales, Scotland or Northern Ireland) or beyond and could have had an impact on reported 
readmissions. A future study may focus on what the secondary diagnoses were that led to 
patient deaths and if they are linked to primary diagnosis of SCD or unrelated. We also did not 
examine post-discharge factors that could influence the risk of admission. These factors include 
the characteristics of the home environment and the quality and continuity of health care of 
patients after they have been discharged from hospital, including use of community/primary 
care facilities. Incorporating the impact of post-discharge factors on readmission (Arbaje, Wolff, 
Yu, et al., 2008) may have provided further explanation into the pattern of SCD readmissions. 
(Aljuburi, Laverty, Green, et al., 2013a). 
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4.4. KEY POINTS FROM CHAPTER 4 
1. The groups at highest risk of readmission were patients living in the most 
socioeconomically deprived areas (54.2%). 
2. Inpatient mortality amongst readmissions was highest in patients living in the most 
deprived areas. 
3. SCD patients from the most socioeconomically deprived areas and with comorbidities 
are at highest risk of both SCD readmission as well as in-hospital mortality, suggesting 
that there are inequalities in health care access and health outcomes amongst people 
with SCD. 
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5. HOSPITAL ADMISSION COSTS 
5.1. BACKGROUND 
Previous chapters showed trends in admissions and socioeconomic impact on admissions due 
to SCD in England. Both trends demonstrate a burden on the health care system from a disease 
perspective, but critical to any analysis of the burden of disease is the cost associated with such 
admissions. Globally, we are seeing a growing burden when it comes to SCD-associated costs. 
One rationale is that this is partially due to advances in research and science that have increased 
the life expectancy of patients living with SCD (Weatherall, 2010) and additionally because SCD 
patients receive care in acute care facilities, including emergency departments (Nietert, 
Silverstein & Abboud, 2002) under circumstances that could potentially be curbed through 
preventive care or treated at the primary care level. SCD care in the United States amounts to 
over $1.1 billion in healthcare expenditures annually (Kauf, Coates, Huazhi, et al., 2009); 
paediatric medical costs from SCD each year are estimated to be at least $335 million (Kauf, 
Coates, Huazhi, et al., 2009). Medical expenditures for children with SCD are up to eleven times 
that of a child without SCD (Amendah, Mvundura, Kavanagh, et al., 2010a). In my research on 
England, I noticed that we had very little published on what the cost is for a typical hospital visit 
for a patient with SCD.   This became for me an important part of the full picture along with the 
2013 Nuffield Trust observational study showing that hospital admissions for potentially 
avoidable conditions have been growing over the last ten years and account for an estimated 
£1.4 billion a year (Blunt, n.d.). 
5.2. AIM AND OBJECTIVE 
The aim was to assess the costs associated with hospital admissions in England for SCD.  By 
doing so, we can more accurately link the impact of SCD on the NHS. 
 
The objective is that expenditures associated with SCD can also be used to raise awareness of 
the severity of this condition and serve as a basis for exploring innovations in prevention or 
management strategies for SCD complication. 
 
5.3. METHODS 
Unlike NICE, our cost study used HES data, the same data set that we used to understand trends 
in SCD and its link to socioeconomic deprivation. We limited the cost study to the period from 
April 2010 to March 2011. The analysis was carried out at the national level for England and the 
results are reported for England, London and London PCTs. We used ICD-10 coding with the 
following primary diagnoses: 
 Sickle cell anaemia with crisis (D57.0) 
 Sickle cell anaemia without crisis (D57.1) 
 Double heterozygous sickling disorders (D57.2) 
 Sickle cell trait (D57.2) 
 Other sickle cell disorders (D57.2-8) 
HES data contain a number of administrative and demographic variables on patients admitted 
to hospitals and their healthcare providers. These variables, which can be seen in Table 9, 
include the patients’ Primary Care Trust (PCT), their Strategic Health Authority (SHA), their sex, 
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ethnicity, age, length of hospital stay as well as whether the admission was emergency or 
elective (Pizzo, Laverty, Phekoo, et al., 2014). As in our other analyses of the HES data which 
helped identify trends in admissions, The ICD-10 codes above were used to split admissions into 
two groups: 
 Sickle cell crisis (D57.0), or 
 Sickle cell without crisis (D57.1-8) 
As data regarding the cost and resource consumption for SCD admissions were not available, we 
used the Healthcare Resource Group (HRG) tariffs as a proxy of costs. HRGs form the basic 
currency for payment of NHS services by relying on an informed assumption that health care 
costs are exclusively driven by diagnosis or procedure. The English HRG tariffs provide cost data 
for elective and non-elective hospital episodes and additional per diem cost for very long stays 
that exceed the so-called ‘trim point’, which marks the expected length of stay (LOS) for each 
HRG. Estimated costs are reported as a national schedule of reference costs and are also 
aggregated by hospital to provide the reference cost index (Street & Dawson, 2002; Geue, 
Lewsey, Lorgelly, et al., 2012). 
This was a first attempt to assess the cost of admissions due to SCD using the HES data. The 
available HRG tariffs for SCD are coded as (Table 10): 
 PA47Z Sickle cell anaemia with crisis (for paediatric admissions); 
 SA10D Sickle cell anaemia with complications (CC) (including SCD with crisis); 
 SA10F Sickle cell anaemia without complications (CC) (Pizzo, Laverty, Phekoo, et al., 
2014). 
Because there are no specific tariffs for each ICD-10 code, we made certain assumptions: 
a. ICD-10 ‘Sickle cell anaemia with crisis’ (D57.0) is linked to HRG PA47Z ‘Sickle cell 
anaemia with crisis’ for paediatric admissions (age between 0-19 years); 
b. ICD-10 ‘Sickle cell anaemia with crisis’ (D57.0) is linked to HRG SA10D ‘Sickle cell 
anaemia with CC’ for adult admissions (age >20 years); 
c. ICD-10 ‘Sickle cell anaemia without crisis and other sickle cell disorders (D57.2-8) might 
be linked with HRG code SA10F ‘Sickle cell anaemia without CC’ (Pizzo, Laverty, Phekoo, 
et al., 2014). 
All admissions where SCD did not appear as a primary diagnosis were eliminated from this 
analysis. We saw many episodes in which SCD appears as a secondary, tertiary or further 
underlying diagnosis. We understand that even if the main cause of admission is not an SCD 
crisis, the disease’s underlying characteristics may have predisposed the patient to be admitted 
to hospital or increased the risk of comorbidity or complications. We excluded all of these 
episodes. This underestimated the cost of admission linked to SCD, but we elected to engage a 
conservative approach which excluded any costs that were not seen to be direct linked to SCD. 
Both emergency and elective admissions were analysed in isolation. They have different tariffs 
and by analysing elective and emergency separately, we were able to show the impact of 
emergency admissions due to SCD (Pizzo, Laverty, Phekoo, et al., 2014). 
The LOS for each admission was also considered in order to assess hospital costs that exceeded 
the trim point of the HRG tariff. The trim point identifies the LOS covered by the tariff, after 
which an extra daily payment is required for each specific HRG. The trim points vary according 
to the type of HRG and type of admission (emergency versus elective admission) and extra days 
carry an extra cost. For HRG PA47Z Sickle cell anaemia with crisis, the trim point is 9 days for 
emergency admissions and 8 days for elective admissions; for HRG SA10D Sickle cell anaemia 
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with CC1, the trim point is 30 days both for emergency and elective admissions (Appendix 1). 
Therefore, an LOS exceeding the trim point will increase the cost by £234 for each extra day for 
paediatric admissions and £204 for adult admissions. When we refer to the total cost of 
admissions for SCD, this amount is the combined sum of the cost of admissions in emergency 
and elective for both paediatrics and adults (Pizzo, Laverty, Phekoo, et al., 2014). 
When we refer to the cost of extra LOS for admissions associated to SCD, this is the difference 
between the number of days spent in hospital (LOS) and the trim point from the HRG tariff. The 
total number of days in hospital exceeding the trim point is multiplied by the daily extra cost 
(£234 per day for paediatric admissions and £204 for adults). The total cost of extra LOS is the 
sum of the extra cost of LOS of emergency and elective admissions for both paediatrics and 
adults (Pizzo, Laverty, Phekoo, et al., 2014). 
5.4. RESULTS 
In 2010-2011, England had 6,077 admissions associated with SCD with crisis as a primary 
diagnosis. The total cost for these admissions was £18,798,255. Ninety-one percent (91%) of 
these costs were due to emergency admissions (Table 9). Adult admissions represent 84.5% of 
all admissions, representing a cost of £14,370,931 for emergency admissions. Admissions for 
children represent 15.5% of total admissions, and the cost of emergency admissions was 
£2,714,357. The NICE report estimated £16.2 million in costs (Anon, 2012) and our study 
estimated approximately £17.1 million in costs. Our study would have likely found even a 
greater cost burden had we taken into account all of the day case activities (which the NICE 
report did) or admissions that have SCD with crisis as a secondary, tertiary or further diagnosis 
which explains the cost discrepancy between our study and the NICE report. The approximately 
£1 million difference in cost estimation is likely due to the different data set used and/or the 
different time period. Neither study had a standard to go by (Pizzo, Laverty, Phekoo, et al., 
2014). 
In total, the LOS exceeded the trim point by 1,144 days, for an extra cost of £294,697 (93.1% for 
emergency admissions) (Table 9). For emergency admissions, the extra LOS is 438 days for 
children and 624 days for adults, for an added cost of £274,104. Because the tariff for children 
has a shorter trim-point compared to adults (9 days instead of 30 days) and an extra day costs 
more, long admissions for children represent a higher cost in terms of LOS (Pizzo, Laverty, 
Phekoo, et al., 2014). 
Within England, London had the highest number of admissions associated with SCD, with 4,363 
admissions for SCD crisis as the primary diagnosis at a total cost of £14,223,139, of which 
£13,984,884 were for emergency admissions (89.9%) (Table 9). In line with the national data, 
adults represent 87.1% of total admissions and children account for 12.9%. London accounts 
for 75.6% of all of England’s costs for admissions associated to SCD and 80.8% of all of 
England’s days beyond the trim point (extra days). This is consistent with our previously 
published analysis measuring trends for admissions related to SCD (Aljuburi, Laverty, Green, et 
al., 2012a). Table 10 shows a summary for all PCTs in England, with the cost of admissions for 
SCD and the rate of admissions every 100,000 (Pizzo, Laverty, Phekoo, et al., 2014). 
  
                                                             
1 Haemoglobin C Disease 
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TABLE 9: COSTS FOR ADMISSIONS AND EXTRA LOS ASSOCIATED WITH SICKLE CELL ANAEMIA WITH 
CRISIS (ICD-10 D57.0) IN ENGLAND AND LONDON, 2010-11 
Admissions (England) Emergency Elective Total 
admissions 
D57.0 primary diagnosis admissions (total) 5,514 563 6,077 
D57.0 primary diagnosis admissions 
(paediatrics) 
1,462 154 1,616 
D57.0 primary diagnosis admissions (adults) 4,052 409 4,461 
HRG tariff PA47Z (to be adjusted by MFF) £1,534 £1,210  
HRG tariff SA10D (to be adjusted by MFF) £2,959 £2,950  
Total cost for admissions £17,085,288 £1,712,966 £18,798,255 
Long stay trim point (days) for paediatric 9 8  
Long stay trim point (days) for adults 30 30  
Total days exceeding the trim point 
(paediatrics) 
438 7 445 
Total days exceeding the trim point (adults) 624 75 699 
Per day long stay payment (for days exceeding 
trim point) paediatrics (£) 
£234 £234  
Per day long stay payment (for days exceeding 
trim point) adults (£) 
£204 £204  
Total cost for extra LOS £274,104 £20,592 £294,697 
Admissions (London) Emergency Elective Total 
admissions 
D57.0 primary diagnosis admissions (total) 3911 452 4363 
D57.0 primary diagnosis admissions 
(paediatrics) 
877 107 984 
D57.0 primary diagnosis admissions (adults) 3034 345 3379 
Total cost for admission in London £12,788,339 £1,434,799 £14,223,139 
Long stay trim point (days) for paediatric 9 8  
Long stay trim point (days) for adults 30 30  
Total days exceeding the trim point 
(paediatrics) 
246 5 251 
Total days exceeding the trim point (adults) 586 75 661 
Total extra cost for extra LOS in London £218,153 £20,101 £238,254 
Source: our elaboration using HES data and HRG tariffs 2010-2011 (Pizzo, Laverty, Phekoo, et al., 2014) 
There was high variability in the number of admissions across PCTs in England, but City and 
Hackney was the PCT with the highest number and the highest costs in 2010-2011, followed by 
Haringey and Brent (Appendix 1). In these PCTs, the rate of SCD admissions was the highest in 
England, i.e. 346.67 and 153.38 for every 100,000 people, respectively. City and Hackney also 
had the highest costs associated with LOS beyond the trim point, followed by Redbridge and 
Westminster (Appendix 1). Outside London, Luton was the PCT with the highest rate of SCD 
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admissions (39.41 every 100.000), followed by Nottingham (32.47), Manchester (20.01) and 
South Birmingham (20.10) (Appendix 1) (Pizzo, Laverty, Phekoo, et al., 2014). 
TABLE 10: COST OF NON-ELECTIVE ADMISSIONS 
Healthcare Resource Group Number of 
Admissions 
Cost of Non-Elective 
Admissions (£’000) 
PA47Z Sickle cell anaemia with 2,489 4,198 
SA10E Sickle cell anaemia with crisis 
or with co-morbidities 
7,714 11,367 
SA10F Sickle cell anaemia without 
co-morbidities 
906 637 
Total 11,109 16,202 
 
The regression models performed to check whether age and gender are significantly associated 
with SCD costs showed that admissions in adults cost more than in children (Table 11). The 
total cost increases with age: admissions in age<9 and age 10-19 cost £1,740 and £1,686 
(p<0.001) less compared to age 20-29; admissions costs £65 more in the group age 30-49 
compared to 20-29. There was no statistically significant difference in the cost for patients over 
50 years. 
Admissions were more costly for males than females, but the differences are not statistically 
significant. The results for London are similar to those for the rest of England (Pizzo, Laverty, 
Phekoo, et al., 2014). 
TABLE 11: REGRESSION OF TOTAL COSTS OF ADMISSION ON AGE AND SEX AT THE NATIONAL LEVEL 
AND LONDON LEVEL ONLY 
National 
 
 
 
Geometric mean cost (£) Comparison (as % of reference group costs) p-value 
Age <1 1758 50.26 <0.001 
1 to 9 1732 49.53 <0.001 
10 to 19 1812 51.83 <0.001 
20 to 29 3499 ref ref 
30 to 39 3564 101.87 <0.001 
40 to 49 3565 101.94 <0.001 
50+ 3535 101.10 0.194 
Sex Men 3021. ref ref 
Women 2854 99.59 0.195 
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London 
 
Geometric mean cost (£) Comparison (as % of reference group costs) p-value 
Age 
<1 1828 50.27 <0.001 
1 to 9 1804 49.61 <0.001 
10 to 19 1881 51.71 <0.001 
20 to 29 3636 Ref ref 
30 to 39 3640 100.11 <0.001 
40 to 49 3638 100.03 <0.001 
50+ 3622 99.55 0.605 
Sex Men 3182 Ref ref Women 3052 100.36 0.278 
Source: (Pizzo, Laverty, Phekoo, et al., 2014) 
The logistic regression to examine the association between age and gender on incurring extra 
bed days shows that patients 10-19 years old are much more likely to incur an extra bed days 
(odds ratio of 8.3 with p<0.001) compared to patients aged 20-29 years old. The results for 
other age groups and for gender did not show statistically significant differences (Table 12) 
(Pizzo, Laverty, Phekoo, et al., 2014). 
TABLE 12: LOGISTIC REGRESSION OF THE ASSOCIATION BETWEEN AGE AND GENDER ON INCURRING 
EXTRA BED DAYS AT THE NATIONAL LEVEL AND LONDON LEVEL 
National 
 
% staying extra days Odds Ratio p-value 
Age 
<1 0 - - 
1 to 9 1.31 1.26 0.576 
10 to 19 8.08 8.38 <0.001 
20 to 29 1.04 Ref ref 
30 to 39 1.11 1.07 0.834 
40 to 49 0.93 0.90 0.8 
50+ 1.27 1.22 0.745 
Sex Men 1.98 Ref ref Women 2.47 1.00 0.985 
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London 
 
% staying extra days Odds Ratio p-value 
Age 
<1 0 - - 
1 to 9 0.82 0.54 0.316 
10 to 19 8.1 5.65 <0.001 
20 to 29 1.47 ref ref 
30 to 39 1.26 0.84 0.616 
40 to 49 0.85 0.56 0.24 
50+ 1.7 1.09 0.895 
Sex Men 1.78 ref ref Women 2.73 1.35 0.162 
Source: (Pizzo, Laverty, Phekoo, et al., 2014) 
5.5. DISCUSSION 
My research showed that the studies that assess the cost of SCD are either primarily referring to 
children, not appropriately updated, or have been conducted in the United States (Amendah, 
Mvundura, Kavanagh, et al., 2010b; Ballas, 2009; Bilenker, Weller, Shaffer, et al., 1998; Kauf, 
Coates, Huazhi, et al., 2009; Nietert, Silverstein & Abboud, 2002). Studies conducted in the 
United States show that patients with SCD who are frequently admitted to emergency 
departments account for the majority of health care expenses associated with the disease 
(Carroll, Haywood & Lanzkron, 2011). 
In England, the National Institute for Health and Clinical Excellence (NICE) has assessed, 
according to guidelines, the costs (and potential savings) attributed to managing an SCD acute 
painful episode (Anon, 2012). The cost savings may vary significantly depending on current 
practice and measuring the local prevalence of SCD. The NICE costing report for SCD provides 
an estimate for the cost of admission for ‘sickle cell anaemia with crisis’ in children and adults 
according to the National Schedule of Reference costs in 2010/11. The national schedules of 
reference costs show the national average unit cost for each service for which costs were 
collected in 2010-11. According to the report, the approximate total cost to the NHS of these 
admissions and some day-case activity was approximately £16.2 million. This total did not 
include elective admissions and showed a resulting estimate at £589 per day for children and 
£456 per day for adults. The costs were based on NHS Reference Costs for 2010/2011, but it 
was not clear if the period 2010-2011 was a calendar or fiscal year (Pizzo, Laverty, Phekoo, et 
al., 2014). 
In our study, the admissions having SCD with crisis as a primary diagnosis represented 92.5% of 
all admissions for SCD with crisis (including also secondary, third, fourth and fifth diagnosis), so 
almost 7.5% of admissions are not included here. Assuming we can apply the same HRG tariffs 
for the excluded admissions (those after the primary diagnosis), the total cost for admissions 
linked to SCD with crisis will increase to £20,376,822, a difference of £1,578,567 (Pizzo, Laverty, 
Phekoo, et al., 2014).  Our study also showed that the cost of admissions in adults cost more 
than in children but that those aged 10-19 years are more likely to incur longer hospital stays. 
The other 13,589 admissions were linked to SCD without crisis (ICD-10 codes D57.1-8) as the 
primary or further diagnosis, but the cost for these admissions was not taken into account in 
this study. We cannot accurately estimate the cost of these admissions without knowing the 
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HRG tariff applied when the patient was discharged. However, the primary diagnosis of these 
admissions was mainly for SCD without complications, anaemia, respiratory infections and 
asthma. Taking into account that 25% of these admissions were in the emergency department, 
the cost of admissions for SCD is even higher (Pizzo, Laverty, Phekoo, et al., 2014). 
The bottom line is that, in England, we are spending well over £16.1 million a year on hospital 
costs due to SCD and that approximately 90% of these costs are emergency admissions. 
Furthermore, over three-fourths of these admissions occur in London.   This information can be 
of great value to health economists, policy makers and commissioners.  From a policy 
perspective, the combination of trends and costs related to SCD should raise a red flag as to how 
we are managing this disease. It may be a disease minor in nature compared to other chronic 
diseases and one predominantly affecting minorities, but from a cost and efficiency perspective, 
SCD has a major impact on emergency hospital admissions and costs to the NHS.   
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5.6. KEY POINTS FROM CHAPTER 5 
1. This is the first study in England to try to assess the cost of a hospital admission due to 
SCD using HES data. 
2. In 2010-2011, England had 6,077 admissions associated with SCD with crisis as the 
primary diagnosis. The total cost for these admissions for commissioners was 
£18,798,255. 
3. Over 90% of hospital admission costs were for emergency admissions. 
4. London accounts for over 75% of all of England’s costs for admissions associated with 
SCD. 
5. SCD represents a significant cost for commissioners and the NHS. SCD patients must be 
managed better in order to potentially lead to a reduction in admissions and length of 
stay and associated costs. 
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6. TRANSLATING RESEARCH INTO PATIENT CENTRIC CARE 
6.1. BACKGROUND AND OBJECTIVE 
The first four studies within this thesis look at trends and costs of SCD management. The next 
two studies focus on patient input.  One clear objective of patient participation is to help 
translate research into more patient-centric care. In fact, achieving patient-centric care has been 
a primary motive behind the majority of CLAHRC-funded projects (Renedo & Marston, 2011), 
including our project on SCD. (Parsons, 2010).  
Based on the findings from the trends pieces, we are better able to see what the impact of 
disease is and what areas would be considered high prevalence.  Using these high impact areas, I 
looked at the use of focus groups and patient questionnaires as methods for patient engagement 
in the design of health services that would be targeted to such areas. 
6.2. FOCUS GROUPS AS A METHOD FOR PATIENT ENGAGEMENT IN THE 
DESIGN OF SERVICES 
6.2.1. BACKGROUND 
Focus group discussions are one of the methods that have been used to obtain patient 
involvement in design of health services and can be particularly useful for people with long term 
or chronic diseases. They provide a forum for a broad range of participants to express their 
concerns about the quality of care they receive from their care providers, their opinions on what 
the role of their care providers should be in managing their disease and to discuss their 
perceived barriers to utilising different level of care services (Underutilised, In & 1987;14:411–
48, n.d.). 
Furthermore, focus groups can provide a space for an open dialogue tailored to the level of the 
participants (Kitzinger, 1995) and allow the facilitator to clarify and push for more detailed 
responses to enrich the understanding of the issues (Wong, 2008). The use of a focus group as a 
data collection technique can be particularly useful with SCD to ensure sensitivity to cultural 
variables, which is why they are now so often used in cross-cultural research and work 
particularly well with ethnic minorities. SCD is a disease that disproportionately impacts people 
of African and Caribbean origin; the focus group setting allows the patients to reveal the 
frustration felt as an ethnic minority receiving health care services for a predominantly race-
related disease. 
Consequently, it makes them useful in studies examining why different sections of the 
population make differential use of health services (Underutilised, In & 1987;14:411–48, n.d.; 
Kitzinger, 1995). The group dynamic also works to facilitate the discussion of difficult or 
uncomfortable topics because the less reserved members of a focus group can ‘break the ice’ for 
the more reserved participants (Kitzinger, 1995). Some researchers have also noted that group 
discussions can generate more criticism of the health care system than interviews (Watts & 
Ebbutt, 1987). For example, Geis et al. found in their study that ‘there were more angry 
comments about the medical community’ in the group discussions than in the individual 
interviews: ‘perhaps the synergism of the group “kept the anger going” and allowed each 
participant to reinforce another's vented feelings of frustration and rage’ (Geis, Fuller & Rush, 
1986). Some researchers argue that focus groups are limited in their ability to draw inferences 
for large groups or populations and their incapacity to test hypotheses in traditionally designed 
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experiments (Heary & Hennessy, 2002). Others have also claimed that focus groups can lead to 
‘tagging’ which means that participants agree for the sake of the group’s momentum and that 
with regards to more sensitive topics, interviews worked better because the participant feels a 
greater level of anonymity than when part of a group discussion (Heary & Hennessy, 2002). 
Such points show that the use of focus groups may be subject to bias and need to be individually 
evaluated (Wong, 2008). Focus groups may not add value to every study but can work well 
when combined with other forms of qualitative and quantitative methods (Morgan, 1997; Heary 
& Hennessy, 2002). In general, however, qualitative methods such as interviews and focus 
groups help to determine what matters to people so that services are designed to better meet 
these needs (NHS England, 2013). 
6.2.2. METHOD AND RESULTS 
We sought to engage SCD patients and carers in designing a local intervention aimed at better 
educating general practitioners on SCD through the use of a focus group discussion. On 12th 
August 2010, we held a focus group discussion at the Sickle Cell Society in the London Borough 
of Brent. We aimed to identify patient and carer perspectives of GP knowledge and treatment of 
SCD, and to identify areas in which improvements could be made in its coordination. 
The discussion lasted for approximately two hours. The participants were recruited through the 
Sickle Cell Society in Northwest London and comprised people of a mixture of ages and genders. 
Specifically, the group was made up of ten patients; two males and eight females, aged 9-56 
years, all of African/Afro-Caribbean heritage. The focus group was held at the Sickle Cell Society, 
which is conveniently located to where many people with SCD live. The location is also a 
familiar meeting point where all of the participants felt secure and at ease to voice their 
opinions. The focus group participants were recruited through a purposive sampling process 
which aimed to canvas the views of sickle patients and carers living within the specific locality 
in which the service improvement and evaluation work was being undertaken. Participants 
were recruited via the Sickle Cell Society, a national UK sickle cell charity, through a general 
mail out to members of the charity living within this area with information about the study. This 
was subsequently followed up by a telephone call (from Comfort Ndive of the Sickle Cell 
Society) to assess interest in participating in the focus group. The discussion was facilitated by a 
clinical psychologist (Dr. Kofie Anie) from a local NHS Trust experienced in handling patients 
with SCD who explained the aims of the project to the participants; and who then asked the 
participants questions regarding their personal experience with primary health care in London. 
The questions were open-ended and focused on general practice utilisation, what patients do 
first when they are in an SCD crisis, and overall satisfaction with primary care. Eleven observers 
from the project group were present; two were scribes. As well as making written notes, the 
discussions were also video recorded (AlJuburi, Phekoo, Okoye, et al., 2013b). 
The key themes used to explore the participants perceptions and aspirations regarding primary 
care services for SCD are listed in Table 13. The participants were also encouraged to raise their 
own concerns about SCD management. Following the focus group, the project team (Ghida 
AlJuburi and Dr. Karen Phekoo) read the transcripts independently and grouped the responses 
into key themes that would help inform planning of future SCD services. Each item in the data 
collected during the discussions was compared with the rest of the data to establish analytical 
groups. Consensus regarding categories and a final list of key themes identified during the 
discussions was achieved iteratively through discussion and re-reading of transcripts. As we 
aimed to present viewpoints, the data are not presented numerically (AlJuburi, Phekoo, Okoye, 
et al., 2013b). 
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TABLE 13: KEY THEMES USED TO GENERATE GROUP DISCUSSION 
 Frequency in accessing GP care for managing a crisis 
 Satisfaction level with primary health care services 
 Current use of primary health care services 
 What do you do first when in an SCD crisis? 
The transcripts and recordings were reviewed to identify common perceptions and experiences 
among the participants. 
Accessibility 
GP access was an important issue. The participants highlighted that difficulty in obtaining an 
appointment with the GP and long waiting times led to patients’ sidestepping their GP in the 
event of a painful crisis or other issues relating to SCD. Although GPs were seen as useful for 
prescribing antibiotics and other repeat prescriptions, they were seen to be unreliable during 
crises. Hospitals were seen to be more accessible. Participants proposed that GPs should offer 
more ‘out of hours’ and house calls for pain management, since many crises occur at night 
(AlJuburi, Phekoo, Okoye, et al., 2013b). 
I cannot walk in [to a General Practitioner’s office] and I even if I could, I probably won’t be 
able to see a GP immediately, so I go straight to the hospital if I am sick. 
Doctor-Patient Relationships 
Participants raised the issue of the lack of time to build up rapport and relationships with their 
GPs. This left patients with SCD with a feeling of dissatisfaction with the quality of the doctor-
patient relationship. They felt that GPs were not actively interested or engaged in the progress 
and treatment of their condition. They encouraged GPs to take a proactive approach and 
interest in getting to know their SCD patients and to focus on preventive care, including 
preventive management of crises (AlJuburi, Phekoo, Okoye, et al., 2013b). 
If I take my son to hospital now, the doctors like to have a relationship and know how he is 
doing. If I take him to the GP there is no relationship; he is a stranger. 
[You have a] five minute conversation with the GP. You are in and out. I prefer to go to the 
hospital, I know them there. I am safe. My nurse knows me. 
I know my GP, but does he really know me? I go to the hospital. They know me. 
GP Knowledge 
There was a general feeling amongst the participants that GPs lack comprehensive knowledge of 
SCD, and the hospitals were viewed as more specialised in dealing with the condition. They 
expressed an interest in seeing GPs better informed about SCD, and its implications for 
management. One participant suggested a GP SCD ‘champion’ or specialist who could further 
inform their health professional colleagues about SCD. Another participant added that GPs who 
are not specialised in SCD need to be briefed by an expert before seeing an SCD patient in the 
surgery (AlJuburi, Phekoo, Okoye, et al., 2013b). 
They take time to know about other diseases; I feel my disease is not important, I feel I am 
not important. 
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Concerns about Pain Management & the Treatment Process 
Because of the organisational barriers previously mentioned, many of the participants had 
difficulty in seeing the benefit of utilising a GP during an uncomplicated sickle crisis. They 
subscribed to a process that seemed to utilise the emergency department during a crisis and to 
utilise the GP for repeat prescriptions and immunisations. Patients are still waiting for 
facilitating factors highlighted  by the below patient quote which would encourage them to use 
the GP as a means of support, prevention, and maintenance during crisis-free periods or during 
uncomplicated crisis pain episodes (AlJuburi, Phekoo, Okoye, et al., 2013b). 
It takes too long to see a GP. Sometimes something goes wrong while you are waiting for 
your appointment. Other than a prescription or a non-sickle illness, there is no need for the 
GP. It is a waste of time. When you have access to a seven day hospital, why go to a GP? 
They [General Practitioners] don’t take the time to find out about the patients they have on 
their books anyways. 
Continuity of Care & Follow-Up 
One discussion point that surfaced several times was the seeming lack of cohesion and 
communication between GPs, hospitals, and specialty centres. Participants emphasised that 
there was never follow-up from their GP after they were discharged from the emergency 
department, hospital or a specialty centre. Participants felt strongly that GPs should liaise with 
other healthcare professionals involved in the management of their sickle condition, and should 
follow-up with the patient soon after hospital discharge (AlJuburi, Phekoo, Okoye, et al., 2013b). 
This Institutional and patient management is what we define in this paper as both integration 
and coordination of care, and I discuss this further in Chapter 10 where approaches to policy are 
summarised. 
[There should be] review letters from the hospital. They [General Practitioners] should see 
how you are doing. That will be good. 
[Following discharge from hospital] why don’t they [GPs] ever call the patient and follow 
up? 
Chronic Illness Management – Wellbeing Management 
There was agreement amongst the focus group participants   that many of the frustrations felt 
by patients with SCD are also shared by sufferers of other chronic illnesses. GPs were seen as 
treatment and medication prescribers rather than actively engaged in the management of their 
patients’ well-being through prevention of disease and maintenance of health (AlJuburi, Phekoo, 
Okoye, et al., 2013b). 
[GP consultation] five minute conversation with the GP… [to get your] medication or 
antibiotics, or certain jabs, they don’t take the time. 
The key issues identified through the focus groups are summarised in Table 14. 
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TABLE 14: ISSUES IDENTIFIED BY FOCUS GROUP DISCUSSION 
Access & difficulty in obtaining urgent appointments 
Poor communication between health professionals 
Poor follow-up and discharge planning processes 
No proactive role in maintaining health and in preventive care 
Limited knowledge about sickle cell disease 
Limited knowledge about the standards and guidelines for disease management 
Concerns about pain management 
 
6.2.3. DISCUSSION ON FOCUS GROUP 
Our focus group discussion results could have benefited by having more participants and more 
sessions. However, the discussion on SCD provided an opportunity to not only voice the 
frustrations of participants but created a venue whereby solutions could be proposed. The 
discussion was candid, clear and offered perspectives about the participants’ individual and 
collective needs that could not otherwise be obtained from healthcare professionals. They 
offered constructive advice on what they needed to feel satisfied as health care consumers and 
gave a clear understanding about which areas we needed to focus on regarding the design of 
primary care practice intervention. They also earmarked issues that need to be addressed in 
future research, including auditing and improving communication between the different 
providers of health care and recommending quality improvement schemes in areas with a high 
prevalence of SCD (AlJuburi, Phekoo, Okoye, et al., 2013b). 
6.3. PATIENT QUESTIONNAIRE AS A METHOD FOR PATIENT 
ENGAGEMENT IN THE DESIGN OF SERVICES 
6.3.1. BACKGROUND 
In addition to focus group studies such as the one we conducted, other studies have shown that 
SCD patients are dissatisfied with the quality of care they receive from their GPs (Anie, Steptoe 
& Bevan, 2002).,Primary care, however, is still a good place to deal with chronic       illness as it 
offers continuity, coordination, and comprehensiveness (Rothman & Wagner, 2003). These 
studies also show that assessing satisfaction is an important part of evaluating comprehensive 
quality of care (Ireys & Perry, 1999). Patient satisfaction has been regarded as the ‘ultimate 
outcome of the delivery of health care’, and measuring and responding to satisfaction can be 
important with regards to treatment compliance and over or underutilising the health care 
system (Kelley, Alexander & Morris, 1991). 
While properly constructed patient questionnaires can be useful in measuring patient 
satisfaction (Grogan, Conner, Norman, et al., 2000), they are also considered another way in 
which we can engage patients in the design of health services. More specifically, we can measure 
patient satisfaction in primary care, the design of healthcare services in primary care, and the 
measurement and management in primary care of SCD. 
One study showed that a questionnaire is a valid and valuable tool to use for assessing health-
related quality of life in children with SCD and could serve as ‘an important adjunct to 
determine the effect of SCD on the lives of children’ (Panepinto, Mahar, DeBaun, et al., 2004). 
Other studies have shown that questionnaires are a valuable tool in measuring quality of care or 
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patient satisfaction in primary care (Raat, Landgraf, Bonsel, et al., 2002), particularly where the 
questionnaire assesses a specific area that enables the GP or other health care provider to 
identify which aspects of service patients find unsatisfactory. This in turn allows for the 
opportunity to improve a specified area (Harris, Swindle, Mungai, et al., 1999). A separate study 
discussing patient survey programmes showed that this method is a beneficial way of 
‘monitoring performance across the system’, because they require providers to survey patient 
experiences and to publish these results (Coulter, 2005). 
In a historical context, survey data can offer valuable insight as ‘they let us recapture what 
ordinary people really thought about critical issues’, like health services. Furthermore, regardless 
of whether people have a clear understanding of a particular health reform (or in our case, this 
can be held equally true for a particular health service), people always have a clear opinion about 
their experience which should not be dismissed or ignored because of a lack of detailed 
knowledge about a particular reform or service (Hayes, 2013). 
Our analysis of emergency department admissions between January 2008 and July 2010 in the 
northwest London Borough of Brent showed that patients with SCD tend to use the emergency 
department rather than seek advice and support from their GP (Green, Aljuburi, Majeed, et al., 
2012a). Our focus group study aimed at obtaining patient perspectives held in Brent and showed 
that one of the reasons patients utilise the emergency department over their GP is because they 
perceive GPs as having limited knowledge of SCD (Aljuburi, Phekoo, Okoye, et al., 2012). We also 
know that SCD clinical guidelines recommend that patients see a general practitioner (GP) for 
routine examination every six months, or more often if new problems arise or their treatment 
protocol changes (NHS Sickle Cell and Thalassaemia & Screening Programmes, 2010). In 
addition, immunisations, prescriptions, and other preventive care measures need to be delivered 
effectively by GPs to prevent recurring infections and pain crises (Wong, 2001). 
We designed a pilot questionnaire to elicit the views of patients about the quality of care they 
have been receiving from their primary health care providers and what they thought about the 
role of primary care in SCD management (Aljuburi, Okoye, Majeed, et al., 2012). 
6.3.2. METHODS 
The study consisted of the development and administration of a 14-item study-specific 
questionnaire devised by a sickle cell steering committee which examined patients’ perceptions 
towards SCD and key management issues in primary care, including the severity of disease, how 
many times patients visited the emergency department in the last year, how many times 
patients saw or called their GP for sickle and non-sickle related illnesses, and general questions 
about GP satisfaction (Figure 12). The validation process for the questionnaire followed several 
drafts reviewed by seven GPs practising across inner London, a professor of paediatric 
haematology specialising in SCD, a haematologist specialising in SCD in adults, an SCD specialist 
nurse, an SCD social worker, an SCD clinical psychologist, a number of quality improvement 
project managers, public health specialists, patient representatives with SCD, and directors of 
the Sickle Cell Society (a national UK sickle cell charity) (Aljuburi, Okoye, Majeed, et al., 2012). 
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FIGURE 12: A SELECTION OF QUESTIONS FROM THE PATIENT QUESTIONNAIRE 
Question 
In the past year, how many times have you seen or called your GP for help with a sickle cell crisis? 
 
………………………………………………………………………………………………… 
 
Question 
 
Rank the three main things you do most often when in crisis: 
( ) Do nothing ( ) Go to GP 
( ) Call Sickle Cell Specialist Nurse ( ) Go to A&E 
 
( ) Stay at home (  ) Other (please state):…………………………………………. 
 
Question 
 
How often do you utilise your GP to: 
 
a) Manage a painful crisis 
 
Never Rarely Sometimes Fairly often A lot 
 
(1-2/year) (3-4/year) (monthly) (weekly) 
 
b) Collect repeat prescription for antibiotics, folic acid, analgesia 
 
Never Rarely Sometimes Fairly often A lot 
 
(1-2/year) (3-4/year) (monthly) (weekly) 
 
c) Get general advice about sickle cell disease 
 
Never Rarely Sometimes Fairly often A lot 
 
(1-2/year) (3-4/year) (monthly) (weekly) 
 
d) Get help with non-sickle related illness (e.g. coughs, colds, etc.) 
Never Rarely Sometimes Fairly often A lot 
 
(1-2/year) (3-4/year) (monthly) (weekly) 
Other reasons (please specify) 
………………………………………………………………………………………………… 
 
Question 
 
How satisfied are you with assistance given by your GP to help manage your sickle cell disease 
 
0 1 2 3 4 5 6 7 8 9 10 
 
(0=Not satisfied at all) (10=Very satisfied) 
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 Question  
 
List the kind of support you currently receive from your GP 
Pain control 
Collecting prescription 
General SCD advice 
Contraception 
Other (please state)  
Question 
List the kind of support you would like to receive from your GP ……………………………………… 
* Full version of the questionnaire can be found in the Appendix. 
Participants 
One hundred questionnaires were distributed by post and in person over a nine-month period 
from November 2010 to July 2011 to members of the Sickle Cell Society and to patients that 
attended the Sickle Cell and Thalassaemia Centre, using a purposive sampling method. Forty 
questionnaires were properly completed and suitable for analysis (Aljuburi, Okoye, Majeed, et 
al., 2012). 
6.3.3. RESULTS 
A response rate of 40% was achieved. Fifty percent (20) were completed by males and 50% 
(20) by females. The highest percentage of respondents (27%) was in the age range of 25- 39 
years. Five percent of respondents were aged 65+years. The majority (62%) of the respondents 
were in good health and mobile. Nineteen (47%) respondents did not use their GP to manage a 
painful crisis and preferred to attend the emergency department. Twenty-four (59%) 
respondents went to their GP to collect repeat prescriptions. Twenty-two (55%) respondents 
did not visit their GP to get general advice about SCD (Table 16). Nine (23%) rarely visited their 
GP with four (10%) visiting sometimes or fairly often (Table 15). When asked how satisfied 
patients are with assistance given by their GP to help manage their SCD based on a scale of 0-10 
(0 being not satisfied at all and 10 being very satisfied), the majority (54%) scored satisfaction 
with their GP as 5 or less while 43% scored a 6 or above and 3% did not answer the question at 
all. 
Collecting prescriptions was the reason most cited for visiting the GP’s office (Table 16). Some 
examples of comments around the services provided by GPs include: 
‘The GP should know about this disease.’ (Patient Questionnaire 1) (Aljuburi, Okoye, Majeed, et 
al., 2012) 
‘The GP does not know anything about SCD pain and crisis. I would rather manage … at home or 
[go] to A+E where immediate action will be taken rather than call the GP who will ask us to book 
an appointment and more or less does not understand how to manage the pain or how severe or 
serious the pain is.’ (Patient Questionnaire 2) (Aljuburi, Okoye, Majeed, et al., 2012). 
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TABLE 15: HOW OFTEN DO YOU USE YOUR GP TO GET GENERAL ADVICE ABOUT SCD? 
 Number of Respondents % of Respondents 
Never 22 55 
Rarely 9 23 
Sometimes 4 10 
Fairly often 4 10 
Not answered 1 3 
Source: (Aljuburi, Okoye, Majeed, et al., 2012) 
TABLE 16 
 Number of Respondents % of Respondents 
Pain control 1 4 35 
Collecting prescription 3 7 93 
General SCD advice 3 8 
Contraception 2 5 
Other (please state) 1 3 
Source: (Aljuburi, Okoye, Majeed, et al., 2012) 
The results from the survey show that many patients are generally not satisfied with the quality 
of care that they are receiving from their primary health care providers for SCD. Thus, most do 
not make use of GP services for management of their SCD.  More importantly, the majority of the 
group did wish for greater involvement from their GP services, even if it was just to refer them 
to a tertiary care facility or social support (Aljuburi, Okoye, Majeed, et al., 2012). 
6.3.4. DISCUSSION ON PATIENT QUESTIONNAIRE 
The pilot study successfully identified issues with SCD management at the primary care level 
through the use of a questionnaire which could help inform the planning of a larger survey. 
Moreover, this study also identified a need to improve patient satisfaction and engagement with 
primary care. Raising awareness amongst GPs about SCD management was identified as a key 
method to improve GP-patient relationships and improve primary care clinic attendance 
(Aljuburi, Okoye, Majeed, et al., 2012). 
Although this pilot study increased our understanding of the barriers associated with SCD 
management in primary care, it has certain limitations which could limit its transferability to 
areas outside of northwest London. The questionnaire was based in an area with high 
prevalence of SCD and the sample size was small and consisted of a purposive or volunteer 
sample (Aljuburi, Okoye, Majeed, et al., 2012). Despite its limitations, the study, along with the 
results of the focus group discussion which reinforced these findings (Green, Aljuburi, Majeed, 
et al., 2012a), provides some valuable information that provide an opportunity to develop a 
disease specific intervention which aims to improve patient care and help to ensure that 
management in primary care is optimised through the establishment of a local policy initiative 
(Aljuburi, Okoye, Majeed, et al., 2012). 
Shared decision making between clinicians, health policy makers and patients is important in 
the design of health services, but how patient involvement is defined and the mechanism for 
involvement is not always clear and has been a source of debate between patients and health 
care providers (Renedo & Marston, 2011). 
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6.4. DISCUSSION 
6.4.1. PATIENT SATISFACTION AND THE MERITS OF INVOLVING PATIENTS IN 
THE DESIGN OF SERVICES AND CARE PATHWAYS 
There have been few data collected about SCD patients and their level of satisfaction with 
primary care services. However, one study showed a 46% non-adherence rate for routine 
primary care appointments for SCD patients during an eight-month period (Robinson N, Huber 
H & Jenkins P, 2006). One of the reasons cited for non-adherence was the patient-provider 
relationship. Those with a positive patient and GP relationship were more likely to attend their 
clinic appointments (Modi AC, Crosby LE, Guilfoyle SM, et al., 2009; Freed, Ellen, Irwin, et al., 
1998). Other studies of chronic disease management showed that poor communication, 
multiple treating physicians, long waiting periods, and past negative experiences with health 
care providers all contributed to patient dissatisfaction with primary care and poor attendance 
at clinics (McCarthy, McGee & O’Boyle, 2000). 
With patient satisfaction established as an important indicator of health outcomes, researchers 
and health care providers have become increasingly interested in measuring patient satisfaction 
as an indicator of quality of care. In fact, assessing patient satisfaction is one of the core 
requirements of contract for GPs in the UK (Grogan, Conner, Norman, et al., 2000). One study 
showed that assessing patient satisfaction allows GPs to investigate ‘the extent to which their 
service meets the needs of their client group’ (Avis, Bond & Arthur, 1995). Another study 
showed that satisfied patients are more likely to follow a treatment protocol because the patient 
is more likely to believe that the treatment will be effective (Hardy GE, West MA & Hill F, 1996). 
In order for satisfaction to be measured in a meaningful way, a valid and reliable measure 
should be applied. The use of patient questionnaires is one reliable way to assess patient 
satisfaction (Grogan, Conner, Norman, et al., 2000) and also one of the Institute of Medicine’s 
suggestions for achieving patient centred care (IOM). 
The US-based Institute of Medicine has also included patient-centric care as one of the six aims 
of quality. Patient-centric primary care, in particular, has been defined to include seven 
attributes including ‘access to care, patient engagement in care, information systems, care 
coordination, integrated and comprehensive team care, patient centred care surveys, and 
publicly available information’ (Davis, Schoenbaum & Audet, 2005). In the US, a 2003 
Commonwealth Fund National Survey found that only one in four primary care physicians 
incorporate one or more of the above named patient centred attributes in their practices. Some 
have suggested addressing this issue with a new system of primary care reimbursement that 
combines monthly per diems with a traditional fee for service payment alongside new 
incentives for patient-centred care (Davis, Schoenbaum & Audet, 2005). 
The push for patient input relies on the premise that ‘far more than clinicians, patients 
understand the realities of their condition, the impact of disease and its treatment on their lives, 
and how services could be better designed to help them’ (Richards, Montori, Godlee, et al., 2013; 
Young, 2013). In other words, in order to foster patient-centric health care services, patients 
need to be involved in the design of these services. As a response to this growing consensus, 
England has seen the enactment of the Health and Social Care Act of 2012, which legally enables 
patients and their carers to participate in the planning and management of their health care and 
health care services. It also calls for the participation of the public in commissioning of health 
care services in order for services to reflect local needs (Anon, n.d.).  This was followed by the 
introduction of legislation mandating basic levels of quality of care following the Francis Report 
in 2013, which highlights the apparent lack of compassion within some parts of the health 
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service and the importance of working with patients (Francis, 2013). Both the legislation and 
inquiry create impact in strategy and shared values, almost providing a mandate to improve the 
quality of care patients receive and involving them directly in these initiatives. 
Patient participation has also been shown to improve outcomes, provide value for money and 
improve quality of life (NHS England, 2013). One systematic review on involving patients in the 
planning and development of health care examined reports (which were written in English) 
between 1966 and 2000 to determine the effects of involving patients in the planning and 
development of health care. Changes to services (such as appointment simplification, extending 
opening times, improving access for people with disabilities, improving sources of information 
for patients) were seen as the most impactful. Organisational changes such as the attitudes of 
staff were also reported as being impactful (Crawford, 2002). 
The King’s Fund also studied engaging patients in the design of primary healthcare services and 
found that patients want: 
 their health care professionals to have excellent interpersonal skills, as well as 
demonstrable up-to-date clinical knowledge and the willingness to provide timely and 
meaningful information; 
 easy access to their clinicians; 
 clean, accessible premises; 
 continuity of care and smooth handovers between health care professionals; 
 opportunities to take part in their own health care; 
 a sense that the best possible care will be available when they need it; and 
 to understand that this care will be equitably distributed, and that public money is 
being used efficiently (Parsons, 2010). 
Engaging patients in research such as the study conducted by the King’s Fund creates a baseline 
for policy makers to start addressing gaps and encourages systems of care that are bespoke to 
the service user – in our case, the patient with SCD and/or their caregiver. 
6.4.2. MODELS OF PATIENT INVOLVEMENT AND ENGAGEMENT 
While research in the UK has shown that patient input can lead to change in health provider 
access, continuity of care and patient self-care and empowerment, patient involvement and 
engagement is a growing health care service trend not only in the UK but also internationally. 
Canada, the US and Europe have all taken substantive steps in allotting for patient input in 
health service design, and low income countries such as Tanzania have gone as far as 
implementing initiatives that engage patients in the clinical delivery of health care. 
6.4.2.1. INTERNATIONAL ENGAGEMENT 
In 2010, the Canadian Foundation for Healthcare Improvement (CFHI) collaborated with local 
and national decision makers to design and deliver affordable patient centred healthcare for 
Canadians. CFHI since then has supported 17 teams across Canada whose aim is to involve 
patients and their families in decisions about service design and delivery. The teams used 
multiple strategies to engage patients in this exercise including advisory councils, surveys, and 
workshops. The results confirmed that by improving health care provider and patient 
67 
 
communication, the patient experience and care process efficiency also improved. The teams 
were able to share their lessons learned through the dissemination of papers and webinars2 
(Edgman-Levitan, Brady & Howitt, 2013b). 
A study conducted in a large health care delivery system in Minnesota found that the least 
engaged patients from the perspective of understanding one’s own role in the care process 
(what the researchers are naming patient activation levels) had an average cost 8% higher in 
the base year and 21 percent higher in the first half of the next year than the costs of patients 
with the highest engagement levels. Patient engagement was reported as a significant predictor 
of cost, even after adjustment (Hibbard, Greene & Overton, 2013). 
Recent regulations in the United States have also encouraged the use of patients in decision 
making where patients and health care providers share the decision making process based on 
evidence based care pathways. One study found that barriers to shared decision making 
included overworked physicians, insufficient provider training, and clinical information systems 
incapable of prompting or tracking patients. Methods identified to improve shared decision 
making included a recommendation for ‘substantial investments in provider training, 
information systems, and process reengineering’ (Friedberg, Van Busum, Wexler, et al., 2013). 
This is similar to our findings and the intervention approach we applied for SCD. We engaged in 
a patient informed intervention designed through the use of a focus group and a patient 
questionnaire and created outputs which included a GP educational intervention, an SCD 
template to be installed in primary health care practices and a policy recommendation to 
integrate primary secondary and tertiary delivery systems in the care of patients with SCD (see 
Chapters 7 and 8). 
Patient engagement in a more developing health care system context can also be seen as 
growing in priority. Some examples can be found in the World Health Organization, which has 
set up initiatives including one global initiative for patient health and safety engaging patients in 
design and delivery (WHO, http://goo.gl/rY8lFI). In places like Tanzania, an organisation called 
Upendo Disadvantaged Group recruits former tuberculosis patients who help to organise 
community gatherings featuring music and poetry to educate their neighbours about 
tuberculosis and also help in the training and administration of drug therapy (Hockstein, 2009). 
6.4.2.2. ENGAGEMENT IN THE UK 
Government initiatives in the UK have been developed to facilitate patient engagement in the 
design of health care services. Local involvement networks (LINks) were implemented in 2008 
to identify what people like and dislike about their local services and then to work with local 
service providers and commissioners to help make them better (Parsons, 2010). LINks provided 
an opportunity to improve services by investigating specific issues of concern, holding 
accountable services to get results, carrying out spot checks and drafting reports and 
recommendations (WCC PPI Steering Group, 2008). 
Today, LINks are being taken over by local healthwatch organisations. Healthwatch 
organisations are similar to LINks in many of their strengths, but differ in that they take into 
account not only adult experiences, but also children’s user experiences; they have a statutory 
place on the local health boards, and they are linked to a national network (Healthwatch 
England, http://bit.ly/1GYWRmv). 
The World Class Commissioning (WCC) framework is a national programme launched by the 
Department of Health in 2007 based upon the intent to commission best practice and to engage 
                                                             
2 http://goo.gl/BH7Xqy 
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patients in the commissioning of best practice (Parsons, 2010). The WCC requires that Clinical 
Commissioning Groups (CCGs) partner with clinicians, local authorities, communities and the 
providers of healthcare services in order to develop quality and integrated care that are aligned 
with the needs of the local population (WCC Introduction Publication found at 
http://bit.ly/1HcKwk6). The NHS has also developed the Smart Guides to Engagement series for 
those working in or with CCGs. The Smart Guides to Engagement have been written by experts 
to give user friendly advice on patient engagement (NHS Networks, http://bit.ly/1F2aKSx). 
The Quality and Outcomes Framework (QOF) is a pay for performance scheme that financially 
rewards NHS GPs for implementing good practice in their clinics. The QOF scheme is voluntary, 
but it is also one way a GP can make a difference in their income. The criteria were grouped into 
four areas: clinical, organisational, patient experience and additional services. Patient 
engagement has been raised as an additional criteria area (Parsons, 2010) (National Institute 
for Health and Care Excellence, http://goo.gl/AaU2MK). 
NHS England and CCGs encourage GP practices to operate patient participation groups (PPGs). 
PPGs are considered a partnership between the patient, the GP and the GP practice and a forum 
where suggestions can be made on quality improvement measurements and the way healthcare 
services are delivered. The suggestions are local, relevant and have the potential of creating 
more cost and process efficient ways forward. While PPGs have been around since 1972 
(National Association for Patient Participation, http://goo.gl/vWtb9R), their importance and 
popularity have recently increased as the NHS becomes more focused on patient centred 
healthcare (Parsons, 2010). 
There are other programmes that have been nationally initiated but locally implemented which 
help patients in accessing information and creating a culture of feedback on their health care 
such as Patient Advice and Liaison Service (PALS). Every NHS Trust must have a PALS, which is 
a service focused focal point (team or individual) who help patients solve problems, provide 
advice and information. PALS are also a good resource when it comes to understanding trends 
locally and can support in patient engagement activities. There is also a national system for 
responding to complaints and all NHS organisations are required to comply with the majority of 
organisations having a local and dedicated complaints team to both respond to complaints and 
monitor their trends (Renedo & Marston, 2011). 
Several instruments have been used to measure the use of patient engagement and its impact 
including surveys, appraisal of GPs, and performance management reward structures. Some 
challenges to measuring patient engagement in primary care include knowing whether the 
samples being measured are representative and unbiased, what to do with the results of 
measuring patient engagement once they are collected, and the ability to benchmark the results 
against other practices. One of the issues is that without a proper framework or policy guideline 
on how patients should be engaged in service development, there is little in the way of creating 
sustainable impact (Shared decision making between clinicians, health policy makers and 
patients is important in the design of health services, but how patient involvement is defined and 
the mechanism for involvement is not always clear and has been a source of debate between 
patients and health care providers (Renedo & Marston, 2011). 
6.5. KEY POINTS FROM CHAPTER 6 
1. Patient engagement in the design of health services has been shown to improve 
outcomes, provide value for money and improve patient satisfaction. 
2. Focus groups are a means of engaging patients in satisfaction and design of services. 
3. Patient questionnaires are a successful tool in measuring patient satisfaction. 
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7. POLICY IMPLICATIONS 
7.1. SUMMARY OF FINDINGS 
With the help of six studies, I was able to show SCD admission rates in England, the readmission 
rates, local admissions, costs associated with admission and patient perspectives in both care 
and prevention. Because of this work, there is a clearer picture in the trends and health care 
utilization of patients with SCD in England. 
Using HES data, trends for SCD hospital admissions in England showed a rise in 50% of hospital 
admissions over a 10 year period.  The most deprived areas had a higher rate of readmission 
and in-patient mortality among those with SCD.  Adolescents had a higher rate of readmission 
possibly identifying a gap in health care access.  Local findings in a high prevalence area showed 
that the majority of admissions were for short length of stay and 74% accounted for multiple 
admissions while the patient focus group and questionnaire both identified potential gaps in 
care and prevention. 
Laying down these results allows us to look into the broader literature of chronic disease 
management and thereafter make policy recommendations bespoke to SCD that may help to 
reduce hospital admissions due to SCD. 
7.2. CHRONIC DISEASE PREVALENCE IN ENGLAND 
The Department of Health estimates that 17.5 
million adults in the UK live with at least one chronic 
disease, and many of these people will experience 
more than one chronic condition at the same time 
(Department of Health, 2005). Chronic diseases 
account for 50% of general practice consultations 
and 70% of inpatient bed days per year within the 
UK (Langer, Chew-Graham, Hunter, et al., 2013; 
Department of Health, 2010). Two thirds of patients admitted as medical emergencies have an 
‘exacerbation of chronic disease’ (Health, n.d.). They constitute a major challenge for healthcare 
services in general, and unscheduled care in particular (Langer, Chew-Graham, Hunter, et al., 
2013). 
Many interventions aimed at managing and preventing chronic disease are delivered in the 
primary and community care setting. Improving care and services for people with such 
conditions are also seen to have a beneficial impact on secondary and emergency care (Health, 
n.d.). 
7.3. CHRONIC DISEASE MANAGEMENT FRAMEWORKS 
Improving Care for People with Long-Term Conditions, a review of UK and international 
frameworks, identified four broad frameworks for chronic disease management: (1) the Chronic 
Care Model, (2) the Innovative Care for Chronic Conditions Model, (3) the Public Health Model, 
and (4) the Continuity of Care Model. ((Singh & Ham, 2006)). 
The Chronic Care Model is the best known framework and suggests six elements to improve 
initiatives in chronic care: community resources, the healthcare system, patient self- 
 
‘We want to give patients the
most intensive care in the least
intensive setting’ (Department of
Health, 2005). 
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management, decision support, delivery system redesign, and clinical information systems. The 
report states that ‘while there is evidence that single or multiple components of the Chronic 
Care Model can improve quality of care, clinical outcomes, and healthcare resource use, it 
remains unclear whether all components of the model, and the conceptualisation of the model 
itself, is essential for improving chronic care.’ (Singh & Ham, 2006). 
The Innovative Care for Chronic Conditions Model focuses on ‘improving care at three different 
levels: micro level (individual and family), meso level (healthcare organisation and community), 
and macro level (policy)’ (Singh & Ham, 2006). 
The Public Health Model is a less-known version and focuses on a system wide perspective 
which ‘emphasises the determinants of disease as well as social, cultural, and economic factors’ 
that could affect quality and quantity of care (Singh & Ham, 2006). 
The Continuity of Care Model outlines ‘how chronic conditions develop in response to risk 
factors in the community and suggests points at which to target prevention efforts, medical 
intervention, treatment, rehabilitation, and palliative care’ (Singh & Ham, 2006). 
Based upon the mentioned frameworks and the models that have been developed which focus 
on how to deliver services, there is growing evidence that some of the essential components of 
good chronic disease management include: 
 Using information systems to access key data on individuals and populations; 
 Identifying patients with chronic disease; 
 Involving patients in their own care (self-care); 
 Coordinating care; 
 Integrating care; and 
 Aiming to minimise emergency visits and hospital admissions (Health, n.d.). 
7.4. PATIENT ACCESS TO HEALTH INFORMATION IN PROMOTING 
CHRONIC DISEASE MANAGEMENT 
Facilitating access to health information can ‘promote patient engagement in care’ (Woods, 
Schwartz, Tuepker, et al., 2013). As a response, many organisations are creating programmes 
that enable their patients to access and download their own medical records. The Blue Button 
program, established by the US Veterans Administration, has branded a recognisable prompt on 
websites that allows electronic access to health information3. At the Mayo Clinic, downloading a 
smartphone application gives patients full access to their medical notes, pathology and radiology 
and is striving to deliver it in layman language (Richards, 2013). Other organisations allow 
patients to create personal health records that enable patients to create their own measures and 
share them with their providers. One such programme is called True Colours4, which is reported 
as being a ‘self-monitoring and management system’ that uses simple technology accessible to 
the patient such as a mobile phone or computer device and turns quantitative responses from 
patients into easy to read graphs for patient or provider use. Patients even have the option of 
creating their own questions and responses which may be unique to them. This programme was 
initially developed for mental health disorders but now has been expanded to include chronic 
                                                             
3  
4 http://bit.ly/1IwSGm8  
71 
 
diseases such as diabetes and arthritis, which shows that the programme can be easily adaptable 
and transferrable to other disease categories (Edgman-Levitan, Brady & Howitt, 2013a). 
One CLAHRC initiative was the creation of the ‘My Medication Passport’5, which allows patients 
to carry a portable record of their medications and thereby improves communication across 
different care settings. Because it was originally developed for the elderly, it comes in both paper 
form and as a smartphone application (Edgman-Levitan, Brady & Howitt, 2013a). This 
application would be easily transferrable to patients with SCD, especially as part of their pain 
management protocol. 
7.5. PRIMARY CARE INTERVENTION AS A MODEL OF CHRONIC DISEASE 
MANAGEMENT 
A study by the BME Health Forum reported that when people with long-term conditions were 
asked why they went to emergency before trying to go to their GP first, 67% answered because 
they ‘would not be seen quickly enough’. Similarly, when they were asked what change would 
make them go to the GP rather than the emergency, 59% of the respondents suggested same-
day appointments, which according to the study ‘suggests that changes in how quickly people 
could be seen in primary care would have the biggest impact in terms of reducing[emergency] 
attendances.’ (BME Health Forum, 2014). Both our focus group study and our patient 
questionnaire found similar results with SCD patients. Another study showed that NHS hospital 
emergency department visits increased by 20% between 2007-2008 and between 2011- 2012 
(Cowling, Cecil, Soljak, et al., 2013), with a similar finding that (some) patients in the emergency 
attributed their visit to the inability to see a GP (Cowling, Cecil, Soljak, et al., 2013). 
A recently published study conducted an analysis that estimated the number of emergency 
department attendances in England during 2012-2013 which were preceded by the patient being 
unable to access an appointment at their general practice. The study found that approximately 
5.8 million emergency department attendances were preceded by the patient being unable to 
obtain either an appointment or a convenient appointment. This accounted for approximately 
27% of unplanned emergency attendances in England for 2012-2013, suggesting that a large 
number of emergency attendances each year are likely to be preceded by ‘unsuccessful attempts 
to obtain convenient general practice appointments’ (Cowling, Harris, Watt, et al., 2014). 
Such studies have triggered a response from the UK Department of Health (DH). In April 2014, 
the DH launched a scheme including 1147 general practices in England and 7.5 million 
registered patients offering appointments from 8:00-20:00, seven days a week (outside of the 
current GP opening hours), with priority to the most vulnerable populations (Department of 
Health. Millions to benefit from improved GP care [press release]6. 
Studies have also found that the GPs who did provide more timely access to primary care had 
‘fewer self-referred discharged [emergency] visits per registered patient’ (Cowling, Cecil, Soljak, 
et al., 2013). Furthermore, those admissions with conditions that may have escalated over time 
(as is often seen in chronic and long-term conditions) and with the potential to be intercepted in 
primary care could also indicate ‘suboptimal care (because the individual’s health had 
deteriorated avoidably to the extent that hospitalisation was necessary) (Blunt, n.d.). Hence, 
while access to primary care is a recurring challenge that may explain some unnecessary 
hospital visits and is repeatedly identified in the literature, we can also see that relocating some 
hospital services to primary care will not only reduce unnecessary hospital admissions 
                                                             
5 http://goo.gl/Pk7mXB  
6 https://goo.gl/DeIcTQ  
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(Cowling, Cecil, Soljak, et al., 2013), but may actually improve the equity (Sibbald, McDonald & 
Roland, 2007) and quality of services (Blunt, n.d.). 
The intent is not to replace primary care health services for secondary health care services, but 
rather to allow secondary care to supplement primary care instead of the reverse. 
Primary care is a major aspect of England’s NHS, and responsible for ‘approximately 300 million 
consultations per year with GPs in England, which represents 70-90% of all patient contacts with 
the NHS’ (Gibbons, Bindman, Soljak, et al., 2012). 
Another necessary step is to encourage policy makers to link primary care and public health. 
Primary care is defined as ‘providing medical services to individual patients with immediate 
health needs’, and public health is defined as ‘offering a broader array of services across 
communities and populations that collectively will help people to be healthy.’ This union of 
primary care and public health can begin to offer a more holistic approach to the management 
of diseases that are considered chronic or long term  (Primary Care and Public Health: Exploring 
Integration to Improve Population Health, released 28 March, 2012, Institute of Medicine). 
7.6. SUPPORT FOR SELF-CARE FOR PATIENTS WITH CHRONIC DISEASE 
For patients with long-term or chronic disease, there is a growing interest in self-care 
programmes that emphasise the patient’s role in managing their illness. Policies and 
interventions that strengthen the role of the patient in managing their health care not only 
contribute to improved outcomes (Hibbard & Greene, 2013), but can also save the NHS 
substantial amounts of money. A 2013 study by Nesta estimated that £4.4 billion could be saved 
in the NHS through greater participation and self-management of long term conditions 
(Richards, 2013; Anon, n.d.). 
An article in the BMJ suggests that support for self-care has the potential to improve the 
management of long-term conditions. Furthermore, 
 Current interventions have only modest effects on patient health and use of health 
services; 
 One possible explanation is that interventions tend to focus solely on the patient; 
 Interventions need to reflect the ways in which patients and professionals respond to 
long- term illness; and 
 Approaches need to target patients, professionals, and healthcare organisations 
(Kennedy, Rogers & Bower, 2007). 
Supporting patient self-management is about ‘acknowledging their central role in managing 
their own care and empowering them, their family and carers to handle their condition as 
effectively as possible’ (Department of Health, 2005). This means ensuring the appropriate skills 
and knowledge to understand how to best handle their condition, providing information that is 
easily accessible, enabling and empowering patients and carers to manage the condition more 
effectively such as by implementing self-monitoring or applications that prompt or remind the 
patient when they should be doing something, providing a trusted and consistent person to 
contact and ensuring community network support or a patient mentor (Department of Health, 
2005). There are several disease specific programmes currently being implemented such as the 
Diabetes Education and Self-Management for Ongoing and Newly Diagnosed (DESMOND) 
programme which focus on ‘enhancing the patients skills and confidence in managing 
symptoms and medication’ (Department of Health, 2005). Similar programmes could be 
implemented for a disease such as SCD. 
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One study measured the effects of a self-management programme on patients with chronic 
disease through a seven-week intervention attended by people with different chronic 
conditions; the authors reported that, after one year, the participants in the programme 
experienced a statistically significant improvement in health behaviour and had fewer visits to 
the emergency department. Although not statistically significant, they also found fewer 
outpatient visits to physicians and fewer days in hospital (Lorig, Sobel, Ritter, et al., 2001). 
Another study created an intervention for a group of patients with a mix of chronic diseases, 
which included patients with comorbidities, and found that a chronic disease self- management 
programme was both feasible and beneficial with respect to improving health behaviour and 
status and resulted in few hospitalisations and days of hospitalisation (Lorig, Sobel & Stewart, 
1999). 
The Stanford School of Medicine has developed different chronic disease self- management 
programmes, including online programmes7 (Lorig & Holman, 2003). The School of Medicine 
engages patients in developing the self-management programmes in order to enhance the 
impact and sustainability of the programmes themselves. Topics include both physical and 
emotional aspects. Some focus on medication use, others on effective communication or 
nutrition. Those who complete the six-week course experience ‘fewer hospitalisations and 
report improved general health.’ Organisations in 22 countries have now been licensed to offer 
the programme (Edgman-Levitan, Brady & Howitt, 2013a). 
The above programmes, along with research and policy reports are substantially leaning toward 
a holistic focus that supports patients and their carers to become more functional, independent 
and resilient. They encourage patients to manage their condition in the home environment as 
‘preferable to a purely clinical focus on managing or treating medical symptoms’ (Goodwin, 
Sonola & Thiel, 2013). 
7.7. MANAGING SCD AS A CHRONIC DISEASE 
Historically, the management of SCD, particularly when it comes to pain management, has been 
through an acute care model. For the most part, SCD is still being treated under an acute care 
model (Maxwell, Streetly & Bevan, 1999b), despite studies that show the essential components 
of chronic disease management such as self-care (Jenerette & Murdaugh, 2008; Jenerette, 
Brewer & Leak, 2011), coordinated and integrated care (Mitchell, Lemanek, Palermo, et al., 
2007), and the use of technology (McClellan, Schatz, Puffer, et al., 2009), all of which have 
successfully been used in the management of SCD. Additional evidence also suggests that 
patients with SCD who manage their disease at SCD-specific care clinics have a lower rate of 
emergency room visits and inpatient admissions than those who do not (Yang, Shah, Watson, et 
al., 1995). 
Self-care for SCD 
One study on self-management models for sickle cell disease indicated the benefits of expanding 
self-management resources to improve health outcomes of sickle cell patients (Jenerette & 
Murdaugh, 2008). Another study further supports this by stating that ‘the current structure of 
pain management placed patients too dependent on the hospital setting for treatment, while a 
more empowering and self-management approach could be more beneficial’ (Maxwell, Streetly 
& Bevan, 1999b). 
                                                             
7 http://goo.gl/QXgpWU  
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Examining popular self-management programmes for chronic disease such as the one at 
Stanford Medical School can also benefit SCD self-management programmes, since the 
underlying objectives are similar. However, care needs to be taken in selecting the appropriate 
model. For example, the Expert Patient Programme8 is an NHS sponsored programme in the UK 
based on the Stanford model and is considered a major public health initiative. The self- 
management course is taught by laypersons who mostly suffer from chronic disease themselves. 
The programme has received considerable promotion and positive press, but there are critics 
that argue that laypersons are not the best option for teaching self-management. Instead of 
creating efficiency and lowering costs, as touted by the programme, it could yield more frequent 
consultations with providers and higher associated costs (Griffiths, Foster, Ramsay, et al., 2007). 
SCD Interface 
Health information technology is becoming more important in the management of SCD and its 
assessment. One study piloted an interactive web-based tool for SCD in paediatrics. The Take- 
Charge Programme assessed adherence to clinic visits and drug protocol along with their 
barriers and found that the tool offered an innovative approach to integrate newer technology 
to assess adherence and clinical outcomes for paediatric patients with SCD (Crosby, Barach, 
McGrady, et al., 2012). Another study used a web-based assessment tool to determine barriers 
to SCD clinic attendance and to build problem-solving strategies around these barriers (Modi, 
Crosby, Hines, et al., 2012). 
In our study, the issues identified during the focus group discussion and the pilot questionnaires 
helped define key areas in need of improvement for SCD management. Some of the key themes 
and useful suggestions were used to develop a GP education intervention to improve GP 
management of SCD in primary care, and part of this education intervention was facilitated by 
developing an SCD template for data entry compatible with the main electronic patient record 
systems used by GPs in the UK. These electronic medical record systems are now widespread in 
UK primary care and have helped improve recording on patients with other chronic diseases 
(Majeed, 2004). In the longer term, these electronic patient records could be linked to disease 
recording templates to help improve the recording of information by primary care teams and 
the quality of primary care received by patients (Pappas, Anandan, Liu, et al., 2011). 
The SCD specific template9 was installed in 17 general practices across Brent with the intent to 
follow up with wider roll-out across northwest London. The template allowed GPs to register 
important aspects of management and co-morbidities associated with SCD. The template has 
the potential to ensure that key information about patients with SCD is recorded on their 
electronic medical record and GPs are better able to monitor the management of these patients 
both from the perspective of preventive care as well as managing comorbidities such as 
hypertension and kidney disease often found in SCD patients. The template can also ensure that 
the clinical investigations and treatment provided by hospital specialists are recorded. This can 
help improve communication with specialists and lead to the coordination of care of SCD 
patients. 
                                                             
8 http://bit.ly/1J5RDdt (accessed 2nd July 2014) 
9 A screen shot of the template is available in the Appendix. 
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Smartphone applications or the use of wireless 
technology to implement pain management 
protocols have significant potential to improve 
symptom monitoring and improve 
communication between SCD patients and their 
healthcare providers (McClellan, Schatz, Puffer, et 
al., 2009). A recent search for SCD- related 
smartphone applications returned 10 results 
which included three games, one SCD resource 
locator, a newsletter application, an application 
that identified SCD-related conferences, a pain 
crisis application, and two others that appeared to 
be related more to other blood disorders such as 
haemophilia; one application is available that has 
been developed by Imperial College London called 
SiKL10. One of the areas that has previously been 
explored with SCD and patient access to health 
information is a patient-held record (attached as 
Appendix 2). The idea is that a patient-held record 
would enable patients with SCD to communicate 
better about their disease with health care 
professionals for prompt and effective treatment. 
The SiKL smartphone application has been developed as a modern interpretation of the patient-
held record11. An electronic health records access programme could be another way to 
modernise this previously raised study area. 
Primary Care Intervention and Sickle Cell as a Chronic Disease 
Transferring what we know works for other chronic diseases, such as improving quality at the 
primary care level, may also increase the effectiveness and cost-efficiency of health care 
outcomes in SCD. However, at times, cost-efficiency may not be immediately evident. For 
example, many at-risk pregnant women and fathers are offered SCD screening too late in 
pregnancy to allow for reproductive choice. One study compared the costs of three screening 
approaches: 1) primary care screening with a test offered to the mother and father together, 2) 
primary care screening with a test offered to the mother and then the father only if the mother is 
a carrier, and 3) screening at the first midwife consultation. The study showed that screening at 
primary care had a higher cost per screening of £13, but it did not assess policy wise whether the 
higher cost per screening had a value of at least £13 GBP suggested a further study to investigate 
this point (Bryan, Dormandy, Roberts, et al., 2011). 
As stated previously, the National Confidential Enquiry into Patient Outcome and Death A Sickle 
Crisis? report criticised the lack of primary care involvement in healthcare for SCD while another 
study claimed that patients are being cared for by ‘primary care providers with limited 
experience’ (Raphael & Oyeku, 2013). We wanted to test a local intervention that could actively 
addresses the quality of primary care received by patients with SCD living in a high prevalence 
community such as northwest London by engaging both primary care providers and patients. 
  
                                                             
10 Apple Store search conducted on 28 May 2014. 
11 http://apple.co/1F95bTM 
FIGURE 13: SIKL APP 
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We had the following objectives: 
 To improve management of SCD at the primary care level; 
 To better educate GPs on SCD; 
 To raise awareness about national SCD standards and guidelines; 
 To increase GP confidence in managing SCD; 
 To increase patient confidence in GPs with regards to SCD knowledge; and 
 To increase patient satisfaction and well-being. 
We conducted a three-month GP educational intervention as a pilot initiative. This intervention 
was designed based upon the two preliminary exercises discussed earlier – the focus group 
study and the patient questionnaire; both outputs informed the intervention. 
The intervention was conducted with a group of GP practices in northwest London that have 
come together and refer to themselves as the Harness Group. The number of practices in the 
group is 15, plus one GP access centre12. There are approximately 20 full-time and 9 part-time 
GPs and an estimated 50 registered patients with SCD within the Harness Group. This was our 
study group (Aljuburi, Okoye, Majeed, et al., 2012). 
The number of practices in northwest London that are not part of the Harness Group is 55. 
There are approximately 122 full-time and 61 part-time GPs and an estimated 155 registered 
patients with SCD in the non-Harness group. The non-Harness Group of GP practices did not 
receive the intervention. This was our control group (Aljuburi, Okoye, Majeed, et al., 2012). 
A patient satisfaction survey of patients with SCD and a GP Questionnaire were used as tools to 
design the intervention (attached as Appendix 3). The patient satisfaction survey was conducted 
during a three-month pre and three month post intervention period. Patients and GPs were 
meant to complete the questionnaire twice to reveal any change in responses pre- and post- 
intervention. In the end, only the patient questionnaire was used. The survey was administered 
one-on-one by a researcher. The survey took approximately twenty minutes to complete. For 
outpatients, the researcher was the clinic nurse. For patients surveyed via support groups and 
for the targeted Harness Group patients, the researcher was the patient representative for that 
community (Aljuburi, Okoye, Majeed, et al., 2012). 
The intervention was based on two things: 
1. Clinical educational sessions for GPs that were conducted over three months. The first 
was piloted on 2 December 2010 and further sessions were held on 13 January 2011 
and 11 February 2011. 
2. An education package on SCD management that was made available to the GPs. 
Outcome 
The desired outcome was to identify if there are any changes (expected improvements) in 
patient satisfaction, to identify whether GPs have made any changes in the way they manage 
SCD pre- and post-intervention, and whether they feel more confidence in managing SCD post-
intervention. 
                                                             
12 1. Church End Medical Centre 2. Buckingham Road Surgery; 3. The Stonebridge Practice 
4. Harness Harlesden Practice 5. Aksyr Medical Practice 6. Brentfield Medical Centre 7. Church Lane 
Surgery 8. Freuchen Medical Centre 9. Oxgate Gardens Surgery 10. Park Road Surgery 11. Harrow Road 
Practice 12. Hilltop Medical Practice 13. Acton Lane Surgery 14. Chaplin Road Surgery 15. Wembley Park 
Medical Centre and 16. Brent GP Access Centre 
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Intervention group Control group 
SCD patient whose GP is not within the Harness
Group 
SCD patient not
registered with a GP 
FIGURE 14: GP INTERVENTION CHART 
 
 
Chart Source: CLAHRC Study Design  
 
   
Because the questionnaires were administered one-on-one, we were able to collect sufficient 
feedback and saw remarkable success in designing an intervention, i.e. the GP Educational 
Packet. The GP Educational Packet is attached as Appendix 4. With respect to identifying if there 
were any improvements in patient satisfaction or identifying whether GPs had made any 
changes in the way they manage SCD pre- and post-intervention and whether they felt more 
confidence in managing SCD post-intervention, we did not feel like we had sufficient 
participation to make any link between the intervention and patient satisfaction or to link the 
intervention and improved GP management of SCD. However, we were able with confidence to 
continue making available the educational intervention for GPs to engage at their option 
(Aljuburi, Okoye, Majeed, et al., 2012). 
Through the implementation of GP educational intervention, we also learned that auditing and 
improving communication between different health care providers is also necessary. This could 
be facilitated by GPs receiving timely information on hospital admission and hospitals advising 
patients to book an appointment with their GP for review after discharge. Receiving proactive 
care from the GP could also be achieved by identifying areas with a relatively high prevalence of 
SCD and designing a local quality improvement scheme. Many patients with chronic illnesses do 
receive proactive care from their GPs; these are generally patients with diseases covered in the 
GP Quality and Outcomes Framework (HSCIC, 2013). At present, SCD is not a part of this 
framework, but could be considered for future inclusion in areas where there is a high 
prevalence of SCD (AlJuburi, Phekoo, Okoye, et al., 2013b). 
Community Approach to SCD 
A ‘community hub’ has also been proposed for SCD. The community hub can be defined as a 
patient centred approach which integrates non-clinical determinants of public health that can 
drive an innovative and collaborative solution to SCD challenges. The SCD community hub 
proposes creating a centre where all non-clinical services that could support sickle cell patients 
are centralised. Local members of the community ‘should be seen as integral to the care-giving 
Patients with sickle cell disease in northwest London 
Estimated n=5 Estimated n=150 
SCD patient whose GP is in 
the Harness Group 
Estimated n=50 
Opprtunistic 
capture at Central 
Mid Hospital
Outpatient clinic 
for children and 
for adults. Weekly 
attendance of
approximately 10-15 patients. 
Opportunistic capture 
at Patient Support 
Group meetings in 
Brent, St Mary's, 
Ealing,
Hammersmith and Fulham 
 
Identified as 
having no GP from 
hospital episode
database. Targeted
capture by letter . 
 
 
Targeted capture. 
Letter written to 
patient requesting 
survey participation 
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process’. Community awareness and trust ‘promotes legitimacy and engagement which can 
provide an essential resource within care coordination programmes’ (Goodwin, Sonola & Thiel, 
2013). The SCD community hub is one such community coordinated programme. It was first 
introduced by the Sickle Cell Society’s Comprehensive Care Project. The SCD community hub 
supports an integrated sickle care pathway that incorporates mental, social, acute, and primary 
care needs. The view is that an all-encompassing model may increase user satisfaction and 
could assist in reducing unnecessary admissions to hospitals (Pizzo, Laverty, Phekoo, et al., 
2014). 
7.8. TRANSLATING RESEARCH INTO POLICY 
The first part of this chapter has shown that many interventions aimed at managing and 
preventing chronic disease are delivered in the primary and community care setting, and that 
SCD should be included.  It has also shown us that the use of information systems can be a 
critical tool in the support of SCD management, policies and interventions aimed at 
strengthening the role of patients in managing their own care (self-care) also contribute to 
improved outcomes. SCD should be included in such interventions and policies.  These 
interventions are activated through policy reform.    
The historical review of health policy reform in England shows a long and quite protracted 
approach. Both those proposing and opposing health reforms have put forward equally selective 
interpretations of history. These arguments often pose significant barriers to change or 
objectivity in health policy making, and reduce the space for policy innovations. Some of the 
health policies that pre-dated the NHS were effective in tackling health inequalities, and 
contemporary policy makers should not let public wariness of this imagined past blind them to 
its potential to inform policy today (Hayes, 2013). 
In order for a change in health policy to have an impact and to be sustainable, such a change 
demands the cooperation and collaboration of governments, health authorities, and patients. A 
strategy with goals and objectives needs to be agreed with clear actions for implementation at 
the national, regional, and local levels. Regardless as to whether the decision is to improve 
quality, to reduce cost, or to engage patients, the process to affect that change has to have a 
holistic approach that assesses and intervenes at different entry points within the health care 
delivery system. Furthermore, local experiences should inform national strategies. This can be 
said to influence any health policy change, but in this case we are speaking specifically to SCD. 
Policies specific to SCD in England have been few and far between. The NHS Sickle Cell and 
Thalassaemia Screening Programme was set up in 2001 in order to introduce an effective 
antenatal and neonatal screening programme for haemoglobinopathies (UK National Screening 
Committee, 2006). The programme gave way to universal neonatal screening for SCD which was 
introduced in England in 2006, with a primary aim of reducing mortality due to pneumococcal 
sepsis in the first few years of life by introducing antibiotic prophylaxis (Dick, 2008). National 
implementation of newborn screening in England has increased the number of children (Green, 
Aljuburi, Majeed, et al., 2012a) identified with SCD, and in many areas it has doubled the disease 
caseload. England is the first country in Western Europe to introduce a national screening 
programme (Streetly, Clarke, Downing, et al., 2008). It now serves as model for other countries, 
including those in Africa where the WHO is supporting implementing newborn screening. Those 
who are not identified by newborn screenings are picked up through their GP or through 
hospital admission due to co-morbidity diagnoses (Streetly, Latinovic, Hall, et al., 2009). 
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7.9. THREE POLICY RECOMMENDATIONS TO REDUCE HOSPITAL 
ADMISSIONS DUE TO SCD 
The ability to control the rate of emergency admissions is a common indicator of success for a 
health system, particularly for conditions where ‘preventive management is possible in the 
community’ (Blunt, n.d.).  Accordingly, this is achievable for SCD through three policy objectives 
that summarise our findings: the need to integrate and coordinate SCD management across 
health care sectors, the need to engage and educate primary care physicians on SCD, and the 
need to strengthen targeted and community based solutions for SCD (Figure 14). 
TABLE 17: THREE POLICY OBJECTIVES 
Integrate and coordinate SCD management across health care sectors 
Engage and educate primary care physicians on SCD 
Create and strengthen targeted and community based solutions for SCD 
 
Chronic diseases require us to move away from acute care and reorient towards ‘prevention, 
self-care, more consistent standards of primary care, and care that is well coordinated and 
integrated.’ (Anon, n.d.) Hence, our policy approach to SCD should be multi- dimensional, in the 
same way that our clinical approach to a chronic disease is multi-dimensional. Policies for SCD 
should be not only coordinated and integrated but also commissioned and targeted. Previous 
studies have shown successful interventions that moved the management of SCD, particularly 
uncomplicated sickle cell pain episodes, from tertiary to primary care (Coleman, Irons & Nicholl, 
2001; Benjamin, Swinson & Nagel, 2000). Our policy focus should continue to emphasise the 
importance of primary care in managing SCD, keeping in mind this multi-pronged approach. 
We have been able to show that SCD is a chronic disease with a high prevalence in some parts of 
England, with a prevalence and cost impact warranting attention to policy. Patients with SCD 
who are admitted to emergency departments account for the majority of health care expenses 
associated with the disease (Carroll, Haywood, Fagan, et al., 2009; Pizzo, Laverty, Phekoo, et al., 
2014). In 2010-2011, England had 6,077 admissions associated with SCD with crisis as a 
primary diagnosis. The total cost for these admissions was £18.8 million, of which 
approximately £17 million (91%) was for emergency admissions (Pizzo, Laverty, Phekoo, et al., 
2014). In addition to the cost analysis study, both the study on admission trends using HES data 
and the NHS Brent local study suggest that the SCD admissions with a short length of stay and 
multiple admissions could be potentially avoidable hospital admissions(Aljuburi, Laverty, 
Green, et al., 2012a; Green, Aljuburi, Majeed, et al., 2012a). 
Hospital readmission rates in England have been used as a measure of poor healthcare 
performance at a local level or when making comparisons over time between hospitals (Mason, 
Daly & Goldacre, 2000). However, there is a need to better understand the different factors that 
influence readmission rates for any disease-specific category (including SCD) to control for 
extenuating factors that would impact on readmissions by allowing a more thorough 
assessment of healthcare outcomes as well as more accurately defining potentially preventable 
readmissions (Nolte, Roland, Guthrie, et al., 2012). Our study shows that SCD patients coming 
from the most deprived areas nationally experience higher rates of SCD hospital readmissions 
as well as inpatient mortality related to SCD, suggesting that there may be inequalities in access 
to health care and health outcomes amongst people with SCD. This continued to be true after 
adjustment for age and comorbidities between these populations, which might commonly be 
thought to contribute to these differences in readmission rates (data not shown). Also, the age 
and comorbidity breakdowns were similar between the least and most deprived groups (data 
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not shown) (Aljuburi, Laverty, Green, et al., 2013a). All this suggests that better integration, 
coordination, engagement of both patient and provider, and targeted community based 
solutions could mitigate the challenges faced by the health system from SCD. 
7.9.1. OBJECTIVE 1: INTEGRATE AND COORDINATE SCD DISEASE MANAGEMENT 
ACROSS HEALTH CARE SECTORS 
There are no universal definitions for coordinated care or integrated care and, in fact, these 
terms are often used interchangeably, although the consensus seems to be that co- ordinated 
care refers specifically to a patient’s clinical coordination of care whereas integrated care refers 
more to the system of health care organisation (Anon, n.d.). For our purposes, we will infer that 
coordination of care refers to the patient and integration of care refers to the system. 
There is evidence that SCD admissions are increasing as an effect of readmissions of patients 
with SCD and that effective discharge planning with a link between hospitals, primary and 
community care might help prevent readmissions (Ballas & Lusardi, 2005a; Ballas & Lusardi, 
2005a; Aljuburi, Phekoo, Okoye, et al., 2012). 
According to the NICE guidelines, better 
coordination of SCD care, including training of 
health care professionals, pain management, 
administration of analgesia, and patient monitoring, 
may yield better results and reduce length of 
hospital stay (Anon, 2012). 
In addition, one of the observations of the focus 
group that we held was that SCD care was neither 
coordinated nor integrated. The questionnaire pilot 
study also reinforced this observation (Aljuburi, 
Phekoo, Okoye, et al., 2012; Aljuburi, Okoye, Majeed, 
et al., 2012). 
One of the integrated and coordinated approaches to SCD care in the US that has recently 
received attention is the patient-centred medical home (PCMH). It is being touted as the 
‘cornerstone of efforts to reform chronic disease management in the US health care system and 
to transform primary care into a centrepiece for improving health care quality’ (Raphael & 
Oyeku, 2013; Landon, Gill, Antonelli, et al., 2010). The PCMH functions like a multidisciplinary 
team of providers through the use of primary care that is focused on the specific patient’s needs 
to ensure integration and coordination. PCMH implementation has shown improvements in 
quality and efficiency for both adults and children and has been advocated as the model to 
follow for every patient with SCD (Raphael & Oyeku, 2013). 
A study conducted by the Hemoglobinopathy Learning Collaborative (HLC) in the US identified 
five key drivers of improved outcomes; included amongst them were reliable identification and 
follow-up and seamless co-management between primary and specialty care. The data was 
collected via a web-based system linked to a reporting portal. Participants included community 
organisations and primary and specialty care providers (Oyeku, Wang, Scoville, et al., 2012). 
Coordination and integration of care for SCD can also follow successful pilot projects for other 
chronic diseases. Wales has initiated a shared care model for people with multiple chronic 
illnesses which coordinates care between primary, secondary, and social care. A reduction in 
emergency admissions for chronic illness of 27% was found between 2007 and 2009, which 
resulted in a cost savings of £2,224,201 (Goodwin, Sonola & Thiel, 2013). 
 
[There should be] review letters
from the hospital. They [general
practitioners] should see how
you are doing. That will be
good. [following discharge from
hospital] why don’t they [GPs]
ever call the patient and follow-
up? 
(AlJuburi, Phekoo, Okoye, et
al., 2013a) 
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Other international models using primary care as a basis to integrating and coordinating care 
could be studied as adaptable models. In Denmark, primary care practices are what policy 
makers would consider patient-centred. The reimbursement is a mix of per diem and fee for 
service. Primary care physicians are paid monthly to retain the patient in the practice and then 
through government negotiated fee schedules for additional individual services. They have 
electronic prescribing systems connected to local pharmacies and an off-hours service which 
includes a telephone service that is operated by physicians who have access to the patient’s 
health registry information. The physicians providing off-hours services are paid for the 
telephone consultations and can either manage the problem by phone, fill a prescription 
electronically or ask the patient to see a physician in the clinic. After the telephone consultation, 
an email is sent to the patient’s registered GP updating them of any off-hours services and 
facilitating any necessary handover to the GP (Davis, Schoenbaum & Audet, 2005). 
There are some organisational and policy barriers as well as critics of integrated and 
coordinated care who claim that without a robust shared electronic patient record, integration 
is challenged. Integrated care is usually implemented through short-term pilot programmes, so 
there may be a lack of sustainability; currently, there is no single outcome framework that 
creates joint accountability. In order to address such barriers, one solution is a programme 
approach to a specific population group that includes good access to extended primary care 
services, supporting health promotion and primary prevention, and co-ordinating community-
based packages for rehabilitation, re-enablement, and independent living (Ham, Imison, 
Goodwin, et al., 2011). 
National Voices, a national coalition of health and social care charities in England suggested that 
commissioners track patients across the continuum of care (Goodwin, Smith, Davies, et al., 
2012). A King’s Fund study suggested that a significant investment in primary and community 
care services is needed in order to achieve well-coordinated care where general practices act as 
the hub of a ‘wider system of care that takes direct responsibility for coordinating and 
signposting individuals to services within the NHS as well as beyond healthcare on a 24/7 basis’ 
(Goodwin, Smith, Davies, et al., 2012). A Nuffield Trust analysis suggested encouraging 
integrated care through payment incentives (Bardsley, Smith & Car, 2013). 
Another option is to use an accountable care model where providers are held jointly 
accountable for delivering outcomes for a certain population over a certain time at an agreed 
cost (McClellan, Kent, Beales, et al., 2013). The idea of moving from a supply-led health care 
system to a demand-led health care system speaks to the core of the accountable care model 
(McClellan, Kent, Beales, et al., 2013). 
Five components deliver accountable care: 
1. Jointly accountable designated population (such as an SCD population within a 
borough); 
2. Outcomes that are targeted and respond to the patients’ needs; 
3. A measuring tool to monitor the performance of outcomes and to learn from the 
variation; 
4. Payments and incentives aligned with target outcomes; and 
5. Co-ordinated delivery across a range of providers organised in a way to achieve the 
desired outcome mentioned in the second point above (McClellan, Kent, Beales, et al., 
2013). 
Accountable care models have been used successfully in emerging and even developing health 
care systems. In Singapore and the United States, these models have been used for the elderly, 
for people with diabetes, and for other chronic disease populations. Because reimbursement is 
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linked to patient outcomes, cost savings can be realised eventually, but what is realised more 
immediately is the quality and value for money in the actual care received. The approach also 
encourages patient engagement. The approach of accountable care takes a broader perspective 
than illness. Outcomes expand beyond the hospital and include primary and community care, 
public health and social and behavioural care. For policy makers, ‘this may mean working across 
funding streams, agreeing on key outcomes, creating mechanisms to link datasets, and pushing 
for data transparency’(McClellan, Kent, Beales, et al., 2013). In other words, goals should be to 
adjust pay mechanisms to reward outcomes, collaborate across multiple providers, and enable 
information systems that allow for multiple providers and patients to share data. 
Bundled care payments have seen success in dealing with patients with specific diseases such as 
diabetes. A particular episode of care is paid as a bundle across a range of services for that 
episode of care. This is particularly relevant for long-term or chronic diseases (Bloom, Graf, 
Anderer, et al., 2010). 
The overlapping idea behind all of these approaches of care is the alignment of services and the 
providers of those services. There is no point in looking at the individual areas if the areas 
themselves are unable to form a full map of care. 
Policy Recommendation: Coordinate and integrate care across primary secondary and 
tertiary care for better management of SCD. 
7.9.2. OBJECTIVE 2: ENGAGE AND EDUCATE PRIMARY CARE PHYSICIANS ON SCD 
Our study assessing the views of patients with SCD 
showed that patients and carers often bypass their 
general practitioner for acute problems and head 
straight for the emergency department, suggesting 
that better primary care interventions could 
reduce emergency department attendances and 
emergency admissions (Aljuburi, Phekoo, Okoye, et 
al., 2012; Aljuburi, Okoye, Majeed, et al., 2012). A 
study in the East Midlands looked at 145 general 
practices and showed that as the proportion of 
patients able to consult their primary care 
physician increased, emergency admission rates 
decreased (Bankart, Baker, Rashid, et al., 2011). 
Another study conducted in London showed that 
overnight admissions decreased as a result of 
better pain management, use of analgesia, 
transfusions, community support, and improved 
education at home (Day, Thein, Drasar, et al., 
2011). Moving certain treatments from the hospital and into a primary, community, or home 
setting could help curb unnecessary hospital admissions. Elective transfusions, for example, are 
an essential treatment in SCD and can now be provided in an ambulatory setting instead of 
admitting the patients in hospital to receive the treatment (Day, Thein, Drasar, et al., 2011). 
Another study emphasised the need for ‘a preventative and comprehensive model of care in 
addition to care management’ (Kanter & Kruse-Jarres, 2013). Adults with SCD need coordinated 
care led by a primary care physician in coordination with a provider experienced in SCD (Inati, 
Chabtini, Mounayar, et al., 2009). However, patients and GPs need to collaboratively have the 
confidence to manage aspects of SCD at the primary care level; this can be better accomplished 
by engaging and educating primary care physicians on SCD. Our focus group and questionnaire 
If I take my son to hospital now,
the doctors like to have a
relationship and know how he is
doing. If I take him to the GP
there is no relationship; he is a
stranger. 
[You have a] five minute
conversation with the GP. You
are in and out. I prefer to go to
the hospital, I know them there.
I am safe. My nurse knows me.
I know my GP, but does he
really know me? I go to the
hospital. They know me.
(Aljuburi, Phekoo, Okoye, et al., 
2012) 
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study showed a gap in this area. Our limited GP intervention which provided two outputs, an 
SCD database template and an educational packet aimed at primary care physicians, showed 
that there is both a need and a desire for educational support (Aljuburi, Phekoo, Okoye, et al., 
2012; Aljuburi, Okoye, Majeed, et al., 2012). 
Policy Recommendation: Engage and educate primary health care providers for better 
management of SCD. 
7.9.3. OBJECTIVE 3: CREATE AND STRENGTHEN TARGETED AND COMMUNITY 
BASED SOLUTIONS FOR SCD 
According to the King’s Fund, coordinated care programmes flourish at the neighbourhood level 
where the ‘benefits of engagement with local communities sit alongside the need to have close 
working relationships within multidisciplinary care teams’ (Goodwin, Sonola & Thiel, 2013). 
Nationally and globally, there is growing evidence that this grassroots approach goes to the 
heart of public health policy. 
In one study taking place in the thick forest-covered Indian mountains of Niligiris, an 
intervention for SCD care and immunisation was implemented. The intervention was very 
successful and the results of the study showed that even in a vastly disadvantaged area, people 
can overcome socioeconomic and cultural barriers related to health care at the community level. 
This community ownership is what the researchers credited the success of the programme to 
and what they claimed as being ‘perhaps the most important lesson that could potentially be 
translated to other low-income settings’ (Nimgaonkar, V, et al., 2014). 
A study with a focus on reducing avoidable emergency admissions also boldly stated that the 
key to avoiding preventable hospital admissions is through ‘preventive care delivered in the 
community, whether through improved technology or service design’; otherwise, we are likely 
to continue seeing potentially avoidable emergency admissions (Blunt, n.d.). This locally grown 
approach to reducing avoidable emergency admissions is just as applicable to SCD. SCD 
management must be targeted and local. 
In our study of the HES data, we saw that the rate of hospital admissions in England has 
increased for SCD; London accounts for the majority of admissions in England and the majority 
of these hospitalisations are short-stay. These data show that SCD is a growing concern in 
England and provides a basis to continue further investigations into explaining such trends. Our 
study also highlighted that the majority of patients admitted with SCD were discharged within 
24 hours, suggesting that these admissions could potentially be prevented through better 
ambulatory and community care of patients. This includes better care in emergency 
departments, which is an area that PCTs with a high prevalence of SCD should consider 
investigating (Aljuburi, Laverty, Green, et al., 2012a). 
In two more of our studies – the one examining socioeconomic deprivation and the link to 
admission, and the one examining the costs associated with SCD admissions, we noted that 
adolescents are a high risk age group. The highest inpatient mortality for those with SCD 
occurred in patients living in the most socioeconomically deprived areas, with the highest risk 
of admission for patients aged 10-19 years. We also examined the association between age and 
gender on incurring extra bed days, showing that patients 10-19 years old are much more likely 
to incur extra bed days. In the study examining trends on admission using the HES data, we saw 
that those in the age group 20-29 years had a higher proportion of crisis admissions than the 
other groups (Aljuburi, Laverty, Green, et al., 2013a). This flags the issue of a gap in addressing 
the management of adolescents and young adults when it comes coordinating their care. 
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Adolescents need a bespoke policy that can provide them and their health care providers a 
bridge from the paediatric guidelines to the adult guideline, in what some researchers refer to 
as adolescent transitional care (Jordan, Swerdlow & Coates, 2013; Quinn, Rogers, McCavit, et al., 
2010; Telfair, Ehiri, Loosier, et al., 2004). This supports a concept analogous to the inverse care 
law, where differentials in access to care vary inversely with the (SCD) population most at need 
(Lyratzopoulos, Havely, Gemmell, et al., 2005; Hart, 1971). Targeted intervention programmes 
that concentrate on a small number of high risk patients, such as improving access to 
appropriate care or adherence to medication protocols (Bloomberg, Trinkaus, Fisher, et al., 
2003; Frei-jones, Field & DeBaun, 2009), provide genuine opportunities to prevent a large 
number of recurrent hospitalisations. Adolescents with SCD are one target group. 
Some readmissions may also be prevented through policy initiatives such as the development 
and implementation of Local Enhanced Services for people with SCD. Local Enhanced Services 
are designed to meet local health needs and may therefore be particularly suitable for a 
condition such as SCD where the burden of disease is highest in a few urban areas such as 
London. 
The assumption is that this local and targeted approach can come via a primary care 
intervention. Patients with short length of stay and multiple admissions may be potentially 
amenable to primary care intervention. The practices which have the highest numbers of sickle 
cell disease patients who frequently seek emergency care can be earmarked for educational 
intervention designed to help further engage general practitioners in the care and management 
of their sickle cell patients. This assumption is calculated in that it was built on the results from 
our three targeted exercises introduced in previous chapters. 
1. A focus group to inform on patient feelings regarding SCD and how its care is handled. 
2. A quantitative questionnaire to better assess the design of an intervention. 
3. Installation of a disease specific primary care template that GPs can use when they 
receive SCD patients in their office. 
Policy Recommendation: Create and strengthen targeted and community based solutions 
for SCD. 
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7.10. CONCLUSION 
The results of this research have helped to inform a primary care educational intervention 
geared toward general practitioners. Supplementary to the educational intervention was the 
development of an SCD database template that could be uploaded into patient databases in GP 
surgeries, which could prompt GPs to ask necessary questions when an SCD patient visits his or 
her GP. The research opened an opportunity to both identify future areas of growth related to 
this study and to make policy recommendations specific to the management of SCD in England.  
We have been fortunate to realize several key outputs from this project. The research has 
resulted in several ouputs that provide an opportunity for future research and policy 
implementation for SCD. It has produced the first national study on trends for hospital 
admission rates for SCD using HES data in England. It has produced the first study using HES 
data to assess the cost of admissions due to SCD, and it has delivered both a GP educational 
intervention guideline and a GP template with the potential for wider roll-out.  
This study also identified adolescent care as an area that needs to be addressed.  When studying 
hospital admissions that may be avoidable, counselling the adolescent age group may be an 
important way to teach how this disease is passed on and that responsible choices should be 
made.  Counselling may also be relevant for not only disease carriers, but also for trait carriers 
as genetic counselling becomes a part of education for prevention of the next generation of 
disease.    
HES data is a comprehensive database which allows us to see all NHS admissions even those 
that are carried out in private hospitals.  Its limitation is that it does not allow one to understand 
the patient.  For example, we are unable to see severity of disease; what was going on prior to 
admission or what happens after discharge which then may impact things such as readmission.  
The patient led studies, i.e., the patient focus group and questionnaire mitigated this, but future 
studies could further explore this as a broader picture or also examine the rise of hospital 
admissions due to SCD as compared to the rise in all hospital admissions. This will become more 
feasible in the future through the availability of new NHS data sets that can link data on 
individual patients across different parts of the health system and also with external data sets 
such as mortality records.  But knowing this limitation also shows that not only do the findings 
of the studies give opportunity for future research and policy building, but so do the limitations 
of this study. 
The outputs of the study have helped to inform the community hub project, the SiKL 
smartphone application, and also helped to secure second round funding for the NW London 
CLAHRC from the NIHR for continued research for the period 2013-2018. In the feedback from 
the application for CLAHRC funding, the work on sickle cell disease and the high level of patient 
participation were highly commended and a key factor in the successful application for funding. 
Recently, SCD has also achieved specialised commissioning status, although the current 
specifications focus mainly on the provision of acute care (Pizzo, Laverty, Phekoo, et al., 2014). 
This research has provided the groundwork for policy recommendations related to SCD from a 
public health perspective, an economic perspective, and an equity perspective. Further research 
is needed for a detailed implementation plan and the absorption of any innovation. 
Despite these outputs and the future goals of SCD policy, one thing to critically keep in mind is 
that the challenge and the reason for why many policies never actually succeed are not in the 
policies themselves but rather the execution of the policies. There is a disconnect between 
policy and implementation. In order to create policies that are actually successful and 
sustainable, including those mentioned above for SCD, there needs to be a bridge across this 
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divide. Future research will need to address this gap (Gauld, Blank, Burgers, et al., 2012). This 
will be taken forward in the new phase of CLARHC funding in work led by Professor John 
Warner and colleagues from Imperial College London and the NHS in NW London. 
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APPENDIX 1: COSTS FOR ADMISSIONS BY SHA AND PCT 2010-11 
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Liverpool 3.94 28,514.06 2,515.16 31,029.22  31,029.22 
Q.31 
North 
5N 
T 
Manchester 20.01 264,153.72 4,787.14 268,940.86 240.89 269,181.75 
Q.31 
North 
5N 
F 
North Lancashire 
T. 
0.30 3,028.49 3,028.49  3,028.49 
Q.31 
North 
5J5 Oldham 1.79 6,338.40 3,111.88 9,450.28  9,450.28 
Q.31 
North 
5F5 Salford 4.68 17,895.42  17,895.42  17,895.42 
Q.31 
North 
5N 
J 
Sefton 0.37 3,087.41  3,087.41  3,087.41 
Q.31 
North 
5F7 Stockport 1.40 6,502.53  6,502.53  6,502.53 
Q.31 
North 
5N 
R 
Trafford 0.93 6,620.55 6,620.55  6,620.55 
Q.31 
North 
5J2 Warrington 1.01 6,184.42  6,184.42  6,184.42 
Q.31 
North 
5N 
K 
Wirral 0.33 1,594.32  1,594.32 1,945.61 3,539.93 
Q.32 
Yorkshire 
5JE Barnsley 0.84 3,043.71 3,043.71 6,087.42  6,087.42 
Q.32 
Yorkshire 
5N 
Y 
Bradford  
& Airedale 
6.92 89,905.22 5,590.79 95,496.01  95,496.01 
Q.32 
Yorkshire 
5J6 Calderdale 1.46 4,799.20 4,799.20  4,799.20 
Q.32 
Yorkshire 
5N 
5 
Doncaster 2.02 18,349.76  18,349.76  18,349.76 
Q.32 
Yorkshire 
5N 
X 
Hull Teaching 4.08 30,279.89  3,090.16  3,090.16 
Q.32 
Yorkshire 
5N 
2 
Kirklees 4.94 61,715.86  61,715.86  61,715.86 
Q.32 
Yorkshire 
5N 
1 
Leeds 7.30 153,191.20 3,119.09 156,310.29 1,233.30 157,543.59 
Q.32 
Yorkshire 
TA 
N 
North East 
Lincolnshire 
0.61 1,565.62 1,565.62  1,565.62 
Q.32 
Yorkshire 
5N 
V 
North Yorkshire 
and York 
0.38 9,118.57 9,118.57  9,118.57 
Q.32 
Yorkshire 
5H 
8 
Rotherham 1.22 7,670.81 7,670.81  7,670.81 
Q.32 
Yorkshire 
5N 
4 
Sheffield 4.62 56,370.18 19,511.22 75,881.40  75,881.40 
Q.32 Yorkshire 5N Wakefield District 0.88 3,208.70 1,265.49 4,474.19 4,474.19 
 
  
 
 
and H. 3 
Q. 33 
East 
5N 
7 
Derby City 5.64 28,385.27 3,077.73 31,463.00  31,463.00 
Q. 33 
East 
5N 
6 
Derbyshire 
County 
0.57 7,705.67 1,255.50 8,961.17  8,961.17 
Q. 33 
East 
5P 
C 
Leicester City 2.71 221,819.63 3,107.22 224,926.85 8,108.81 233,035.66 
Q. 33 
East 
5P 
A 
Leicestershire 
County R 
3.16 38,297.65  38,297.65 1,965.77 40,263.42 
Q. 33 
East 
5N 
9 
Lincolnshire 
Teaching 
0.69 10,679.28  10,679.28 237.54 10,916.83 
Q. 33 
East 
5E 
M 
Nottingham City 32.47 283,754.21 8,092.28 291,846.49  291,846.49 
Q. 33 
East 
5N 
8 
Nottinghamshire 
C.T 
0.15 3,070.27  3,070.27  3,070.27 
Q.34 
West 
5P 
G 
Birmingham East 
and N. 
10.73 104,037.47 1,257.54 105,295.01 243.19 105,538.21 
Q.34 
West 
5M 
D 
Coventry 
Teaching 
3.57 37,170.42 1,270.55 38,440.97  38,440.97 
Q.34 
West 
5P 
E 
Dudley PCT 4.29 22,268.98 1,270.55 23,539.52  23,539.52 
Q.34 
West 
5M 
X 
Heart of 
Birmingham T 
5.40 262,470.11 9,225.77 271,695.88 3,931.35 275,627.23 
Q.34 
West 
5P 
H 
North 
Staffordshire 
0.97 3,133.15  3,133.15  3,133.15 
Q.34 
West 
5P 
F 
Sandwell 10.39 68,804.28 1,270.55 70,074.82 491.42 70,566.24 
Q.34 
West 
5M 
2 
Shropshire 
County 
0.69 6,041.01  6,041.01  6,041.01 
Q.34 
West 
5Q 
W 
Solihull 1.42 7,819.73  7,819.73  7,819.73 
Q.34 
West 
5M 
1 
South 
Birmingham 
20.10 190,790.53 4,345.80 195,136.34 491.42 195,627.76 
Q.34 
West 
5P 
K 
South 
Staffordshire 
0.50 6,271.39  6,271.39  6,271.39 
Q.34 
West 
5PJ Stoke on Trent 3.44 25,741.22  25,741.22  25,741.22 
Q.34 
West 
5M 
K 
Telford and 
Wrekin 
4.29 13,759.16 3,020.50 16,779.66  16,779.66 
Q.34 
West 
5M 
3 
Walsall Teaching 4.76 33,876.12  33,876.12  33,876.12 
Q.34 
West 
5M 
V 
Wolverhampton 
City 
1.24 9,316.41  9,316.41  9,316.41 
Q.34 
West 
5P 
L 
Worcestershire 1.45 14,133.78 1,257.54 15,391.32  15,391.32 
Q.35 East 
of England 
5P2 Bedfordshire 3.29 31,726.42 10,217.96 41,944.38 1,317.60 43,261.98 
Q.35 East 
of England 
5P 
P 
Cambridgeshire 1.98 32,019.07 3,908.06 35,927.13  35,927.13 
Q.35 East 
of England 
5P 
R 
Great Yarmouth 
and W 
0.44  1,218.32 1,218.32  1,218.32 
Q.35 East 
of England 
5Q 
V 
Hertfordshire 8.92 263,068.06 55,312.47 318,380.53 1,211.88 319,592.41 
Q.35 East 
of England 
5G 
C 
Luton 39.41 203,152.33 3,332.28 206,484.61  206,484.61 
Q.35 East 
of England 
5P 
X 
Mid Essex 2.42 25,239.97  25,239.97  25,239.97 
Q.35 East 
of England 
5P 
Q 
Norfolk 0.26 4,764.59  4,764.59  4,764.59 
Q.35 East 
of England 
5P 
W 
North East Essex 0.30 3,082.23  3,082.23  3,082.23 
Q.35 East 
of England 
5P1 South East Essex 0.30 9,672.14  9,672.14  9,672.14 
Q.35 East 
of England 
5P 
Y 
South West Essex 3.56 41,255.26 8,715.70 49,970.96  49,970.96 
Q.35 East 
of England 
5P 
T 
Suffolk 2.72 30,894.60 1,260.39 32,154.99 1,306.27 33,461.26 
Q.35 East 
of England 
5P 
V 
West Essex 3.32 26,353.86  26,353.86  26,353.86 
Q.36 London 5C 
2 
Barking and 
Dagenham 
68.56 364,400.50 64,994.92 429,395.42 8,953.02 438,348.44 
Q.36 London 5A 
9 
Barnet 23.06 230,222.55 12,512.72 242,735.27 2,977.07 245,712.35 
Q.36 London TA 
K 
Bexley Care Trust 30.65 163,582.69 14,821.25 178,403.94 570.66 178,974.61 
Q.36 London 5K 
5 
Brent Teaching 102.7 
1 
816,513.50 12,279.81 828,793.31 14,464.82 843,258.13 
Q.36 London 5A 
7 
Bromley 17.00 112,356.40 15,740.26 128,096.66 290.30 128,386.95 
Q.36 London 5K 
7 
Camden 18.20 132,341.63 28,954.52 161,296.15 6,676.22 167,972.36 
Q.36 London 5C City and Hackney 346.6 2,263,929.38 534,160.71 2,798,090.0 63,582.41 2,861,672.49 
3 Teach. 7 8 
 
 
Q.36 London 5K 
9 
Croydon 77.91 745,439.97 19,714.91 765,154.88 9,894.25 775,049.14 
Q.36 London 5H 
X 
Ealing 34.82 303,962.39 20,635.42  
324,597.81 
2,557.92 327,155.73 
Q.36 London 5C 
1 
Enfield 68.49 592,207.17 29,422.94 621,630.11  621,630.11 
Q.36 London 5A 
8 
Greenwich 
Teaching 
70.42 419,118.03 26,249.18 445,367.22  445,367.22 
Q.36 London 5H 
1 
Hammersmith and 
Fulh. 
48.24 238,238.83   238,238.83 4,193.96 242,432.79 
Q.36 London 5C Haringey 153.3 1,203,689.40 42,598.08 1,246,287.4 5,895.77 1,252,183.26 
9 Teaching PCT 8 8 
Q.36 London 5K 
6 
Harrow 33.19 196,649.77 3,700.03 200,349.81  200,349.81 
Q.36 London 5A 
4 
Havering 10.94 92,387.46 1,437.84  
93,825.30  93,825.30 
Q.36 London 5A 
T 
Hillingdon 14.02 89,094.73  89,094.73  89,094.73 
Q.36 London 5H 
Y 
Hounslow 5.06 36,578.71 3,670.89 40,249.60  40,249.60 
Q.36 London 5K 
8 
Islington 31.80 165,137.17 50,453.93 215,591.10 14,279.81 229,870.91 
Q.36 London 5L 
A 
Kensington and 
Chelsea 
34.38 193,403.20 34,192.20 227,595.40 532.01 228,127.41 
Q.36 London 5A 
5 
Kingston 14.89 65,249.58 7,280.35 72,529.93  72,529.93 
Q.36 London 5L 
D 
Lambeth 78.54 701,592.68 67,198.84 768,791.52 10,316.11 77,514.96 
Q.36 London 5L 
F 
Lewisham 92.44 667,443.96 57,368.46  
724,812.42 
13,694.84 738,507.26 
Q.36 London 5C 
5 
Newham 62.55 498,489.48 51,103.68 549,593.16 10,189.18 559,782.34 
Q.36 London 5N 
A 
Redbridge 67.95 602,773.58 32,508.31 635,281.89 23,964.23 659,246.12 
Q.36 London 5M 
6 
Richmond and 
Twicken. 
0.53 1,918.17  1,918.17  1,918.17 
Q.36 London 5L 
E 
Southwark 60.62 461,880.46 61,307.34 523,187.80  523,187.80 
Q.36 London 5M 
7 
Sutton and 
Merton 
28.74 252,620.20 57,982.86 310,603.05 2,548.21 313,151.26 
Q.36 London 5C 
4 
Tower Hamlets 8.90 69,996.30 7,816.12 77,812.42  77,812.42 
Q.36 London 5N 
C 
Waltham Forest 51.25 315,550.09 97,761.35 413,311.44 5,391.55 418,702.99 
Q.36 London 5L 
G 
Wandsworth 35.78 309,506.58 35,640.86 345,147.45 17,807.38 362,954.83 
Q.36 London 5L 
C 
Westminster 32.25 263,911.91 23,190.68 287,102.59 19,475.12 306,577.70 
Q.37 
South 
5L 
Q 
Brighton and 
Hove City 
11.73 91,234.47 6,851.82  
98,086.29  98,086.29 
Q.37 
South 
5P7 East Sussex 
Downs W. 
0.60 3,214.69   
3,214.69 
 3,214.69 
Q.37 
South 
5Q 
A 
Eastern and 
Coastal Kent 
0.54 50,565.20 6,932.11 57,497.31  57,497.31 
Q.37 
South 
5P8 Hastings and 
Rother 
1.71 7,808.30   7,808.30  7,808.30 
Q.37 
South 
5L 
3 
Medway 9.93 62,161.74 1,333.59 63,495.33  63,495.33 
Q.37 
South 
5P5 Surrey 2.35 88,227.56  8,227.56  88,227.56 
Q.37 
South 
5P9 West Kent 5.69 71,170.18 4,035.28 75,205.46 580.59 75,786.05 
Q.37 
South 
5P6 West Sussex 2.36 ,060.35 7,816.12 54,876.47 251.55 55,128.02 
Q. 38 
South 
5Q 
G 
Berkshire East 1.98 19,666.46 3,196.18 22,862.64  22,862.64 
Q. 38 
South 
5Q 
F 
Berkshire West 6.85 94,427.94  94,427.94 1,082.14 95,510.08 
Q. 38 
South 
5Q 
D 
Buckinghamshire 3.72 49,435.48 7,051.63 56,487.11  56,487.11 
Q. 38 
South 
5Q 
C 
Hampshire 0.47 14,625.91  14,625.91  14,625.91 
Q. 38 
South 
5Q 
T 
Isle of Wight 
NHS 
0.70 3,075.99  3,075.99  3,075.99 
Q. 38 
South 
5C 
Q 
Milton Keynes 0.41 3,279.96  3,279.96  3,279.96 
Q. 38 
South 
5Q 
E 
Oxfordshire 4.73 67,009.44 8,047.49 75,056.93  75,056.93 
Q. 38 
South 
5F 
E 
Portsmouth City 
Teaching 
3.27 20,859.09  20,859.09  20,859.09 
Q. 38 
South 
5L 
1 
Southampton City 9.71 66,712.88 6,326.39 73,039.27  73,039.27 
Q.39 
South 
5F 
L 
Bath and North 
East Som. 
7.36 36,330.77 9,567.15 45,897.92  45,897.92 
 
 
Q.39 
South 
5Q 
J 
Bristol 17.02 180,505.09 33,917.74 214,422.84 8,768.54 223,191.38 
Q.39 
South 
5Q 
Q 
Devon 0.53 12,038.89  12,038.89  12,038.89 
Q.39 
South 
5Q 
H 
Gloucestershire 2.85 38,148.60 3,189.05 41,337.65  1,337.65 
Q.39 
South 
5M 
8 
North Somerset 0.47 3,189.05  3,189.05  3,189.05 
Q.39 
South 
5F1 Plymouth 
Teaching 
4.44 20,585.88 2,608.15 23,194.02  3,194.02 
Q.39 
South 
5A 
3 
South 
Gloucestershire 
2.34 15,945.25 1,304.07 17,249.32  17,249.32 
Q.39 
South 
5K 
3 
Swindon 0.48 1,594.40  1,594.40  1,594.40 
Q.39 
South 
5Q 
K 
Wiltshire 0.22 1,589.00  1,589.00  1,589.00 
(1) The rate is given by the number of admissions in emergency and elective over the number of population in the PCT for 
2011. 
(2) Source of population at PCT level: NHS 2011 https://goo.gl/hPkQ67 (Pizzo, Laverty, Phekoo, et al., 2014 
  
 
 
APPENDIX 2: PATIENT QUESTIONNAIRE 
 
SECTION 1: DEMOGRAPHIC INFORMATION
 
 What year did you qualify as a physician? ................................ 
 Did you qualify in the UK?  Yes No 
 How many full-time equivalent GPs work in your practice? 
 How many full-time equivalent nurses work in your practice? 
 What is your practice list size? 
 Do you hold any of the qualifications listed (tick all that apply): 
MRCGP/FRCGP 
MRCP/FRCP 
 Is your practice: 
Postgraduate training practice 
Undergraduate teaching practice 
 Which, if any, clinical computer system or electronic patient record (EPR) system does 
your practice use? 
EMIS 
Vision  
System One 
Other .................... 
None 
 Does your practice use an electronic disease register with specific read codes for 
haemoglobinopathies? 
Yes  
No 
  
 
 
 Does your practice use a computer driven call/recall system to identify patients with 
long-term illness due for a periodic review? 
Yes  
No 
 GP name and practice address 
...................................................………………………………………………................................................................
.....................................................................................................................................................................................
.......................... Post Code ……………………………………… 
  
 
 
 
SECTION 2:  SCREENING and IMMUNISATIONS 
Question 1. 
Do you arrange for high risk patients to be screened for haemoglobinopathies if there is no 
record of prior testing? 
Yes  
No 
Question 2. 
a. For children with SCD, do you keep a record in the EPR system of whether they have 
undergone Transcranial Doppler Ultrasonography (TCD) screening? 
Yes  
No 
b. If there is no record, would you seek advice from a paediatric haematologist to ensure 
they have received a TCD? 
Yes  
No 
Question 3. 
For your patients with SCD, do you liaise with a haematologist to ensure they receive regular 
comprehensive medical exams including screening for renal, pulmonary, and liver disease? 
Yes  
No 
Question 4. 
a. Do you carry out an annual general health review of your SCD patients or keep a 
record of the results of their annual review with a haematologist? 
Yes 
No 
b. If  YES, please tick what items are measured at these annual reviews: 
( ) height ( ) weight ( ) blood pressure ( ) urinalysis ( ) liver function 
      ( ) cholesterol ( ) glucose ( ) renal function ( ) smoking status ( 
) alcohol intake 
  
 
 
Question 5. 
Which of the following vaccines do you administer as a standard practice to your SCD patients? 
( ) Influenza Vaccine for above age 6 months ( ) pneumococcal conjugate vaccine (PREVNAR) 
( ) Pneumovax vaccine at 2 years ( ) Meningococcal vaccine at age 2 year + with follow-up 
dose at 7 and 12 yrs 
( ) Hepatitis B ( ) Other (please state)…………………………………………. 
  
 
 
 
SECTION 3: INTERVENTIONS
 
Question 6. 
How often do you prescribe: 
a) For children 5 and under, twice Daily Penicillin V or an equal antibiotic as prophylaxis 
Never Rarely Sometimes Regularly 
 (1-2/year) (3-4/year) (Monthly) 
 
b) Folic acid, zinc and/or other supplements 
 
 
c) 
 
 
d) Other (please specify) 
…………………………………………………………………………………………............ 
Question 7. 
For patients who experience frequent vaso-occlusive painful episodes (3 or more per year), 
would you consider referring to a haematologist to see if they would benefit from hydroxyurea 
therapy? 
Yes 
No 
Question 8. 
How confident are you with your clinical knowledge of SCD and the treatment options given to 
your patient to manage their disease? 
0 1 2 3 4 5 6 7 8 9 10 
(0=Not confident at all) (10=Very confident) 
  
Never Rarely 
 
Sometimes 
 
Regularly 
 
Analgesia or other pain control protocol 
Never Rarely 
 
Sometimes 
 
Regularly 
 
 
 
Question 9. 
List the kind of support you currently give to your patients or ensure they receive this from a 
specialist clinic 
Pain Control  
Prescriptions 
General SCD advice 
General health and lifestyle advice  
Contraception advice 
Genetic and pre-conceptual counselling  
Immunisation 
Specialist Referral  
Other (please state) 
 
Question 10. 
List the kind of support or intervention you would like to receive from the NHS in order to 
better manage SCD at the primary care level or any other comments you may have 
……………………………………………………………………………………………………………………………………………… 
……………………………………………………………………………………………………………………………………………… 
……………………………………………………………………………………………………………………………………………… 
……………………………………………………………………………………………………………………………………………… 
……………………………………………………………………………………………………………………………………………… 
……………………………………………………………………………………………………………………………………………… 
……………………………………………………………………………………………………………………………………………… 
……………………………………………………………………………………………………………………………………………… 
……………………………………………………………………………………………………………………………………………… 
End of questionnaire 
 
 
APPENDIX 3: PATIENT COMMENTS SNAPSHOT 
 
 
  
 
 
APPENDIX 4: GP QUESTIONNAIRE 
SECTION 1: DEMOGRAPHIC INFORMATION 
 
 What year did you qualify as a physician? ................................ 
 Did you qualify in the UK?  Yes No 
 How many full-time equivalent GPs work in your practice? 
 How many full-time equivalent nurses work in your practice? 
 
 What is your practice list size? 
 Do you hold any of the qualifications listed (tick all that apply): 
MRCGP/FRCGP 
MRCP/FRCP 
 Is your practice: 
Postgraduate training practice 
Undergraduate teaching practice 
 Which, if any, clinical computer system or electronic patient record (EPR) system does 
your practice use? 
EMIS 
Vision  
System One 
Other .................... 
None 
 Does your practice use an electronic disease register with specific read codes for 
haemoglobinopathies? 
Yes 
No 
 Does your practice use a computer driven call/recall system to identify patients with 
long-term illness due for a periodic review? 
Yes  
No 
 
 
 
 GP name and practice address 
...................................................………………………………………………................................................................
.....................................................................................................................................................................................
Post Code……………………………………… 
  
 
 
 
SECTION 2:  SCREENING and IMMUNISATIONS 
Question 1. 
Do you arrange for high risk patients to be screened for haemoglobinopathies if there is no 
record of prior testing? 
Yes 
No 
Question 2. 
a. For children with SCD, do you keep a record in the EPR system of whether they have 
undergone Transcranial Doppler Ultrasonography (TCD) screening? 
Yes 
No 
b. If there is no record, would you seek advice from a paediatric haematologist to ensure 
they have received a TCD? 
Yes  
No 
Question 3. 
For your patients with SCD, do you liaise with a haematologist to ensure they receive regular 
comprehensive medical exams including screening for renal, pulmonary, and liver disease? 
Yes 
No 
Question 4. 
a. Do you carry out an annual general health review of your SCD patients or keep a 
record of the results of their annual review with a haematologist? 
Yes  
No 
b. If YES, please tick what items are measured at these annual reviews: 
( ) height ( ) weight ( ) blood pressure ( ) urinalysis ( ) liver function  
( ) cholesterol ( ) glucose ( ) renal function ( ) smoking status ( ) alcohol intake 
  
 
 
Question 5. 
Which of the following vaccines do you administer as a standard practice to your SCD patients? 
( ) Influenza Vaccine for above age 6 months ( ) pneumococcal conjugate vaccine (PREVNAR) 
( ) Pneumovax vaccine at 2 years ( ) Meningococcal vaccine at age 2 year + with follow-up 
dose at 7 and 12 yrs ( ) Hepatitis B ( ) Other (please state)…………………………………………. 
  
 
 
 
SECTION 3: INTERVENTIONS
 
Question 6. 
How often do you prescribe: 
a) For children 5 and under, twice Daily Penicillin V or an equal antibiotic as prophylaxis 
Never Rarely Sometimes Regularly 
 (1-2/year) (3-4/year) (Monthly) 
 
b) Folic acid, zinc and/or other supplements 
 
 
c) 
 
 
d) Other (please specify) 
…………………………………………………………………………………………........................................................................... 
 Question 7. 
For patients who experience frequent vaso-occlusive painful episodes (3 or more per year), 
would you consider referring to a haematologist to see if they would benefit from hydroxyurea 
therapy? 
Yes 
No 
Question 8. 
How confident are you with your clinical knowledge of SCD and the treatment options given to 
your patient to manage their disease? 
0 1 2 3 4 5 6 7 8 9 10 
(0=Not confident at all) (10=Very confident) 
  
Never Rarely 
 
Sometimes 
 
Regularly 
 
Analgesia or other pain control protocol 
Never Rarely 
 
Sometimes 
 
Regularly 
 
 
 
Question 9. 
List the kind of support you currently give to your patients or ensure they receive this from a 
specialist clinic 
Pain Control  
Prescriptions 
General SCD advice 
General health and lifestyle advice  
Contraception advice 
Genetic and pre-conceptual counselling  
Immunisation 
Specialist Referral  
Other (please state) 
 
Question 10. 
List the kind of support or intervention you would like to receive from the NHS in order to 
better manage SCD at the primary care level or any other comments you may have 
……………………………………………………………………………………………………………………………………………… 
……………………………………………………………………………………………………………………………………………… 
……………………………………………………………………………………………………………………………………………… 
……………………………………………………………………………………………………………………………………………… 
……………………………………………………………………………………………………………………………………………… 
……………………………………………………………………………………………………………………………………………… 
……………………………………………………………………………………………………………………………………………… 
……………………………………………………………………………………………………………………………………………… 
……………………………………………………………………………………………………………………………………………… 
End of questionnaire 
  
 
 
APPENDIX 5: SCD TEMPLATE INSTALLED IN GP SURGERIES 
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NIHR CLAHRC 
for Northwest London 
mm 
Brent 
 
The North West London Hospitals IIJ1Ij 
NH ftl.tSt 
 
wm 
National Institute for 
Health Research 
Development and Implementation of Sickle Cell Disease 
Template in Primary Care Services in Northwest London 
Okoye O,Amobi C, Chatlani P, Ansari S, Oni L,AIJuburi G, Green SA, Cho G, Phekoo KJ, Khan I, Nkohkwo A, 
Ojeer P, Ndive C, Majeed A, Knight Y, Anie K, Banarsee R 
 
 
 
The study aims to improve the quality of care for patients with 
SCD in primary care through: 
• Improving GPs knowledge about SCD 
• Raising awareness of new UK care standards 
• Engagement and empowerme nt of patients w ith SCD 
 
 
 
 
Background 
Sickle Cell Disease (SCD) is the most common and fastest 
growing genetic blood  disorder in England., predominantly 
affecting Black and ethnic minority (BME) groups. SCD is a 
most common reason to be admitted to hospital for this 
patient group and has a high rate of multiple admissions for 
individual  patients. 
Problem 
National confidential enquiry into patient outcomes and 
deaths (2008) was critical of the role of GPs in increasing 
vaccination and antibiotic prophylaxis uptake to prevent sepsis 
from hypo-splenism and recommended that management in 
primary care needs to be improved. In addition it had been 
observed that many patients with SCD were using the 
emergency departments of local hospitals rather than consult 
with their GPs. 
 
 
Intervention 
This study was led by NHS Brent and consisted of a 
multidisciplinary team from the NHS, academia and the 
voluntary sector including consultant haematologists, GPs, a 
specialist nurse, public health specialists and researchers. A 
multi-component intervention was designed which comprised : 
• A GP training programme 
• A GP SCD clinical management handbook 
• Primary Care electronic template 
• Awareness raising of primary care services with patients 
and carers 
 
The intervention was designed following engagement with 
patients and carers, through the voluntary sector and primary 
and secondary care staff. 
The Development and implementation of SCD template was 
championed by GPs, the template captures key information on 
UK paediatric and adult standards. 
 
 
 
 
 
Measuringfor improvement 
The template was reviewed by primary care staff and users at 
training sessions, and was piloted on 3 GP practices prior to 
wider roll out. All target practices 100% had templates 
installed and received training on usage. 100% identified SCD 
patients on their system. The baseline of ED admissions has 
been established for each practice this will be used to evaluate 
the effect of the intervention of practices that have engaged. 
 
 
Effects of change 
Sickle Cell leads within practices championing audits and 
review of services for sickle cell patients on their list. 
A  GP  conducted  an audit  of  SCD  patients  in her  surgery, 
identifying at-risk childbearing population, within a day of 
attending.The GP also liaised with a specialist nurse consultant 
to obtain health promotion materials and devised  template 
letter sent to patients to improve uptake of pre-conception 
screening and specialist care. 
 
 
 
Conclusion 
The SCD template provided an effective tool for recording 
patient information in a structured and consistent  way. 
 
In addition the project facilitated joint working between 
primary & secondary care and patients; identified practical 
approaches for joint working to improve user experience. 
It gives users and primary care staff confidence and clarity in 
navigating the system . 
Lessons learnt 
Securing GP champions is key for peer leadership and on- 
going engagement. It is important to involve practice 
managers early on in the project. They play a crucial in 
implementing    data  systems. Incentives  are  beneficial  to 
...enable staff to focus on the additionalwork required. 
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Introduction 
Sickle cell disease (SCD) is a group of inherited blood disor- 
ders in which recurring attacks of acute painful episodes (also 
known as a sickle crisis or vaso-occlusive crisis) are the most 
common reason for hospital admissions1 – 4  and the cause of 
risk of readmission in SCD patients could help in targeting 
groups particularly at risk, thereby improving their health out- 
comes, quality of life and reducing the burden on the National 
Health Service (NHS) from SCD. 
Few prior studies have examined the healthcare utilization of 
9 
frequent hospitalizations.5,6 SCD patients with high rates of 
painful episodes and frequent hospitalizations have also been 
found to have a higher mortality than those with low rates.7 
Hospital admissions for SCD in England have increased 
substantially in recent years, particularly in London.8 Although 
health outcomes have improved with more patients now sur- 
viving into adult life, many patients still experience emergency 
admissions for complications of SCD, with many patients also 
experiencing  readmissions.5,6   Identifying  factors that  predict 
SCD patients in England. In a recent study, we showed that 
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inpatient mortality in England in relation to socio-economic status. 
Methods Data from Hospital Episode Statistics were extracted for all SCD patients admitted in 2005/06. The financial year 2005/06 was taken as
the index year for analysis. We calculated readmission rates and inpatient mortality for patients admitted with a primary or secondary diagnosis of
sickle cell anaemia with crisis and without crisis in the index year during the subsequent 5 years (2006/07 – 2010/11). Charlson Score was used to
measure comorbidity. Using Cox proportional hazards models, we also examined the relationship between patient characteristics and both
 
Results In 2005/06, there were 7679 SCD index admissions. Over the subsequent 5-year period, patients living in the most socio-economically
deprived areas were at highest risk of readmission (54.2% readmitted over the study period compared with 28% of the least deprived group).
Inpatient mortality amongst readmissions was highest in patients living in the most deprived areas [hazard ratio (HR) 2.34, 95% CI 1.41 – 3.90]. 
Conclusion SCD patients from the most socio-economically deprived areas and with comorbidities are at highest risk of both SCD readmissions
and in-hospital mortality, suggesting that there are inequalities in healthcare access and health outcomes amongst people with SCD. 
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admission rates for SCD in England are increasing; and wide 
variations in admission rates amongst primary care trusts, espe- 
cially in London exist.8 There has been limited research in 
England examining the inﬂuence of socio-economic characteris- 
tics on the risk of SCD admission.10 The aim of this study was 
to investigate trends in the rates of emergency readmissions in 
England for patients with SCD, to determine inpatient mortality 
and to assess whether there is an association between deprivation 
and comorbidity with risk of readmission and inpatient mortality. 
 
Methods 
We obtained data over a period of 6 years from the national 
Hospital Episode Statistics (HES) database (April 2005 – 
March 2011). HES is the national administrative database for 
 
 
Table 1 Characteristics of patients admitted and inpatient mortality 
with a primary or secondary diagnosis of sickle cell anaemia with crisis or 
sickle cell anaemia without crisis in index year (2005/06) 
 
 
 
 
 
 
 
20 – 29 1736 22.6 6 0.3 
30 – 39 1739 22.6 6 0.3 
40 – 49 1073 14.0 9 0.8 
50 plus 936 12.2 31 3.3 
Sex     
Male 3049 39.7 32 1.0 
Female 4630 60.3 22 0.5 
 
 
 
 
 
 
 
Primary  2681 34.9 9 0.3 
Secondary 4998 65.1 45 0.9 
ndex admission for crisisa 
Yes  1955 25.5 6 0.3 
No  726 9.5 3 0.4 
 
6265 81.6 10 0.2 
819 10.7 11 1.3 
 
 
 
 
 
 
aThis includes only patients who had an initial primary diagnosis of SCD. 
hospital activity in England and contains data on all admis- 
sions and outpatient appointments  in the NHS, including 
patients whose treatment is funded by the NHS but per- 
formed in private hospitals.11 HES data contain details on the 
diagnoses of every patient admitted to an NHS hospital in 
England; diagnoses are coded using the International 
Classiﬁcation of Diseases version 10 (ICD 10). Patients can 
be coded as having up to 20 different diagnoses. This analysis 
included patients with a primary diagnosis or secondary diag- 
nosis of sickle cell anaemia with crisis or sickle cell anaemia without 
crisis. The ﬁnancial year 2005/06 was taken as the index year 
for this analysis, and all patients admitted with a primary or a 
secondary diagnosis of SCD in this year were identiﬁed and 
classed as SCD patients in our cohort. Secondary diagnoses 
are only meant to be coded if they are related to the reason 
for admission. For patients who were admitted more than 
once in the index year, their ﬁrst admission was used as the 
index admission. 
Pseudonymized patient identiﬁers were used to identify 
subsequent hospital admissions  for  the  patients  identiﬁed 
in the index year. Outcome variables used were emergency 
hospital admissions, in-hospital mortality and emergency 
readmissions to hospital. Predictor variables used in this 
analysis were age group, sex, national deprivation group 
(based  on  lower  super  output  area  index  of  multiple  de- 
privation ranks for the whole of England)12  from 1 (most 
deprived) to 4 (least deprived), whether the index diagnosis 
was a primary or secondary  diagnosis  for  SCD,  whether 
the index diagnosis was for an SCD crisis or not (among 
those with a primary diagnosis of SCD) and Charlson co- 
morbidity index score. The Charlson score  classiﬁes 
patients into groups depending on the number and severity 
of their comorbidities on admission, with higher Charlson 
scores reﬂecting  patients having a higher risk of mortality 
within 10  years.13   For  multivariate analysis, a combination 
diagnosis variable was created to compare those  admitted 
with SCD as a secondary diagnosis; those admitted with a 
primary diagnosis of non-crisis and those admitted with a 
primary diagnosis of a crisis. 
Descriptive statistics for the number of admissions and 
deaths in an index year were ﬁrst produced and then summar- 
ized for study years individually. Cox proportional hazards 
models were used to examine the association between patient 
demographic variables and the likelihood of emergency ad- 
mission over the time period as well as in-hospital mortality. 
For patients admitted more than once during the study 
period, only the ﬁrst readmission was used. All of the vari- 
ables mentioned previously were used in these models. All 
statistical  analyses  were  performed  using  the  programme 
STATAw version 12. 
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Results 
The characteristics of the patients admitted for SCD in 
2005/06 (the index year) can be seen in Table 1 (n ¼ 7679). 
The majority (58.1%) live in the most deprived quartile of 
lower super output areas nationally, with only 9.5% of admis- 
sions coming from patients living in the least deprived quar- 
tile. The majority (65%) involved SCD as a secondary 
diagnosis, and among those admitted with SCD as a primary 
diagnosis, the majority were for an SCD crisis (73%). Overall, 
the percentage of deaths in the index year was low at 0.4%. 
Deaths were higher among those with SCD as a secondary 
diagnosis compared with primary diagnosis (0.6 versus 0.1%), 
and among those with a Charlson comorbidity score of 2 or 
more than a Charlson score of 0 (2.7 versus 0.1%). 
Figure 1 shows the unadjusted cumulative time to readmis- 
sion curves by national deprivation group among those with a 
primary admission for an SCD crisis (n ¼ 1964). Patients in 
the least deprived group were less likely to be readmitted over 
the whole time period compared with all other levels of de- 
privation. For example, 39.6% of the patients in the most 
deprived group were admitted at least once within 2 years, 
compared with 20.2% for the least deprived group (data not 
shown). 
Table 2  shows  the  annual  percentages  of  readmissions 
(n ¼ 7679) by the demographic variables. Over the whole 
period, those patients aged 10 – 19 had the highest risk of re- 
admission  (65.5%),  as  did  those  with  SCD  as  a  primary 
diagnosis (74%) and those with an index admission for an 
SCD crisis (77.5%). Those in the national deprivation group 
1 (most deprived) were more likely to have a readmission over 
the whole period than those in national deprivation group 4, 
the least deprived group (54.2 versus 28.0%). 
Table 3 shows the annual in-hospital mortality by the 
demographic variables. Patients in the national deprivation 
group 1 were more likely to die in hospital over the whole 
period than those in national deprivation group 4 (2.7 versus 
1.4%). Those with an index admission not for an SCD crisis 
were more likely to die than those with an index admission 
for a crisis (2.9 versus 1.9%), and those with a Charlson score 
of 2 or more were most likely to die in hospital over the whole 
period (12.6 versus 1.1 for those with a score of zero). 
Results from Cox proportional hazards models are given in 
Table 4. These show that over the time period, those in na- 
tional deprivation group 1 (most deprived) were more likely 
to be readmitted than those in national deprivation group 4 
(least deprived) [hazard ratio (HR) 2.97, 95% CI 2.57 – 3.43]. 
Those with a Charlson comorbidity score of two or more 
were more likely to be readmitted than those with a score of 0 
(HR 1.71, 95% CI 1.51 – 1.94). Those with a primary diagno- 
sis of SCD crisis were more likely to be readmitted than those 
with a secondary diagnosis of SCD (SCD as a comorbidity) 
(2.76, 95% CI 2.49 – 3.05), as were those with a primary diag- 
nosis of crisis (HR 2.99, 95% CI 2.78 – 3.21). For in-hospital 
mortality, those in national deprivation group 1 were more 
likely to die in hospital than those in national deprivation 
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Table 2 Percentage of patients with emergency readmissions after admission in index year (2005/06) by patient characteristics (n ¼ 7697) 
 
 
 
 
Age group  
,1 32.4 28.9 27.5 24.6 21.1 57.0 
1 – 9 34.8 31.5 30.4 31.8 29.6 64.4 
10 – 19 35.9 34.9 36.4 35.7 38.4 65.1 
20 – 29 29.1 25.2 25.2 23.4 23.6 49.3 
30 – 39 20.6 17.5 18.1 17.4 17.0 43.0 
40 – 49 20.6 17.5 18.9 18.6 19.7 46.7 
50 plus 19.8 16.2 15.4 13.6 12.3 44.2 
Sex       
Male 30.8 27.3 26.4 25.6 25.3 74.3 
Female 23.9 21.1 22.1 21.3 21.5 36.0 
National deprivation group 
Most deprived 29.0 25.1 25.1 24.4 24.6 54.4 
Second most deprived 27.1 25.3 25.2 24.5 24.7 53.8 
Second least deprived 24.0 19.9 22.6 21.8 19.4 48.2 
Least Deprived 13.5 13.1 13.6 12.1 12.5 27.8 
Initial diagnosis       
Primary 44.5 41.2 41.3 39.9 41.3 73.7 
Secondary 17.0 14.1 14.4 14.0 13.2 39.1 
Index admission for crisis       
Yes 49.6 45.1 45.3 43.6 44.2 77.2 
No 30.7 30.7 30.6 29.8 33.2 64.3 
Charlson comorbidity index       
0 26.6 23.8 24.5 23.8 23.5 50.8 
1 26.6 23.2 21.6 21.5 23.4 54.5 
2::2 
N admissions 
26.4 21.5 20.0 17.3 17.1 51.4 
 2044 1807 1829 1767 1767 3392 
 
Percentages relate to patients admitted at least in a year 
 
 
 
group 4 over the time period (HR 2.34, 95% CI 1.41 – 3.90), 
as were those in national deprivation group 3 (HR 2.00, 95% 
CI 1.16 – 3.46). Those with a primary diagnosis of SCD non- 
crisis were more likely to die in hospital than those with a sec- 
ondary diagnosis of SCD (3.58, 2.25– 5.68) as were those with 
a primary diagnosis of crisis (HR 3.04, 95% CI 2.11– 4.39). 
 
Discussion 
Main finding of this study 
There is a higher frequency of SCD readmissions in areas of 
increased socio-economic deprivation. Some of the readmis- 
sions we observe may be due to new hospital episodes, but 
we still observe lower rates in less deprived places. The major- 
ity of readmissions (over 58%) and highest inpatient mortality 
occurred in patients living in the most socio-economically 
 
deprived areas, with the highest risk of admission for patients 
aged 10 – 19 and highest risk of death in people aged .50. 
The highest risk age group highlights the importance of ado- 
lescent transitional care in patients with SCD14 – 16 and sup- 
ports a concept analogous to the ‘inverse care law’ where 
differentials in access to care vary inversely with the (SCD) 
population most at need.17,18 Death rates are higher in those 
with Charlson of 2 or more suggesting death rates are higher 
in patients with increased comorbidities (who are also likely to 
be older). 
Much remains unclear about the inﬂuence of socio- 
economic status (SES) on SCD. However, the wider SES and 
chronic disease literature indicates a number of ways in which 
those coming from the most deprived sector may experience 
increased hospital readmissions,  excess  in-patient mortality 
and consequent inequalities in health care.19 
       
SICKLE CELL DISEASE AND RISK OF EMERGENCY READMISSION 5 
 
 
 
 
Table 3 Percentage of in hospital mortality after admission in index year (2005/06) by patient characteristics (n ¼ 7679) 
 
 
 
 
Age group  
,1 0.0 0.0 0.0 0.0 0.0 0.0 
1 – 9 0.0 0.1 0.1 0.1 0.1 0.4 
10 – 19 0.2 0.2 0.0 0.1 0.2 0.6 
20 – 29 0.2 0.2 0.2 0.1 0.2 0.9 
30 – 39 0.2 0.3 0.3 0.3 0.2 1.4 
40 – 49 0.7 0.6 0.6 0.7 0.6 3.1 
50 plus 3.1 2.8 2.5 1.6 1.3 11.8 
Sex       
Male 0.8 0.6 0.5 0.5 0.5 3.0 
Female 0.5 0.5 0.5 0.3 0.3 2.1 
National deprivation group 
Most deprived 0.8 0.7 0.5 0.3 0.4 2.7 
Second most deprived 0.4 0.4 0.6 0.6 0.4 2.5 
Second least deprived 0.3 0.3 0.1 0.7 0.1 1.6 
Least Deprived 0.1 0.3 0.6 0.3 0.4 1.7 
Initial diagnosis       
Primary 0.3 0.3 0.6 0.5 0.5 2.3 
Secondary 0.8 0.7 0.4 0.3 0.3 2.5 
Index admission for crisis       
Yes 0.2 0.3 0.5 0.5 0.5 2.0 
No 0.6 0.4 1.0 0.6 0.4 3.0 
Charlson comorbidity index       
0 0.2 0.2 0.2 0.3 0.2 1.2 
1 1.2 1.4 1.1 0.6 0.3 4.7 
2::2 
N admissions 
3.5 3.0 3.4 1.3 2.1 14.2 
 46 42 38 31 27 184 
 
What is already known on this topic 
Within London, around 80% of all SCD  admissions  are 
from people living in the most deprived areas.1 A study in 
the London Borough of Brent showed that that 74% of total 
bed days are associated with patients with multiple admis- 
sions.20 Studies have found that, in general, causes of hos- 
pital readmission for patients with SCD included premature 
discharge, withdrawal syndrome and the occurrence of new 
acute [sickle cell crisis] episodes.5 SES may also inﬂuence 
the way healthcare providers manage chronic disease.  A 
study by Struthers et al.21 showed an increased rate of hos- 
pital readmissions in those with lower SES for congestive 
heart failure independent of disease severity. The researchers 
suggest that this may be due to a number of reasons which 
included primary care providers in deprived areas having 
less time to invest in adequate disease management. Primary 
care providers working in deprived areas may also perceive 
their  patients  as  having  less  capacity  to  understand  and 
manage their own condition,16 and patients living in a 
deprived areas may perceive that their community medical 
resources are insufﬁcient to manage them and ‘push’ for 
hospital  admission.21,22 
Another factor that may contribute to increased SCD read- 
missions, particularly amongst the most deprived patients, is 
patient self-discharge. A study in England found that 14% of 
their sample of SCD patients reported having self-discharged 
from hospital. The most common reasons given by the SCD 
patients for self-discharging were being ‘tired of waiting for 
pain relief ’; potential conﬂicts related to suspected analgesics 
abuse and because they just simply wanted to go home.23 
Ballas and Lusardi5 also suggest that the decision by the 
patient to leave the hospital may be due to family pressure, 
childcare or fear of loss of job if the patient is employed. A 
similar study published in the USA found a much higher rate 
with 46.5% of their sample of SCD patients discharging 
themselves from hospital.24 
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Table 4 Multivariate models for risk of emergency re-admission and inpatient mortality in 5 years after at least one admission in the index year (2005/06) 
(n ¼ 7697) 
 
 Hazard ratio for admission Confidence interval Hazard ratio for mortality Confidence interval 
 
Age group     
,1 1.42* 1.12; 1.78 Missing — 
1 – 9 1.46* 1.31; 1.63 0.33* 0.13; 0.84 
10 – 19 1.38* 1.25; 1.54 0.41* 0.19; 0.89 
20 – 29 1.12* 1.01; 1.23 0.76 0.44; 1.33 
30 – 39 1.00 — 1.00 — 
40 – 49 1.10 0.98; 1.23 2.03* 1.27; 3.26 
50 plus 1.15* 1.02; 1.31 5.11* 3.34; 7.81 
Sex     
Male 1.00 — 1.00 — 
Female 1.04 0.97; 1.11 0.71* 0.55; 0.92 
National deprivation group 
4 (Least deprived) 1.00 — 1.00 — 
3 (Second least deprived) 2.54 2.13; 3.03 1.12 0.54; 2.32 
2 (Second most deprived) 2.83 2.44; 3.31 2.00 1.16; 3.46 
1 (Most deprived) 2.97 2.57; 3.43 2.34 1.41; 3.90 
Charlson comorbidity index     
0 1.00 — 1.00 — 
1 1.40* 1.26; 1.55 3.40* 2.33; 4.95 
2::2 
Initial diagnosis 
1.68* 1.48; 1.90 8.15* 5.81; 11.42 
Secondary 1.00 — 1.00 — 
Primary, non-crisis 2.68* 2.42; 2.97 3.46* 2.17; 5.52 
Primary, crisis 2.92* 2.72; 3.14 3.31* 2.30; 4.77 
 
*Statistically significant difference from reference category at P , 0.05. 
 
 
Limitations of this study 
The data may be subject to missing, inaccurate or incomplete 
data not uncommon to the data collection process. However, 
the advent of diagnosis-based payment of hospitals has acceler- 
ated improvement of data quality in HES.25 We were  also 
unable to evaluate the impact of severity of SCD disease which 
may contribute to the risk of readmission and inpatient mortal- 
ity, as information on this is not included in HES. Additionally, 
we know that the UK has a mobile population, especially in the 
young adult group who may be students temporarily resident in 
the low prevalence/least deprived areas.  Their  readmissions 
may therefore be elsewhere in the UK (i.e. Wales, Scotland or 
Northern Ireland) or beyond and could have had an impact on 
reported readmissions. Future papers could also focus on what 
the secondary diagnoses were that led to patient deaths and if 
they are linked to primary diagnosis of SCD or unrelated. We 
also did not examine post-discharge factors that could inﬂuence 
risk of admission. These factors include characteristics of the 
home environment; and the quality and continuity of health care 
of patients after they have been discharged from hospital includ- 
ing use of community/primary care facilities. Including post- 
discharge factors impact on readmission26 could have provided 
further explanation into the pattern of SCD readmissions. 
 
What this study adds 
Hospital readmission rates in England have been used as a 
measure of poor healthcare performance at a local level or 
when making comparisons over time between hospitals.27 
However, there is a need to better understand the different 
factors that inﬂuence readmission rates for any disease specif- 
ic category (including SCD) to control for extenuating factors 
that would impact on readmissions allowing a more thorough 
assessment of healthcare outcomes as well as more accurately 
deﬁning  potentially  preventable  readmissions.28   Our  study 
shows that SCD patients coming from the most deprived 
areas nationally experience higher rates of SCD hospital read- 
missions as well as inpatient mortality related to SCD, sug- 
gesting that there may be inequalities in access to health care 
 SICKLE CELL DISEASE AND RISK OF EMERGENCY READMISSION 7 
 
 
 
and health outcomes amongst people from this population. 
This continued to be true after adjustment for age and co- 
morbidities between these populations, which might com- 
monly be thought to contribute to these differences in 
readmission rates (data not shown). Also, the age and co- 
morbidity breakdowns were similar between the least  and 
most deprived groups (data not shown). Targeted interven- 
tion  programs29,30   that  concentrate  on  a  small  number of 
‘high-risk’ patients, such as improving access to appropriate 
care or adherence to medication protocols31,32 provide 
genuine opportunities to prevent a large number of recurrent 
hospitalizations. Some readmissions may also be prevented 
through policy initiatives such as the development and imple- 
mentation of local enhanced services for people with SCD. 
Local enhanced services are designed to meet local health 
needs and may therefore be particularly suitable for a condi- 
tion such as SCD where the burden of disease is highest in a 
few urban areas such as London. 
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Introduction 
Sickle cell disease (SCD) is a group of inherited blood disor- 
ders in which red blood cells are abnormally formed. The 
 
admissions into hospital.6 SCD is  less  common  than 
chronic diseases such as cardiovascular disease, diabetes and 
cancer,  but  its  high  hospital  utilization  make  the  disease 
7 – 9 
abnormal cells break down causing  anaemia  and can also important  from  a  health  policy  perspective. Thus,  the 
cause severe complications requiring frequent hospitaliza- 
tion, as well as reducing the quality of life and life expect- 
ancy. SCD affects millions of people around the world and 
is  particularly  common  amongst  populations  originating 
from  Africa  and  the  Caribbean.1   SCD  is  now  the  fastest 
growing and most common genetic disorder in  England2 
with "-'12 500 people living with the condition in the UK 
and 240 000 SCD trait carriers.
3 
SCD is also a common 
reason for hospital admissions.4,5 
Although the majority of health care for patients  with 
SCD should be occurring in ambulatory and primary care 
settings, the hallmark of SCD, acute painful episodes also 
known as vaso-occlusive crisis, is often the reason for repeat 
National Health Service (NHS) should be closely 
 
 
# The Author 2012, Published by Oxford University Press on behalf of Faculty of Public Health. All rights reserved 1 
 
  
 
Background Sickle cell disease (SCD) is a rising cause of mortality and morbidity in England and consequently an important policy issue for the
National Health Service. There has been no previous study that has examined SCD admission rates in England. 
Methods Data from Hospital Episode Statistics were analysed for all hospital episodes (2001/10) in England with a primary diagnosis of sickle
cell anaemia with crisis (D57.0) or without crisis (D57.1). Secondary and tertiary diagnoses were examined among those patients admitted
with either of these codes as their primary diagnosis. 
Results The overall SCD admission rate per 100 000 has risen from 21.2 in 2001/02 to 33.5 in 2009/10, a rise of over 50%. London accounts
for 74.9% of all SCD admissions in England. 57.9% of patients admitted are discharged within 24 h. The largest rise in admission rates was
seen among males aged 40 – 49 years where admission rates per 100 000 increased from 7.6 to 26.8 over the study period. 
Conclusions Our data show that SCD admissions are rising in England, particularly in London. Over half of patients admitted with SCD were
discharged within 24 h, suggesting that some of these admissions could be prevented through better ambulatory care of patients. 
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monitoring pathways of care including hospital utilization of 
patients with SCD. 
Little data exist in England about the healthcare utilization 
of SCD patients. Data on hospital admissions in England for 
SCD can provide information about the impact of SCD on 
the NHS and would also be of value to clinicians, commis- 
sioners and healthcare planners. Such data could also highlight 
disease-speciﬁc trends. The aim of this study was to investigate 
trends in the rates of hospital admissions in England for SCD 
and to determine geographic variations. The study period 
covered 2001/02 – 2009/10. We used data from the Hospital 
Episodes Statistics (HES) database, which provides data on all 
NHS  hospital  admissions  in  England.10    HES  have  been 
collected since 1987 by the Department of Health.11 
 
Methods 
We obtained data from the national HES database  from 
April 2001 to April 2010. HES is the national administrative 
database for hospital activity in England and contains data 
on all admissions and outpatient appointments in the NHS, 
including patients whose treatment is funded by the NHS 
but performed in private hospitals.12 HES data contains 
details on the diagnoses of every patient admitted  to  an 
NHS hospital in England, which are coded using the 
International Classiﬁcation of Diseases version 10. Patients 
can be coded as having up to 20 different diagnoses. This 
analysis included patients with a primary diagnosis of ‘sickle 
cell anaemia with crisis’ (D57.0) or ‘sickle cell anaemia 
without crisis’ (D57.1). Primary diagnoses correspond to the 
main reason the patient was admitted to hospital. Secondary 
and tertiary diagnoses were examined among those patients 
admitted with SCD as their primary reason for admission. 
Patients may be under the care of different consultants 
during their stay in hospital, and each of these is known as a 
‘ﬁnished consultant episode’. All data were collected related 
to hospital admissions. Different hospital episodes were 
aggregated into hospital spells (i.e. admissions to hospital) 
using a method recommended by the NHS Information 
Centre, based on patient identifying information, their dates 
of admission and discharge.13 
Data on admissions were broken down by age (,1-year 
old, 1 – 9, 10 – 19, 20 – 29, 30 – 39, 40 – 49 years and .50 
years old), sex and Strategic Health Authority and Primary 
Care Trust (PCT). The admission rates were sex- and age 
standardized. Less than 1-year old was included as a cat- 
egory in its own right to  reﬂect  concern  over  potentially 
high admission rates in this group and in line with previous 
work.7  As London accounts for the majority of the SCD 
cases in England, admission rates by  PCT are  presented 
only for London due to small numbers of  admission  in 
other PCTs. Denominator data for population estimates 
which were used to calculate rates were obtained from the 
Ofﬁce for National Statistics.14  All analyses were conducted 
using Stata, v. 10.0. 
 
 
Results 
Figure 1 and Table 1 show the overall admission rates for 
SCD as a primary diagnosis from 2001/02 to  2009/10. 
From Table 1 we can see that the overall admission rate per 
100 000 population has risen from 21.2 per 100 000 in 
2001/02 to 33.5 per 100 000 in 2009/10. This represents a 
rise of .50% in the admission rate from 2001/02 levels, 
with a consistent year-on-year rise with the exception of 
between 2002/03 and 2003/04. 
Overall admission rate for England per 100 000 
population for Sickle Cell Disease 2001/02-2009/10 
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Fig. 1 Trends in admissions for sickle cell disease in England, 2001/02 – 2009/10. 
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Table 1 Age- and sex-specific admission rates per 100 000 population in England for SCD as a primary diagnosis 2001/02 – 2009/10 
 
Age (years) Year  
  2001/02 
 
2002/03 
 
2003/04 
 
2004/05 
 
2005/06 
 
2006/07 
 
2007/08 
 
2008/09 
 
2009/10 
 
Men overall 
 
20.7 
 
24.1 
 
24.1 
 
25.4 
 
25.9 
 
28.5 
 
31.3 
 
32.7 
 
35.1 
,1 8.8 6.7 7.1 4.6 12.6 16.1 16.7 15.2 14.7 
1 – 9 18.6 21.2 21.5 24.9 22.7 27.8 37.1 41.2 45.5 
10 – 19 24.9 30.6 30.0 35.8 37.8 39.2 44.6 49.9 55.6 
20 – 29 50.0 49.7 54.8 57.1 57.4 70.5 65.0 64.7 68.6 
30 – 39 44.3 54.3 47.7 44.2 39.3 37.8 42.8 41.9 46.8 
40 – 49 7.6 13.7 16.0 17.3 23.5 24.1 28.1 29.0 26.8 
.50 1.6 1.4 1.6 2.3 2.3 2.1 2.7 2.8 3.2 
Women overall 21.6 23.3 21.7 24.6 25.2 25.6 26.1 27.6 31.9 
,1 7.3 7.0 7.9 5.2 12.8 11.9 10.9 13.2 10.8 
10 – 9 12.6 18.5 17.7 20.3 23.0 23.5 26.1 36.5 42.2 
10 – 19 29.1 36.3 31.9 40.3 41.8 47.3 48.5 51.2 56.4 
20 – 29 32.4 35.4 38.0 44.6 51.9 50.9 52.1 52.4 57.9 
30 – 39 52.4 50.1 41.2 41.7 41.4 36.6 35.7 37.0 45.3 
40 – 49 25.4 24.5 25.9 28.0 22.1 25.7 26.0 24.7 29.2 
.50 3.4 4.0 3.8 4.9 4.5 4.2 3.9 4.0 5.1 
Total 21.2 23.7 22.9 25.0 25.6 27.0 28.7 30.1 33.5 
 
This rise in admission rates has occurred in every age and 
sex group with the exception of women aged 30 – 39 years, 
whose admission rate per 100 000 population declined from 
52.4 to 45.3 over the time period. (Table 1) The largest rise 
in  admission  rates  was  seen  amongst  men  aged  between 
40 and 49 years old, where admission rates per 100 000 
population increased from 7.6 to 26.8 over the time period 
(Table 1). 
There were 16 558 admissions for SCD in England in 
2009/10 and 8488 (51.3%) of these were  men  (Table  2). 
The admission rate per 100 000 population in this period 
was slightly higher in men than for women, 35.1 compared 
with 31.9 (Table 1). The highest admission rates in 2009/10 
were amongst men aged 20 – 29 at 68.6 per 100 000 popula- 
tion (Table 1). The lowest rates were amongst people over 
50 years old at 3.2 per 100 000 population for men and 5.1 
per 100 000 for women (Table 1). 
London accounted for almost three quarters of all SCD 
admissions in England (74.9% of all admissions nationally, 
data not shown). The highest admission rate was in City and 
Hackney Teaching PCT at 837.4 per 100 000  population. 
This rate is over twice that of the next highest PCT, 
Newham at  388.1 per  100 000  population (Supplementary 
data, Figure A). The map demonstrates geographical hetero- 
geneity between boroughs with a clustering of boroughs with 
some of the highest admissions occurring in City, Hackney, 
Newham, Haringey, Waltham Forest and Islington (Fig. 2). 
 
Table 2 Age and sex breakdown of crisis and non-crisis primary 
diagnosis, England 2009/10 
 
 
 
 
Table 3 shows the most common secondary and tertiary 
diagnoses for those admitted with SCD as the primary diag- 
nosis. The most common additional diagnostic codes were 
for  respiratory  conditions  including  lower  respiratory tract 
  
 
 
 
 
4509 (53.1) 
34 (68.0) 
1 – 9 478 (38.1) 
10 – 19 855 (47.4) 
20 – 29 1554 (62.8) 
30 – – 39 983 (60.7) 
40 – 49 481 (47.2) 
50þ 124 (46.4) 
8572 (51.8) 
17 (48.6) 
1 – 9 479 (43.0) 
10 – 19 891 (51.3) 
20 – 29 1260 (62.9) 
30 – 39 787 (50.2) 
40 – 49 482 (42.7) 
50þ 147 (30.4) 
Total number overall 4063 (50.3) 
3979 (46.9) 
16 (32.0) 
777 (61.9) 
948 (52.6) 
919 (37.2) 
637 (39.3) 
539 (52.8) 
143 (53.6) 
7986 (48.2) 
18 (51.4) 
634 (57.0) 
847 (48.7) 
744 (37.1) 
780 (49.8) 
648 (57.3) 
336 (69.6) 
4007 (49.7) 
8488 
50 
1255 
1803 
2473 
1620 
1020 
267 
 
35 
1113 
1738 
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1567 
1130 
483 
8070 
D
ow
nloaded from
 http://jpubhealth.oxfordjournals.org/ by guest on June 16, 2012 
4 JOURNAL OF PUBLIC HEALTH 
 
?? ???
???
?? ???
?? ????
??
?
????
?
?
??
?
??
???????????????????????
??????????????
?? ? ?
??? ? ??
??? ? ??
??? ? ??
???? ? ???
?? ???? ? ???
???? ? ???
???? ? ???
Fig. 2 ??????????????????????????????? ????????????????????????????????????????????????????????????????????????????????????????????????????????
??????????????? ??????? ??? ?????????????? ????????????? ??????? ???????????? ???????????????? ?????????? ????? ?? ???????????
infection,   lobar   pneumonia   and   asthma,   followed   by 
vaso-occlusive conditions such as occlusion and stenosis of 
middle cerebral artery, Moyamoya disease, hemiplegia and se- 
quelae of stroke (not specified as haemorrhage or infarction). 
Table  2  shows  the  breakdown  of  crisis  and  non-crises 
admissions in 2009/10. Slightly over half of all admissions 
(50.3%) were for a sickle cell crisis, and those in the age 
group  of  20 – 29  years  had  a  higher  proportion  of  crisis 
admissions than other groups (62.8 and 62.9% for men and 
women, respectively). The lowest proportion of crisis admis- 
sions was in women aged over 50 (30.4%). 
57.9% of all patients were discharged within 24 h  of 
being admitted to hospital, while only 15.4% of admissions 
stayed for longer than a week. The  largest proportion  of 
patients discharged on the same day  was  for  those  aged 
over 50 years old, at 72.1% (data not shown). 
Discussion 
Main finding of this study 
This is the first national study on trends for hospital admis- 
sions rates for SCD using HES data in England. Our data 
have four main findings: (i) the number of admissions due 
to SCD has increased substantially over the study period 
(2001/10); (ii) the majority of admissions are from London; 
(iii)? most  admissions  were  discharged  within  24 h  and 
 
(iv)?there has been an increase in the number of admissions 
of middle-aged men. 
 
What is already known on this topic 
Our data show an increase of ?50% in SCD admissions. 
This will be due to a number of factors, the most important 
of which is likely to be an increased prevalence of SCD in 
England through domestic growth of the current at-risk 
population and population migration from countries where 
SCD is common.15 
A previous study on the national implementation of 
newborn screening in England showed an increased number 
of children identified with SCD in some areas. The authors 
of this study concluded that past under-ascertainment  of 
cases may have led to under-estimation of the needs of 
people with SCD. Under-ascertainment of SCD cases may 
also have contributed to increased infant mortality in urban 
areas because babies were at risk of dying without a diagno- 
sis  of  SCD  being  made  and  appropriate  management 
started.16 
The significant migration of people from the West Indies, 
Africa and Asia also partially accounts for the increasing 
incidence and prevalence of SCD in England. Some studies 
suggest that 6% of the population (in England) and ???10% 
of all births are at risk for haemoglobinopathy disorders.17 
With current trends in at-risk population migration into the 
?
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Table 3 Secondary and tertiary diagnoses among those with SCD as a 
primary diagnosis in NHS Hospitals, England, 2009/10 
 
 
 
 
country and continuing growth in the domestic at-risk popu- 
lation, these conditions will become even  more  common 
over the next decade.18 Platt et al.19 also explained that 
increases in prevalence are due to an increase in life expect- 
ancy of patients living with sickle cell through improved 
secondary and tertiary prevention, including improving the 
management of risk factors associated with haemoglobino- 
pathies; and through earlier detection and management of 
disease-related complications. 
The increases in admissions for SCD may also be due to a 
drop in the threshold for admission of patients with SCD, 
through greater recognition of the importance of SCD crisis, 
or  through  patients  being  discharged  earlier  and  being 
readmitted more frequently for the same episode of illness.20 
Studies from the USA have also shown readmission as an 
important contributor to rising  rates of admissions in 
patients with SCD.21 This may also raise issues of how well 
hospitals are managing these patients,22 and emphasizes the 
importance of good discharge planning for these patients 
which may minimize the risk of hospital readmission. Good 
discharge  planning is the  process that ensures  strong  and 
quality links between hospitals, primary and community care 
services and patients and their carers. Effective discharge 
planning for those with SCD can support the continuity of 
health care for a patient as it links treatment received in the 
hospital to post-discharge care received in the community. 
A study conducted at King’s  College  Hospital  showed 
that there has been a decrease in overnight admission rates 
for King’s patients with SCD over the last 50 years. This is 
due to better disease management and better discharge 
planning. The number of at-risk people served at King’s 
College Hospital has not decreased but the admissions have 
dropped from 111 admissions per 100 SCD patient-years in 
1960 – 1979 to 41 in 2008 – 2009. The study reported that 
this decrease is particularly accounted for by  better acute 
pain management and transfusions. This includes the use of 
hydroxyurea (a chemotherapeutic agent), increased commu- 
nity support, increased use of oral analgesia and improved 
parental education about the management of acute pain at 
home.23 – 26  The study also reported that admission to hos- 
pital for elective blood transfusion was formerly the second 
most common reason for SCD admission but fell from 213 
admissions to 1 over the study period. Elective transfusions 
are still an important aspect of care for SCD but these have 
been largely moved to ambulatory settings.23,27 
SCD is still one of the most common reasons to be 
admitted to hospital and SCD also has one of the highest 
rates of multiple admissions for individual patients. The distri- 
bution of SCD in London also shows that 80% of all admis- 
sions are from people living in the most deprived areas of 
city.4,5,28 Our ﬁnding that the majority of SCD admissions are 
discharged within 24 h was also found in another study that 
was conducted in the London Borough of Brent which 
showed that 36% of SCD patient admissions in Brent resulted 
in a length of stay of ,2 days and that 74% of total bed days 
are associated with patients with multiple admissions.28 
 
 
Limitations of this study 
The strength of our study is  in  its  comprehensiveness  in 
that it covers all NHS hospital admissions in England. Our 
data have the weaknesses associated with missing, inaccurate 
or incomplete routine data, such as incorrect hospital diag- 
noses and coding. However, the advent of diagnosis-based 
payment of hospitals has accelerated improvement  in  the 
data quality. We used primary diagnosis to identify admis- 
sions  from  SCD,  and  87.2%  of  primary  diagnoses  for 
hospital admissions in England are now coded correctly.29 
We did not examine readmissions and multiple admissions 
in the same patient, which could have provided further valu- 
able insight into patterns of SCD admissions. 
Number (% of 
2009/10 total) 
 
Acute lower respiratory tract infection
Chemotherapy 
Asthma 
Urinary tract infection
 
Occlusion and stenosis of middle cerebral artery
 
 
Top 10 tertiary diagnoses
Asthma 
Sequelae of stroke, not specified as haemorrhage
or infarction 
 
 
Acute lower respiratory tract infection
Hemiplegia 
Vitamin D deficiency 
Hyposplenism 
310 (1.9) 
223 (1.3) 
187 (1.1) 
133 (0.8) 
128 (0.8) 
115 (0.7) 
104 (0.6) 
96 (0.6) 
91 (0.5) 
88 (0.5) 
89 (0.5) 
64 (0.4) 
 
 
59 (0.4) 
57 (0.3) 
54 (0.3) 
54 (0.3) 
53 (0.3) 
47 (0.3) 
42 (0.3) 
41 (0.2) 
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We also did not examine the mortality data linked to hos- 
pital episodes,3 which would have given information of 
deaths associated with SCD hospital admissions. However, 
as this was a study about the burden of admissions, re-
admissions and mortality data were not relevant to this 
study. 
 
What this study adds 
We examined trends in hospital admissions associated with 
SCD in England. We found that between 1999/2000 and 
2009/10, the rate of hospital admissions in England has 
increased for SCD; that London accounts for the majority 
of admissions in England and that majority of these hospita- 
lizations are short stay. These data show that SCD is a 
growing concern in England and provides a basis to con- 
tinue further investigation into explaining such trends. The 
study also highlighted that the majority of patients admitted 
with SCD were discharged within 24 h. These admissions 
could potentially be prevented through  better  ambulatory 
and community care of patients, including better care in 
emergency departments, and this is an area that PCTs with 
a high prevalence of SCD should consider investigating. 
 
Supplementary data 
Supplementary data are available at the Journal of Public 
Health online. 
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Introduction 
 
Sickle cell disease (SCD) is the most common 
inherited blood disorder in England. Without 
prompt diagnosis and proper  treatment,  it  can 
be a serious source of morbidity and mortality. 
SCD is caused by a single amino acid substitution 
of valine for glutamic acid in the sixth position of 
the beta (β)-chain of the haemoglobin tetramer.1,2 
The disease damages and changes the shape of 
red blood cells. The change in shape is a response 
to cell deoxygenation. When the oxygen uptake of 
the cell is low, the cells change their shape from 
a healthy round disk to a crescent (sickle shape), 
holly leaf or other similarly distorted shape. The 
sickled cells are rigid, less malleable and stickier 
than a normal cell; consequently, they may stick 
to each other and obstruct blood vessels. This 
obstruction causes harsh and painful compli- 
cations. The complications can lead to frequent 
hospital visits and proper management of SCD is 
needed to minimize the risk of developing such 
complications.3 
SCD clinical guidelines recommend that 
patients see a general practitioner (GP) for 
routine examination every six months and more 
often if new problems arise or their treatment 
protocol changes.4 In addition, immunizations, 
prescriptions and other preventive care measures 
need to be delivered effectively by GPs to prevent 
recurring infections and pain crisis.5 
An analysis of emergency department admis- 
sions between January 2008 and July 2010 in the 
Northwest London Borough of Brent showed 
that patients with SCD tend to use the emer- 
gency department rather than seek advice and 
support from their GP.6 A focus group aimed at 
obtaining patient perspectives held in Brent 
showed that one of the reasons patients utilize 
the emergency department over their GP  is 
because they perceive GPs as having limited 
knowledge of SCD.7 A primary care educational 
intervention has been designed, informed by 
these studies. To further triangulate the experi- 
ence of patients, this pilot study was designed 
to elicit the views of patients about the quality 
of care they have been receiving from their 
primary healthcare providers and what they 
thought was the role of primary care in SCD 
management. 
Methods 
Study design and questionnaire 
The study consisted of the development and 
administration of a 14-item study-specific ques- 
tionnaire devised by a sickle cell steering commit- 
tee which examined patients’ perceptions towards 
SCD and key management issues in primary care 
including severity of disease, how many times 
patients visited the Emergency Department  in 
the last year, how many times patients saw or 
called their GP for sickle and non-sickle-related ill- 
nesses and general questions about GP satisfaction 
(Box 1). The validation process for the question- 
naire followed several drafts reviewed by seven 
GPs practising across inner London, a professor 
of paediatric  haematology  specializing  in  SCD, 
a haematologist  specializing  in  SCD  in  adults, 
a SCD  specialist  nurse,  a  SCD  social  worker, 
a SCD clinical psychologist, a number of quality 
improvement project managers, public health 
specialists, patient representatives with SCD and 
directors of the Sickle Cell Society (a national UK 
sickle cell charity). The pilot study is  in  itself 
part of the mechanism of validation for a larger 
questionnaire study. 
 
Participants 
One hundred questionnaires were distributed by 
post and in person (CN and PO) over a nine- 
month period from November 2010 to July 2011 
to members of the Sickle Cell Society and to 
patients who attended the Sickle Cell and Thalas- 
saemia Centre, using a purposive sampling 
method. Forty questionnaires were completed 
and suitable for analysis (OO and KJP). 
 
Results 
A response rate of 40% was achieved. Fifty percent 
(20) were completed by men and 50% (20) by 
women. The highest percentage of respondents 
(27%) was in the age range of 25 – 39 years. Five 
percent of respondents were aged 65+ years. The 
majority (62%) of the respondents were in good 
health and mobile. Nineteen (47%) respondents 
did not use their GP to manage a painful crisis 
and preferred to attend the  emergency depart- 
ment.  Twenty-four  (59%)  respondents  went  to 
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A selection of questions from the patient questionnaire 
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their GP to collect repeat prescriptions. 
Twenty-two (55%) respondents did not visit their 
GP to get general advice about  SCD (Table 2). 
Nine (23%) rarely visited their GP with four 
(10%) visiting sometimes or fairly often (Table 1). 
When asked how satisfied patients are with assist- 
ance given by their GP to help manage their SCD 
based on a scale of 0 – 10 (0 being not satisfied at all 
and 10 being very satisfied), the majority (54%) 
scored satisfaction with their GP as 5 or less 
while 43% scored a 6 or above and 3% did not 
answer the question at all. Collecting prescriptions 
was the reason most cited for visiting the GP’s 
office (Table 2). Some examples of comments 
around the services provided by GPs include: 
 
‘The  GP  should  know  about  this  disease’. 
(Patient Questionnaire 1) 
 
‘The   GP   does   not   know   anything   about 
SCD pain and crisis. I would rather manage 
… at home or [go] to A + E where immediate 
action will be taken rather than call the GP 
who will ask us to book an  appointment 
and more or less does not understand how to 
manage the pain or how severe or serious the 
pain is’. (Patient Questionnaire 2) 
 
 
Discussion 
Key findings 
The results from the survey show that many 
patients are generally  not satisfied with the 
quality of care that they are receiving from their 
primary healthcare providers for SCD. Thus, 
most do not make use of GP services for manage- 
ment of their SCD. More importantly, the majority 
of the group  did  wish for greater  involvement 
from their GP services, even if it was  just  to 
refer them to a tertiary care facility or social 
support. 
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practitioner 
 
 
 
General SCD
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2 
1 
5 
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Comparison with existing literature 
Primary care satisfaction and SCD 
There are few data collected about SCD patients 
and their level of satisfaction with primary care 
services. However, one study showed a 46% non- 
adherence rate for routine primary care appoint- 
ments for SCD patients during an eight-month 
period.8 One of the reasons cited for the non- 
adherence was patient– provider relationships. 
Those with  a positive  patient and GP relation- 
ship were more likely to attend their clinic 
appointments.9,10 Other studies of  chronic 
disease management showed that poor com- 
munication, multiple treating physicians, long 
waiting periods and past negative experiences 
with healthcare providers all contributed to 
patient dissatisfaction with primary care and 
poor attendance at clinics.11 
 
 
 
be applied. The use of patient  questionnaires 
has been one reliable way to assess patient 
satisfaction.12 
 
The use of questionnaires to measure 
patient satisfaction 
Properly constructed patient questionnaires have 
been found to be useful in measuring patient sat- 
isfaction,12 but they may also be valuable more 
specifically for measuring patient satisfaction in 
primary care and for primary care management 
of SCD. One study showed that a questionnaire 
was a valid and valuable tool to use in assessing 
the health-related quality of life in children with 
SCD and could serve as ‘an important adjunct to 
determine the effect of SCD on the lives of chil- 
15 
Patient satisfaction as an indicator of 
dren’. Other studies showed questionnaires as 
health outcomes 
a valuable tool in measuring quality of care or 
16 
Patient satisfaction is an important indicator of patient satisfaction in primary care particularly 
health outcomes. Researchers and healthcare pro- 
viders have become increasingly interested in 
measuring patient satisfaction as an indicator of 
quality of care. Assessing patient satisfaction is a 
where the questionnaire assesses a specific area 
that enables the GP or other healthcare provider 
to identify with which aspects of service patients 
are less satisfied. This allows for the opportunity 
17 
core requirement of contract for GPs in the UK.12 
One study showed that assessing patient satis- 
faction allows GPs to investigate ‘the extent to 
which their service meets the needs of their 
client group’.13 Another study showed that satis- 
fied patients are more likely to follow treatment 
protocol because the patient is more likely to 
believe that the treatment will be effective.14 In 
order for satisfaction to be measured in a mean- 
ingful way, a valid and reliable measure should 
to improve a specified area. 
 
 
Strengths and limitations of this study 
Our pilot study successfully identified issues with 
SCD management at the primary care level 
through the use of a questionnaire which could 
help inform the planning of a larger survey. 
Moreover, this study also identified a need to 
improve   patient   satisfaction   and   engagement 
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Table 1 
How often do you use your general practitioner to
get general advice about sickle cell disease? 
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with primary care. Raising awareness among GPs 
about SCD management was identified as a key 
method to improve GP– patient relationships and 
improve primary care clinic attendance. 
Although this pilot study increases our under- 
standing of the barriers associated with SCD man- 
agement in primary care, it has certain limitations 
which could limit its transferability to areas 
outside of Northwest London. The questionnaire 
was based in an area with high prevalence  of 
SCD and the sample size was small and consisted 
of purposive or volunteer sample. In addition, it is 
unclear how the identification of barriers in SCD 
management in primary care relates to the actual 
uptake of primary versus secondary care in SCD. 
Future studies would need to examine this link. 
 
Conclusions 
 
Despite its limitations, the study, along with the 
results of the focus group discussion which 
reinforced these findings,6 provides  some valu- 
able information that  will  give  an  opportunity 
to develop a disease-specific intervention which 
aims to improve patient care and help to ensure 
that management in primary care is optimized 
through the establishment of a local enhanced 
service. In the next stage of this  project,  we 
will implement this intervention and evaluate its 
impact on the management of patients with SCD 
by general practices in Northwest London. 
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Introduction 
 
For people with sickle cell disease (SCD), a single 
point mutation on the haemoglobin molecule 
creates a lifetime of episodic and illness, until 
recently, dramatically reduced life-expectancy. A 
better understanding of the disease and improve- 
ments in science, technology, drug therapy and 
health policy have all contributed to patients 
with SCD surviving well into adulthood. 
SCD is the most common and fastest growing 
genetic disorder in England. About 350  babies 
are born each year with SCD and a further 9500 
babies are found to be carriers of the disease.1 
England could be dealing with a sickle cell crisis 
as immigration from Africa and the Caribbean 
increases disease prevalence, while primary 
health-care providers still struggle with the dis- 
ease‟s multidisciplinary management.2 SCD is an 
illness in which recurrent pain, also referred to 
as vaso-occlusive crisis, is a chronic concern. 
Primary care professionals therefore play a key 
role during the initial presentation of symptoms, 
as well as the management of long-term compli- 
cations including such recurrent pain. 
In England, London residents account for 
approximately three quarters of all SCD admis- 
sions to hospitals,2,3 with the London Borough of 
Brent being one of the highest risk areas for 
SCD.4,5 Many aspects of SCD can be effectively 
and efficiently managed in primary care.6 Pre- 
vious studies have shown successful interventions 
that move management  of SCD, particularly 
uncomplicated sickle cell pain episodes, from ter- 
tiary towards primary care.7,8 
Focus groups may be useful for obtaining de- 
velopmental input in managing SCD in primary 
care. Focus groups may be defined as „thoughtful 
planned discussions among participants with 
similar experiences that allow the moderator to 
obtain the individuals‟ cognitive and emotional 
perceptions in a non-threatening and relaxed 
environment‟.9,10 In this paper, we report the find- 
ings of a focus group study held at the Sickle Cell 
Society in the London Borough of Brent. We aimed 
to identify patient and carer perspectives of general 
practitioner (GP) knowledge and treatment of SCD, 
and to identify areas in which improvements could 
be made. This information helped to design an 
educational intervention which could help further 
engage primary health-care professionals in the 
care and management of their sickle cell patients. 
The study was part of a wider service improve- 
ment programme to improve the management of 
SCD in the London Borough of Brent. 
 
 
Methods 
 
As this study was hypothesis generating, we used 
qualitative methods – specifically, a focus group 
design – to learn about the experiences and per- 
ception of SCD patients and their carers. The dis- 
cussion lasted for approximately two hours. The 
participants were recruited through the Sickle 
Cell Society in Northwest London and comprised 
a mixture of ages and genders. Specifically, the 
group was made up of 10 patients: two men and 
eight women, aged 9 – 56 years, all of African/ 
Afro-Caribbean heritage. The focus group was 
held at the Sickle Cell Society which is con- 
veniently located to where many people with 
SCD live. The location is also a familiar meeting 
point where all of the participants felt secure and 
at ease to voice their opinions. The focus group 
participants were recruited through a purposive 
sampling process which aimed to canvas the 
views of sickle patients and carers living within 
the specific locality in which the service improve- 
ment and evaluation work was being undertaken. 
Participants were recruited via the Sickle Cell 
Society, a national UK sickle cell charity, through 
a general mail out to members of the charity 
living within this area with  information  about 
the study. This was subsequently followed up by 
a telephone call (CN) to assess interest in partici- 
pating in the focus group. The discussion was 
facilitated by a clinical psychologist (KA) from a 
local NHS Trust experienced in handling patients 
with SCD who explained the aims of the project 
to the participants; and who then asked the par- 
ticipants questions regarding their personal 
experience with primary health care in London. 
The questions were open-ended and focused on 
general practice utilization, what patients do first 
when they are in a SCD crisis, and overall satisfac- 
tion with primary care. Eleven observers from the 
project group were present; two were scribes. As 
well as making written notes, the discussions 
were also video recorded. 
The key themes used to explore the participants‟ 
perceptions and aspirations regarding primary care 
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services for SCD are listed in Table 1. The partici- 
pants were also encouraged to raise their own con- 
cerns about SCD management. Following the focus 
group, the project team (GA and KP) read the tran- 
scripts independently and grouped the responses 
into key themes that would help inform planning 
of future SCD services. Each item in the data col- 
lected during the discussions was compared with 
the rest of the data to establish analytical groups. 
Consensus of categories and a final list of key 
themes identified during the discussions were 
achieved iteratively through discussion and re-
reading of transcripts. As we aimed to present 
viewpoints, the data are not presented numerically. 
 
Results 
 
The transcripts and recordings were reviewed to 
identify common perceptions and experiences 
among the participants. 
 
Accessibility 
GP access was an important issue. The partici- 
pants highlighted that difficulty in obtaining an 
appointment with the GP, and that long waiting 
times lead to patients’ sidestepping their GP in 
the event of a painful crisis or other issues relating 
to SCD. Although GPs are seen as useful for pre- 
scribing antibiotics and other repeat prescriptions, 
they were seen to be unreliable during crises. Hos- 
pitals were seen to be more accessible. Participants 
proposed that GPs should offer more ‘out of 
hours’ and house calls for pain management, 
since many crises occur at night: 
I cannot walk in [to a General Practitioner’s 
office] and even if I could, I probably won’t 
be able to see a GP immediately, so I go straight 
to the hospital if I am sick. 
Doctor– patient relationships 
Participants raised the issue of the lack of time to 
build up rapport and relationships with their 
GPs. This left patients with SCD with a feeling of 
dissatisfaction with the quality of the doctor– 
patient relationship. They felt that GPs were not 
actively interested or engaged in the progress 
and treatment of their condition. They encouraged 
GPs to take a proactive approach and interest in 
getting to know their SCD patients and to focus 
on preventive care including preventive manage- 
ment of crisis: 
If I take my son to hospital now, the doctors like 
to have a relationship and know how he is 
doing. If I take him to the GP there is no 
relationship; he is a stranger. 
 
[You have a] five minute conversation with 
the GP. You are in and out. I prefer to go to 
the hospital, I know them there. I am safe. My 
nurse knows me. 
 
I know my GP, but does he really know me? I 
go to the hospital. They know me. 
 
GP knowledge 
There was a general feeling among the participants 
that GPs lack comprehensive knowledge of SCD, 
and the hospitals were viewed as more specialized 
in dealing with the condition. They expressed an 
interest in seeing GPs better informed about SCD, 
and its implications for management. One partici- 
pant suggested a GP SCD ‘champion(s)’ or special- 
ists who could further inform their health 
professional colleagues about SCD. Another par- 
ticipant added that GPs who are not specialized 
in SCD need  to be briefed by an expert before 
seeing a SCD patient in the surgery. 
They take time to know about other diseases; I 
feel my disease is not important, I feel I am not 
important. 
 
Concerns about pain management and 
treatment process 
Because of the organizational barriers previously 
mentioned, many of the participants had difficulty 
in seeing the benefit of utilizing a GP during an 
uncomplicated sickle crisis. They subscribed to a 
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process that seemed to utilize the emergency 
department during a crisis and to utilize the GP 
for repeat prescriptions and immunizations. 
Patients are still waiting for facilitating factors 
which would encourage them to use the GP as a 
means of support, prevention and maintenance 
during crisis-free periods or during uncompli- 
cated crisis pain episodes. 
 
It takes too long to see a GP. Sometimes some- 
thing goes wrong while you are waiting for 
your appointment. Other than a prescription 
or a non-sickle illness, there is no need for the 
GP.  It  is  a  waste  of  time.  When  you  have 
access to a seven-day hospital, why go to a GP? 
 
They [General Practitioners] don‟t take the 
time to find out about the patients they have 
on their books anyways. 
 
 
Continuity of care and follow‐up 
One discussion point that  surfaced  several 
times was the seeming lack of cohesion and com- 
munication between GPs, hospitals and specialty 
centres. Participants emphasized that there was 
never follow-up from their GP after they were dis- 
charged from the emergency department, hospital 
or a specialty centre. Participants felt strongly that 
GPs should liaise with other health-care pro- 
fessionals involved in the management of their 
sickle condition, and should follow-up with the 
patient soon after hospital discharge. 
 
[There should be] review letters from the hos- 
pital. They [General Practitioners] should see 
how you are doing. That will be good. 
 
[Following discharge from hospital] why 
don‟t they [GPs] ever call the patient and 
follow-up? 
 
Chronic illness management – wellbeing 
management 
There was a general consensus that  many  of 
the frustrations felt by patients with SCD  are 
also shared by sufferers of other chronic ill- 
nesses. GPs were seen as treatment and medi- 
cation prescribers rather than actively engaged in 
the  management  of  their  patients‟  wellbeing 
through prevention of disease and maintenance 
of health. 
The GP consultation is a five minute conversa- 
tion with the GP… [to get your] medication or 
antibiotics, or certain jabs, they don‟t take the 
time. 
The key issues identified through the focus groups 
are summarized in Table 2. 
 
Discussion 
Key findings 
The focus group study identified a number of 
barriers to patients with SCD and their carers 
engaging fully with primary care services. These 
ranged from practical difficulties accessing ser- 
vices when required, poor communication be- 
tween primary and secondary care professionals 
and a perceived lack of confidence in the ability 
of primary care professionals to provide chronic 
disease management specific to SCD. 
 
Education, communication and quality 
improvement 
The issues identified during the focus group dis- 
cussion have helped define key areas in need of 
improvement for SCD management. Some of the 
key themes and useful suggestions have been 
used to develop a GP education intervention to 
improve GP management of SCD in primary care. 
Part of the education intervention has been facili- 
tated by developing a SCD template for data entry 
compatible with a main electronic patient record 
system  used  by  GPs.  These  electronic  medical 
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record systems are now widespread in UK primary 
care and have helped improve recording on 
patients with other chronic diseases.11 In the 
longer term, these electronic patient records could 
be linked to clinical decision support systems or 
disease recording templates to help improve re- 
cording of information by primary care teams and 
the quality of primary care received by patients.12 
Future studies could focus on other issues 
identified such as auditing and improving com- 
munication between different health-care provi- 
ders. This could be facilitated by GPs receiving 
timely information on hospital admission and 
hospitals advising patients to book an appoint- 
ment with their GP for review after discharge. 
Receiving proactive care from the GP could also 
be achieved by identifying areas with a relatively 
high prevalence of SCD and designing a local 
quality improvement scheme. Many  patients 
with chronic illnesses do receive proactive care 
from their GPs but these are generally patients 
with the diseases covered in the GP Quality and 
Outcomes Framework.13 At present, SCD is not a 
part of this framework but could be considered 
for future inclusion in areas where there is  a 
high prevalence of SCD. 
 
Comparison with existing literature 
Previous studies have shown that SCD patients are 
dissatisfied with the quality of care that they receive 
from their GPs and at the primary care level.14 They 
also show that primary care is still a strong place to 
deal with chronic illness as it offers continuity, 
coordination and comprehensiveness15 and that 
assessing satisfaction is an important part of evalu- 
ating comprehensive quality of care.16 Patient 
satisfaction is regarded as the „ultimate outcome 
of the delivery of health care‟ and measuring and 
responding to satisfaction  can  be  important 
with regard to treatment compliance and over or 
underutilization of the health-care system.17 The 
strengths and limitations of the current focus 
group discussion also support the findings of 
similar studies that have identified focus group dis- 
cussions as a means for qualitative data collection. 
 
Strengths of the focus group discussion 
The focus group discussion provided a forum for a 
broad   range   of   participants  to   express  their 
concerns about the quality of care they received 
from their primary health-care providers, their 
opinions on what the role of primary care in mana- 
ging SCD should be and to discuss their perceived 
barriers to utilizing primary care services. This 
method has been demonstrated as an appropriate 
approach to investigate these issues.18 Further- 
more, focus groups can provide a space for an 
open dialogue tailored to the level of the partici- 
pants19 and allows the facilitator to clarify and 
push for more detailed responses to enrich the 
understanding of the issues.20 
The use of a focus group as a data collection tech- 
nique was particularly useful with SCD to ensure 
sensitivity to cultural variables, which is why they 
are now so often used in cross-cultural research 
and work particularly well with ethnic minorities. 
SCD is a disease that disproportionately impacts 
people of African and Caribbean origin; the focus 
group setting allowed us to reveal the frustration 
felt as an ethnic minority receiving health-care 
services for a predominantly race- related disease. 
Consequently, it makes them useful in studies 
examining why different sections of the population 
make differential use of health services.18,19 
The group dynamic also worked to facilitate the 
discussion of difficult or uncomfortable topics 
because the less reserved members of the group 
„broke the ice‟ for the more reserved participants.19 
Some researchers have also noted that group dis- 
cussions can generate more criticism of the health- 
care system than interviews.21 For example, Geis 
et al., in their study found that „there were more 
angry comments about the medical community‟19 
in the group discussions than in the individual 
interviews: „perhaps the synergism of the group 
“kept the anger going” and allowed each partici- 
pant to reinforce another‟s vented feelings of 
frustration and rage‟.22 
 
 
Limitations of the focus group discussion 
Our focus group discussion results could have 
benefited by having more participants and more 
sessions. Some researchers also argue that focus 
groups are limited in their ability to draw infer- 
ences for large groups or populations and their 
incapacity to test hypotheses in traditionally de- 
signed experiments.10 Others have also claimed 
that  focus  groups  can  lead  to  „tagging‟  which 
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means that participants agree for the sake of the 
group‟s momentum and that, with regard to 
more sensitive topics, interviews work better 
because the participant feels a greater level of 
anonymity than when part of a group discus- 
sion.10 Such points show that the use of focus 
groups may be subject to bias and need to be 
individually evaluated.20 Focus groups may not 
add value to every study but can work well 
when combined with other forms of qualitative 
and quantitative methods.10,23 
 
Implications for future research 
and clinical practice 
The focus group discussion on SCD provided an 
opportunity to not  only  voice  the  frustrations 
of participants but created a venue whereby sol- 
utions could be proposed. The discussion was 
candid, clear and offered perspectives about the 
participants‟ individual and collective needs that 
could not otherwise be obtained from health-care 
professionals. They offered constructive  advice 
on what they needed to feel satisfied as health-care 
consumers and gave a clear understanding about 
which areas we needed to focus the design of the 
primary care practice intervention. They also 
earmarked issues that need to be addressed in 
future research including auditing and improving 
communication between the different providers of 
health care and recommending quality improve- 
ment schemes in  areas  with  a  high  prevalence 
of SCD. 
Including patients in the development and 
implementation of a GP educational intervention 
may be an efficient and effective way to  help 
pilot a new programme aimed at meeting the 
needs of patients with SCD. Future focus groups 
may explore with what areas in particular the par- 
ticipants are not satisfied and how to incorporate 
into future programme planning some of the pre- 
liminary suggestions made at the first focus group. 
 
Conclusions 
 
This study has highlighted that SCD patients and 
carers have many criticisms about the current 
quality of services for managing patients with 
SCD in primary care. The study has helped 
provide key themes and useful suggestions that 
have been used to develop an educational inter- 
vention for general practices that will be used to 
improve SCD management in primary care. 
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Introduction 
 
Sickle cell disease (SCD) is the most common 
genetic disorder worldwide, predominantly 
affecting Black and ethnic minorities (BME) 
groups. Incidence and prevalence in England has 
increased significantly in recent decades, particu- 
larly in urban areas.1 The growth in affected popu- 
lations and the associated rising costs have 
attracted the attention of the healthcare commu- 
nity to SCD as an important public health issue. 
While just twenty years ago, infants born with 
SCD often did not survive childhood, a better 
understanding of the disease and improvements 
in medical technology and drug therapy have all 
contributed to patients with SCD surviving well 
into adulthood. However, positive health and life- 
expectancy outcomes are dependent on disease 
management and continuity of care throughout 
childhood, adolescence and adulthood.2 
SCD is a genetic blood disorder characterized by 
abnormal, crescent-moon shaped red blood cells. 
These so called „sickled‟ cells become lodged 
inside blood vessels, thereby obstructing blood 
flow and impeding efficient oxygen delivery to 
tissues throughout the body. Severe blockages 
cause episodes of acute pain, referred to as 
„crisis,‟ which may be triggered by a range of phys- 
ical and psychological stresses, including but not 
limited to infection, pregnancy, surgery, anxiety, 
or depression. If not treated promptly, crises can 
result in internal organ and tissue damage, particu- 
larly to the lungs, kidneys, liver and bones. The fre- 
quent recurrence of crisis can lead to chronic 
complications such as leg ulcers, blindness, and 
stroke. Acute chest syndrome, or chest crisis, is a 
common and particularly dangerous complication 
that is currently the leading cause of death among 
SCD patients.3 Ambulatory care strategies such as 
nutritional counselling, folic acid supplementation, 
pain medication protocols, vaccinations and anti- 
biotics for the prevention and treatment of infec- 
tion, are essential to SCD management.4 
In England, approximately three quarters of all 
SCD admissions to hospitals are by London resi- 
dents. SCD is also one of the most common 
reasons to be admitted to hospital and has one of 
the highest rate of multiple admissions for indi- 
vidual patients. The distribution of SCD in 
London also shows 80% of all admissions are in 
people living in the most deprived areas.5,6 
The London Borough of Brent is one high 
prevalence area for SCD.7,8 A pre-study focus 
group held at the Sickle Cell Society in Brent 
revealed low patient confidence in general prac- 
titioner (GP) knowledge of management strat- 
egies for SCD. The perception that GPs lack the 
skills to properly treat and control SCD may 
help to explain why SCD patients and their care- 
givers expressed a preference for attending the 
hospital emergency department (ED) during a 
crisis.9,10 
The rising cost of healthcare places the health 
system in England under increasing pressure to 
reduce such inappropriate hospital admis- 
sions.11,12  The   national   confidential   enquiry 
into patient outcome and death reports that a 
multidisciplinary and multi-agency approach is 
needed in the ongoing pain management of 
patients with sickle cell disease, and that this 
should largely be taking place outside of hospi- 
tals.6 The purpose of our analysis of emergency 
admissions of residents in Brent with SCD aims 
to provide a picture of admissions presenting at 
the ED and to identify areas for improving 
primary care intervention to improve the care of 
patients with SCD and reduce such admissions. 
 
Methods 
Data source 
SUS (Secondary Uses Service) data were provided 
by NHS Brent for all admissions through the 
Emergency Department using temporal, admis- 
sion and diagnostic parameters for the period 
January 2008 and July 2010 (Figure 1). Before 
analysis, data quality was checked by ensuring 
that episodes were commensurate with the admis- 
sion and discharge dates of spells. Whilst in hospi- 
tal patients may be under the care of a number of 
different consultants, each known as a finished 
consultant episode (FCE) and a spell is comprised 
of one or more continuous FCE. The FCE data was 
converted to spells by combining contiguous FCEs 
through cross-referencing a combination of post- 
code, age and registered practice. (Figure 2). 
 
 
Analysis and outcome measures 
Analysis was undertaken to compare admis- 
sions across the three diagnostic groups: sickle 
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cell anaemia with crisis, sickle cell anaemia 
without crisis and sickle cell trait. Descriptive 
analysis of patients admitted with a diagnosis 
of sickle cell anaemia with crisis (D570) was 
undertaken; the main outcome measure was 
length  of  stay  (average  and <2  days  versus 
≥2 days) by age group and registered GP prac- 
tice. Additional analysis of the frequency of 
individual patient admission was  completed 
by linking patient spells over the period of 
analysis. 
 
 
 
Results 
Hospital emergency admissions 
A total of 1090 episodes were identified, during 
the period January 2008 and July 2010, as emer- 
gency admissions, with either a primary or sec- 
ondary diagnosis of sickle cell anaemia with 
crisis (D570), sickle-cell anaemia without crisis 
(D571) or sickle cell trait (D573). The conversion 
of episode data to admissions spells resulted in 
632 unique spells, of which 470 spells included 
a diagnostic code for sickle cell anaemia with 
crisis (74.4 percent), 97 spells with sickle-cell 
anaemia without crisis (15.4 percent) and 65 
spells with sickle cell trait  (10.2  percent) 
(Figure 3). Only patients admitted with a 
primary or secondary diagnosis of sickle cell 
anaemia with crisis were included in subsequent 
analysis. 
 
 
 
 
 
J R Soc Med Sh Rep 2012;3:37. DOI 10.1258/shorts.2012.011129 3 
 
Conversion of full consultant episode (FCE) data to admission spell 
 Journal of the Royal Society of Medicine Short Reports 
 
 
 
 
 
 
 
 
 
Length of stay and age 
The most frequently admitted age group were 
patients between 21 – 25 years (85/470 spells). 
Thirty six percent of admissions resulted in a 
length of stay of less than two days (163/470 
spells) (Figure 4). 
 
 
Practice level analysis 
The practice level analysis included all practices 
in NHS Brent where registered patients were 
admitted over the 30 month study period. Prac- 
tices were split into two groups, those involved 
 
in a current Sickle Cell Disease educational pro- 
gramme (Group A) and those not involved 
(Group B). The educational programme started 
after the current study end date (July 2010). 
Group A comprised of 15 GP practices plus one 
GP access centre with approximately 20 full-time 
and 9 part-time GPs and an estimated 50 regis- 
tered patients with SCD. Group B is comprised 
of 55 practices with approximately 122 full-time 
and 61 part-time GPs, and an estimated 155 regis- 
tered patients with SCD. Two practices were ident- 
ified in Group A with the highest numbers of 
admissions A7 (43 spells) and A6 (29 spells), and 
have  some  of  the  highest  rates  of  emergency 
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Multiple admissions 
Seventy-seven patients accounted for multiple 
admissions  (327  spells)  and   143   patients 
were single admissions (143 spells). Multiple 
admissions accounted for 1530 bed days and 
74% of the total number of admissions (Table 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
admissions for Sickle Cell crisis. Within Group B, 
practice B3 had the highest number (47 spells) 
(Table 1). 
Discussion 
Main findings 
This analysis showed that 36% of SCD patient 
admissions resulted in a length of stay of less 
than two days, and 74% of total bed days are inpa- 
tients with multiple admissions. Patients with 
short length of stay and multiple admissions 
may be good candidates for primary care inter- 
ventions to reduce their risk of SCD-related com- 
plications and admissions. They may also benefit 
from more supportive management when they 
attend emergency departments, sickle  cell 
centres and outpatient clinics, as many aspects of 
the management of SCD patients are outside the 
remit  of  primary  care  teams.  The  study  also 
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Table 1 
 
SUS data were provided by NHS Brent for all emergency hospital admissions of patients living in the London 
borough of Brent with one of three ICD-10 codes for the period January 2008 until July 2010 
??????????????? ????? ?????????? ?????????????? ???????
with a high prevalence of SCD. GPs in such 
areas may be more open to the idea of an edu- 
cational intervention and more committed to its 
implementation. In addition, the data did not 
include those patients that attended the ED but 
were not admitted into hospital. Future studies 
may need to account for this subset of patients, 
as they may also have unmet needs and make 
high use of NHS resources. A planned GP edu- 
cational intervention may reduce the number of 
patients admitted for two days or less or with mul- 
tiple admissions, but we do not yet know that 
these patients could be managed in primary care. 
identified two GP practices, currently part of a GP 
education programme, that have patients who fre- 
quently seek emergency care for SCD-related pro- 
blems. The Group A Practices will be assessed to 
identify any benefits realized from an educational 
intervention designed to help further engage GPs 
in the care and management of their sickle cell 
patients. Such benefits may include  increasing 
the quality of care for patients with SCD and redu- 
cing the inappropriate use of the ED. 
Limitations of the analysis 
The analysis has certain limitations which could 
limit its transferability to areas outside of north- 
west London. The analysis is based on an area 
 
Comparison with Existing Literature 
This analysis is consistent with other studies that 
have identified potentially inappropriate use of 
acute inpatient care as a growing concern, and ear- 
marked the important benefits of GP involvement 
and primary care in limiting this utilization.13 – 15 
Inappropriate ED attendance distracts ED staff 
attention and resources from severe and acute 
cases that need urgent hospital care; adds to the 
waiting times in the ED, compromises  the 
quality of care a patient receives and increases 
cost.16 While severe crises require the resources 
of secondary care and tertiary care, the long-term 
management of uncomplicated sickle cell pain 
episodes may be more effectively and efficiently 
managed in a primary care setting.17 Interventions 
that move management of SCD, particularly 
uncomplicated sickle cell pain episodes from ter- 
tiary towards primary care, have been successfully 
implemented  elsewhere.15,18 
One study showed an average annual reduction 
of 804 bed days over a three year period, with the 
average daily cost of a specialist haematology 
inpatient bed estimated at  £356.12,19  Another 
study saw a 40% reduction in sickle cell ED attend- 
ance by introducing a local day hospital concept 
where SCD patients could bypass the ED and 
seek primary care plus within a hospital setting.18 
 
 
Implications for future research and 
clinical practice 
This analysis of Sickle Cell crisis admissions pro- 
vided an opportunity to not  only  characterize 
the  admissions  but  to  identify  practices  with 
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Table 2 
Comparison of patients admitted with sickle cell crisis by length of
 
Most patients admitted were between the ages of 21-25 years and 
admissions with a length of stay less than 2 days form a significant
proportion of all admissions. 
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higher levels of admissions especially related to 
multiple admissions or short length of stays. It 
also establishes a baseline to monitor progress 
and validate associations in relation to improving 
primary care support for patients and reducing 
ED admissions. The strategic engagement of a 
small number of GPs followed by further rollout 
across the London Borough of Brent, will ensure 
that the delivery of the GP education package is 
targeted where needed. This programme will 
make use of the joint work that Brent is carrying 
out with voluntary groups in its locality with the 
aim of improving patient experience and addres- 
sing health inequalities.20 The data analysis can 
also facilitate discussions between primary and 
secondary care as part of the multi-disciplinary, 
multi-professional project team, as well as encou- 
rage ongoing work to explore patient satisfaction 
through the enhanced care delivered by GPs and 
with the aim of improving the patient experience. 
 
Conclusions 
 
Patients with SCD make  relatively high use of 
urgent care services, including inpatient care. 
More appropriate management of these patients in 
the community may limit this demand and contrib- 
ute to better health outcomes for patients, as well as 
economic benefits for the local health economy. 
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Introduction 
Sickle cell disease (SCD) is an inherited blood disorder that 
dominantly affects people of African and Caribbean origin.1 
The disease is known for its painful episodes (also known as 
vaso-occlusive crisis or sickle crisis) which lead to a signiﬁcant 
 
overall cost of health-care utilization associated with SCD and 
hospital admissions in England. In contrast, several studies 
have been conducted in the USA where patients with SCD 
frequently attend emergency  departments  or  are  admitted 
as  inpatients  and  account  for  the  majority  of  health-care 
12 – 16 
number of hospital admissions and readmissions each year.2 – 4 expenses associated with the disease. Expenditure asso- 
A recent study in England showed a 58% increase in the overall 
SCD admission rate between 2001 and 2010 using Hospital 
Episodes Statistics (HES) data for England.5 
SCD is the fastest growing and most frequent inherited dis- 
order in England; "-'12 500 people are living with the condi- 
tion6 and 240 000 have SCD trait.7 SCD may be less common 
than other known chronic diseases8 – 10 but its growth and 
high impact on hospital admissions poses a potential cost 
burden for the National Health Service, in the addition to the 
impact it has on patients and their families, particularly in 
areas with a high prevalence such as London. 
With the exception of a recent National Institute of Clinical 
Excellence  (NICE)  report,11   there  is  little  data  about  the 
ciated with SCD can be used to raise awareness of the severity 
of this condition and to explore innovations in prevention or 
management of disease complications. Given this is the most 
common inherited disorder in the UK, data on costs associated 
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Background Sickle cell disease (SCD) is an inherited blood disorder which may result in a broad range of complications including recurring and
 
Methods Hospital Episodes Statistics data for all hospital episodes in England between 2010 and 2011 recording Sickle Cell Anaemia with Crisis
Groups tariffs. The impact of patients’ characteristics on SCD admissions costs and the likelihood of incurring extra bed days were also examined. 
Results In 2010 – 11, England had 6077 admissions associated with SCD with crisis as primary diagnosis. The total cost for these admissions for
and 19 years old are more likely to stay longer in hospital compared with others. 
Conclusion SCD represents a significant cost for commissioners and the NHS. Further work is required to assess how best to manage patients in
the community, which could potentially lead to a reduction in hospital admissions and length of stay, and their associated costs. 
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with hospital admissions can provide information about the 
impact of SCD on the National Health Service (NHS) and be 
of value to health economists, policy-makers and commis- 
sioners. The aim of this study was to estimate the costs for 
commissioners associated with  hospital admissions due to 
SCD in England. 
 
 
Methods 
HES provide data on all NHS hospital admissions, emergency 
department attendances and outpatient visits in England, in- 
cluding treatment performed in private hospitals but funded 
by the NHS. This study uses HES data on hospital admis- 
sions for the period from April 2010 to March 2011. HES 
data contain details on both the reason that patients are ad- 
mitted to hospital (known as the ‘primary diagnosis’) and any 
other conditions they have, which are coded using ICD-10.1 
This analysis uses patients with a primary diagnosis of ‘sickle 
cell anaemia with crisis’ (D57.0). 
As data regarding the cost and resource consumption for 
hospital admissions, including SCD admissions, were not 
available, we used the Healthcare Resource Groups (HRG) 
tariffs as a proxy to assess the cost for commissioners. HRGs 
form the basic currency for payment of NHS services by 
relying on an informed assumption that health-care costs are 
exclusively driven by diagnosis or procedure. The English 
HRG tariffs provide cost data for elective and non-elective 
hospital episodes and additional per diem cost for very long 
stays that exceed the so-called ‘trim point’, which marks the 
expected LOS for each HRG. Estimated costs are reported as 
a national schedule of reference costs and are also aggregated 
by hospital to provide the reference cost index.17,18 
Despite the tariffs, the real costs of SCD borne by the 
NHS appear not to be reﬂected; this is a ﬁrst attempt to 
assess the cost of admissions due to SCD adopting the com- 
missioners perspective. There are only three available HRG 
tariffs for SCD which are coded as: 
(1) PA47Z Sickle cell anaemia with crisis (for children admis- 
sions). 
(2) SA10D Sickle cell anaemia with complications (CC) (in- 
cluding SCD with crisis). 
(3) SA10F Sickle cell anaemia without complications (CC). 
Because there are no speciﬁc tariffs for each ICD-10 code, we 
made certain assumptions which are consistent with those of 
 
 
 
1The ICD-10 is a system of coding created by the World Health Organization 
that notes various medical records including diseases, symptoms, abnormal 
ﬁndings and external causes of injury. 
the NICE report.11 The tariffs were linked only to primary 
diagnosis: 
(a) ICD-10 ‘Sickle cell anaemia with Crisis’ (D57.0) is linked 
to HRG PA47Z ‘Sickle cell anaemia with crisis’ (age 
between 0 and 19 years); 
(b) ICD-10 ‘Sickle cell anaemia with Crisis’ (D57.0) is linked 
to HRG SA10D ‘Sickle cell anaemia with CC’ for adult 
admissions (age .20 years); 
(c) ICD-10 ‘Sickle cell anaemia without crisis and other 
sickle cell disorders (D57.2 – 8) might be linked with 
HRG code SA10F ‘Sickle cell anaemia without CC; 
All other admissions, in which the SCD with crisis appeared 
in any other of the diagnoses, but not as a primary diagnosis, 
were excluded from our analysis. This will underestimate the 
cost of admissions linked to SCD, but we have adopted a con- 
servative approach and not included extra costs that we are 
not certain have been appropriately coded for SCD. Both 
emergency and elective admissions have been analysed separ- 
ately, as they have different tariffs, and to show the impact of 
emergency admissions due to SCD. 
The length of stay (LOS) for each admission was considered 
in the analysis to assess the cost due to hospitalizations that 
exceed the trim point of the HRG tariff. The trim point identi- 
ﬁes the LOS covered by the tariff after which an extra daily 
payment is required for each speciﬁc HRG. The trim points 
vary according to the type of HRG and type of admission 
(emergency versus elective admission) and extra days carry an 
extra cost. For HRG PA47Z Sickle Cell Anaemia with Crisis, 
the trim point is 9 days for emergency admissions and 8 days 
for elective admissions; for HRG SA10D Sickle Cell Anaemia 
with CC, the trim point is 30 days both for emergency and 
elective admissions. Therefore, an LOS exceeding the  trim 
point will increase the cost by £234 for each extra day for chil- 
dren admissions and £204 for adult admissions. 
HRGs tariffs and extra LOS payments have been adjusted for 
the Market Forces Factor (MFF) to take into account of speciﬁc 
differences in the costs of providing services across providers.19 
For example, admissions in Central London would typically be 
more expensive as labour and building costs are higher and this 
has been reﬂected applying a speciﬁc MFF to each provider.19 
 
Analysis 
The cost of admissions associated with SCD was measured as 
follows: 
(1) The total number of episodes with a primary diagnosis 
containing ICD-10 code ‘Sickle cell anaemia with Crisis’ 
(D57.0.) data was taken from HES with a distinction 
between emergency and elective admissions. 
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(2) The total number of admissions for patients between 0 
and 19 years has been multiplied by the correspondent 
HRG tariff PA47Z ‘Sickle cell anaemia with crisis’, respect- 
ively in emergency and elective admission, adjusted for 
MFF for each provider. 
(3) The total number of admissions for patients 20 years or 
older (adults) has been multiplied by the correspondent 
HRG tariff SA10D ‘Sickle Cell Anaemia with CC’ respec- 
tively in emergency and elective admission, adjusted for 
MFF for each provider. 
(4) The total cost of admissions for SCD is the sum of the 
total cost of admissions in emergency and elective for 
children and adults. 
The cost of extra LOS for admissions associated with SCD 
has been assessed as follows: 
(1) For each episode presenting as primary diagnosis contain- 
ing the ICD-10 code ‘Sickle cell anaemia with Crisis’ 
(D57.0.) the extra LOS has been assessed as the differ- 
ence between the number of days spent in hospital (LOS) 
and the trim point from the HRG tariff. 
(2) The total number of days in hospital exceeding the trim 
point has been multiplied by the daily extra cost (£234 
per day for children admissions and £204 for adults), 
adjusted for the MFF for each provider. 
(3) The total cost of extra LOS is the sum of the extra cost of 
LOS of emergency and elective admissions for adults and 
children admissions. 
The analysis was carried out at a national level for England 
and the results are reported for England, London and 
English Primary Care Trusts (PCTs)2. 
A linear regression model was used to analyse the impact 
of age and gender on SCD cost. Here we have log trans- 
formed the costs and present our results as the percentage 
difference from the reference group. We analysed the data 
separately for London and the rest of the country to examine 
whether any associations differ between locations. We also 
used logistic regression to examine the association between 
age and gender on incurring extra bed days. 
 
Results 
In 2010 – 11, England had 6077 admissions associated with 
SCD with crisis as a primary diagnosis. The total cost for 
 
 
 
2An NHS Primary Care Trust (PCT) was a type of NHS Trust, part of the 
NHS in England. PCTs were largely administrative bodies, responsible for 
commissioning primary, community and secondary health services from 
providers. Primary Care Trusts were abolished on 31 March 2013, but existed 
while this study was conducted. 
these admissions was £18 798 255 of which £17 085 288 
(91%) was for emergency admissions (Table 1). Adult admis- 
sions represent 84.5% of all admissions, representing a cost 
of £14 370 931 for emergency admissions. Children admis- 
sions represent 15.5% of total admissions, and the cost of 
emergency admissions was £2714 357. 
In total, the LOS exceeded the trim point by 1144 days, for 
an extra cost of £294 697 (93.1% for emergency admissions) 
(Table 1). For emergency admissions, the extra LOS is 438 
days for children and 624 days for adults, for an extra total 
cost of £274 104. Because the tariff for children has a shorter 
trim point compared with adults (9 days instead of 30 days) 
and an extra day costs more, long admissions for children re- 
present a higher cost in terms of LOS. 
Within England London had the highest number of admis- 
sions associated with SCD, with 4363 admissions for SCD 
crisis as primary diagnosis at a total cost of £14 223 139 of 
which £13 984 884 were for emergency admissions (89.9%) 
(Table 1). In line  with the national data, adults represent 
87.1% of total admissions and children account for 12.9%. 
London accounts for 75.6% of all of England’s costs for 
admissions associated with SCD and 80.8% of all of 
England’s days beyond the trim point (extra days). In Table 2 
we provide a summary for all PCTs in England, with the 
cost of admissions for SCD and the rate of admissions every 
100 000 (Table 2). 
There is a high variability in the number of admissions 
across PCTs in England. City and Hackney is the PCT with 
the highest number and the highest costs in 2010 – 11, fol- 
lowed by Haringey and Brent (Table 2). In these PCTs, the 
rates of SCD admissions are the highest in England, 347, 153 
and 102 every 100 000, respectively. City and Hackney also 
had the highest costs associated with LOS beyond the trim 
point, followed by Redbridge and Westminster (Table 2). 
Outside London, Luton is the PCT with the highest rate of 
SCD admissions (39.41 every 100 000), followed by Notting- 
ham (32.47), Manchester (20.01) and South Birmingham 
(20.10) (Table 2). 
The regression models performed to check whether age 
and gender are signiﬁcantly associated with SCD costs show 
that admissions in adults cost more than in children (Table 3). 
The total cost increases with age: admissions in age ,9 and 
age 10 – 19 cost £1740 and £1686 (P , 0.001), less, respect- 
ively, compared with the age 20 – 29; admissions costs £65 
more in the group age 30 – 49 compared with the age 20 – 29. 
There is no statistically signiﬁcant difference in cost for 
patients over 50 years. Admissions were more costly for males 
than females, but the differences are not statistically signiﬁ- 
cant. The results for London are similar to those for the rest 
of England. 
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Table 1 Costs for admissions and extra LOS associated with sickle cell anaemia with crisis (ICD-10 D57.0) in England and London, 2010 – 11 
 
Admissions (England) Emergency Elective Total admissions 
 
D57.0 primary diagnosis admissions (total) 
 
5514 
 
563 
 
6077 
D57.0 primary diagnosis admissions (paediatrics) 1462 154 1616 
D57.0 primary diagnosis admissions (adults) 4052 409 4461 
HRG tariff PA47Z (to be adjusted by MFF) £1534 £1210  
HRG tariff SA10D (to be adjusted by MFF) £2959 £2950  
Total cost for admissions £17 085 288 £1 712 966 £18 798 255 
Long stay trim point (days) for paediatric 9 8  
Long stay trim point (days) for adults 30 30  
Total days exceeding the trim point (paediatrics) 438 7 445 
Total days exceeding the trim point (adults) 624 75 699 
Per day long stay payment (for days exceeding trim point) paediatrics (£) £234 £234  
Per day long stay payment (for days exceeding trim point) adults (£) £204 £204  
Total cost for extra LOS £274 104 £20 592 £294 697 
Admissions (London) Emergency Elective Total admissions 
D57.0 primary diagnosis admissions (total) 3911 452 4363 
D57.0 primary diagnosis admissions (paediatrics) 877 107 984 
D57.0 primary diagnosis admissions (adults) 3034 345 3379 
Total cost for admission in London £12 788 339 £1 434 799 £14 223 139 
Long stay trim point (days) for paediatric 9 8  
Long stay trim point (days) for adults 30 30  
Total days exceeding the trim point (paediatrics) 246 5 251 
Total days exceeding the trim point (adults) 586 75 661 
Total extra cost for extra LOS in London £218 153 £20 101 £238 254 
 
Source: our elaboration using HES data and HRG tariffs 2010 – 11.    
 
 
The logistic regression to examine the association between 
age and gender on incurring extra bed days shows that 
patients 10 – 19 years old are much more likely to incur an 
extra bed days (an odds ratio of 8.3 with P , 0.001) com- 
pared with 20 – 29 years old. The results for other age groups 
and for gender do not show statistically signiﬁcant differences 
(Table 4). 
 
 
Discussions 
What is already known on this topic 
Studies that assess the cost of SCD are either primarily refer- 
ring to children, not appropriately updated or have been con- 
ducted in the USA.12 – 15 Studies conducted in the USA show 
that patients with SCD who are frequently admitted as an 
emergency account for the majority of health-care expenses 
associated with the disease.16 
NICE has assessed the costs (and potential savings) attrib- 
uted to managing an adult SCD acute painful episode com- 
pared with their guidelines.11  The costs (and savings) may 
vary signiﬁcantly depending on current practice and variation 
in local prevalence of SCD. 
The same document provides an estimate for the cost of 
admission for ‘sickle cell anaemia with crisis’ in children and 
adults according to the National Schedule of Reference costs3 
in 2010/11. According to the report, the approximate total 
cost to the NHS of these admissions and some day-case activ- 
ity was "-'£16.2  million, not including elective admissions 
(which is similar to our estmated costs £17 085 288). More- 
over, the costs were not based on HES data and it is not clear 
if the period 2010 – 11 was starting in January or in April, with 
the ﬁnancial year. 
Better clinical managment of SCD based on the NICE 
guidelines (health-care prefessionals training, pain manage- 
ment, administration of analgesia and patients monitoring) 
may positively impact on LOS.11 However, the savings cannot 
be  accurately  estimated  because  the  variation  in  current 
 
 
 
3The national schedules of reference costs show the national average unit cost 
for each service for which costs were collected in 2010 – 11 reference costs. 
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Table 2 Costs for admissions and extra LOS associated with sickle cell anaemia with crisis (ICD-10 D57.0) in England PCTs 2010 – 11 
 
SHA Code PCT SCD adm./ 
100 000 pop.a 
Cost non-elective 
(A) (£) 
Cost elective 
(B) (£) 
Cost admiss. 
(A þ B) (£) 
Cost extra 
LOS (c) (£) 
Total cost 
(A þ B þ C) (£) 
 
Q.30 North East 
 
5D7 
 
Newcastle 
 
6.89 
 
36 195.98 
 
1250.92 
 
37 446.90  
 
37 446.90 
Q.30 North East 5KM Middlesbrough 6.11 18 439.87 1241.50 19 681.37 240.09 19 921.46 
Q.30 North East 5E1 Stockton-on-Tees 3.11 18 151.57  18 151.57  18 151.57 
Q.30 North East 5KF Gateshead 1.54 7693.03  7693.03 241.91 7934.94 
Q.30 North East 5D8 North Tyneside 0.48 3059.07  3059.07  3059.07 
Q.30 North East Total  1.45 83 539.52 2492.42 86 031.94 482.00 86 513.94 
Q.31 North West 5NT Manchester 20.01 264 153.72 4 787.14 268 940.86 240.89 269 181.75 
Q.31 North West TAP Blackburn with Darwen 5.93 27 478.61  27 478.61  27 478.61 
Q.31 North West 5NQ Heywood, Middleton R 5.88 31 440.38  31 440.38 738.27 32 178.65 
Q.31 North West 5F5 Salford 4.68 17 895.42  17 895.42  17 895.42 
Q.31 North West 5NL Liverpool 3.94 28 514.06 2515.16 31 029.22  31 029.22 
Q.31 North West 5JX Bury 2.74 10 981.34 3138.11 14 119.45  14 119.45 
Q.31 North West 5NG Central Lancashire 1.99 16 008.56  16 008.56  16 008.56 
Q.31 North West 5HQ Bolton 1.88 11 156.80  11 156.80 992.66 12 149.45 
Q.31 North West 5J5 Oldham 1.79 6338.40 3111.88 9450.28  9450.28 
Q.31 North West 5F7 Stockport 1.4 6502.53  6502.53  6502.53 
Q.31 North West 5J2 Warrington 1.01 6184.42  6184.42  6184.42 
Q.31 North West 5NR Trafford 0.93 6620.55  6620.55  6620.55 
Q.31 North West 5HG Ashton, Leigh and Wigan 0.66 3226.53  3226.53  3226.53 
Q.31 North West 5NJ Sefton 0.37 3087.41  3087.41  3087.41 
Q.31 North West 5NK Wirral 0.33 1594.32  1594.32 1945.61 3539.93 
Q.31 North West 5NF North Lancashire T. 0.3 3028.49  3028.49  3028.49 
Q.31 North West 5NH East Lancashire Teaching 0.27 3053.18  3053.18  3053.18 
Q.31 North West Total  2.74 447 264.72 13 552.29 460 817.01 3917.43 464 734.43 
Q.32 Yorkshire and H. 5N1 Leeds 7.3 153 191.20 3119.09 156 310.29 1233.30 157 543.59 
Q.32 Yorkshire and H. 5NY Bradford & Airedale 6.92 89 905.22 5590.79 95 496.01  95 496.01 
Q.32 Yorkshire and H. 5N2 Kirklees 4.94 61 715.86  61 715.86  61 715.86 
Q.32 Yorkshire and H. 5N4 Sheffield 4.62 56 370.18 19 511.22 75 881.40  75 881.40 
Q.32 Yorkshire and H. 5NX Hull Teaching 4.08 30 279.89  3090.16 3090.16 33 370.05 
Q.32 Yorkshire and H. 5N5 Doncaster 2.02 18 349.76  18 349.76  18 349.76 
Q.32 Yorkshire and H. 5J6 Calderdale 1.46 4799.20  4799.20  4799.20 
Q.32 Yorkshire and H. 5H8 Rotherham 1.22 7670.81  7670.81  7670.81 
Q.32 Yorkshire and H. 5N3 Wakefield District 0.88 3208.70 1265.49 4474.19  4474.19 
Q.32 Yorkshire and H. 5JE Barnsley 0.84 3043.71 3043.71 6087.42  6087.42 
Q.32 Yorkshire and H. TAN North East Lincolnshire 0.61 1565.62  1565.62  1565.62 
Q.32 Yorkshire and H. 5NV North Yorkshire and York 0.38 9118.57  9118.57  9118.57 
Q.32 Yorkshire and H Total  3.25 439 218.72 32 530.30 444 559.29 4323.46 476 072.48 
Q.33 East Midlands 5EM Nottingham City 32.47 283 754.21 8092.28 291 846.49  291 846.49 
Q.33 East Midlands 5N7 Derby City 5.64 28 385.27 3077.73 31 463.00  31 463.00 
Q.33 East Midlands 5PA Leicestershire County R 3.16 38 297.65  38 297.65 1965.77 40 263.42 
Q.33 East Midlands 5PC Leicester City 2.71 221 819.63 3107.22 224 926.85 8108.81 233 035.66 
Q.33 East Midlands 5N9 Lincolnshire Teaching 0.69 10 679.28  10 679.28 237.54 10 916.83 
Q.33 East Midlands 5N6 Derbyshire County 0.57 7705.67 1255.50 8961.17  8961.17 
Q. 33 East Midlands 5N8 Nottinghamshire C.T 0.15 3070.27  3070.27  3070.27 
Q. 33 East Midlands Total  5.25 593 711.98 15 532.73 609 244.71 10 312.12 619 556.84 
Q.34 West Midlands 5M1 South Birmingham 20.1 190 790.53 4345.80 195 136.34 491.42 195 627.76 
Q.34 West Midlands 5PG Birmingham East and N. 10.73 104 037.47 1257.54 105 295.01 243.19 105 538.21 
Q.34 West Midlands 5PF Sandwell 10.39 68 804.28 1270.55 70 074.82 491.42 70 566.24 
        Continued 
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Table 2 Continued  
SHA Code PCT SCD adm./ Cost non-elective Cost elective Cost admiss. Cost extra Total cost 
   100 000 pop.a (A) (£) (B) (£) (A þ B) (£) LOS (c) (£) (A þ B þ C) (£) 
 
Q.34 West Midlands 
 
5MX 
 
Heart of Birmingham T 
 
5.4 
 
262 470.11 
 
9225.77 
 
271 695.88 
 
3931.35 
 
275 627.23 
Q.34 West Midlands 5M3 Walsall Teaching 4.76 33 876.12  33 876.12  33 876.12 
Q.34 West Midlands 5PE Dudley PCT 4.29 22 268.98 1270.55 23 539.52  23 539.52 
Q.34 West Midlands 5MK Telford and Wrekin 4.29 13 759.16 3020.50 16 779.66  16 779.66 
Q.34 West Midlands 5MD Coventry Teaching 3.57 37 170.42 1270.55 38 440.97  38 440.97 
Q.34 West Midlands 5PJ Stoke on Trent 3.44 25 741.22  25 741.22  25 741.22 
Q.34 West Midlands 5PL Worcestershire 1.45 14 133.78 1257.54 15 391.32  15 391.32 
Q.34 West Midlands 5QW Solihull 1.42 7819.73  7819.73  7819.73 
Q.34 West Midlands 5MV Wolverhampton City 1.24 9316.41  9316.41  9316.41 
Q.34 West Midlands 5PH North Staffordshire 0.97 3133.15  3133.15  3133.15 
Q.34 West Midlands 5M2 Shropshire County 0.69 6041.01  6041.01  6041.01 
Q.34 West Midlands 5PK South Staffordshire 0.5 6271.39  6271.39  6271.39 
Q.34 West Midlands Total  6.14 805 633.76 22 918.80 828 552.55 5157.38 833 709.94 
Q.35 East of England 5GC Luton 39.41 203 152.33 3332.28 206 484.61  206 484.61 
Q.35 East of England 5QV Hertfordshire 8.92 263 068.06 55 312.47 318 380.53 1211.88 319 592.41 
Q.35 East of England 5PY South West Essex 3.56 41 255.26 8715.70 49 970.96  49 970.96 
Q.35 East of England 5PV West Essex 3.32 26 353.86  26 353.86  26 353.86 
Q.35 East of England 5P2 Bedfordshire 3.29 31 726.42 10 217.96 41 944.38 1317.60 43 261.98 
Q.35 East of England 5PT Suffolk 2.72 30 894.60 1260.39 32 154.99 1306.27 33 461.26 
Q.35 East of England 5PX Mid Essex 2.42 25 239.97  25 239.97  25 239.97 
Q.35 East of England 5PP Cambridgeshire 1.98 32 019.07 3908.06 35 927.13  35 927.13 
Q.35 East of England 5PR Great Yarmouth and W 0.44  1218.32 1218.32  1218.32 
Q.35 East of England 5PW North East Essex 0.3 3082.23  3082.23  3082.23 
Q.35 East of England 5P1 South East Essex 0.3 9672.14  9672.14  9672.14 
Q.35 East of England 5PQ Norfolk 0.26 4764.59  4764.59  4764.59 
Q.35 East of England Total  4.42 671 228.53 83 965.18 755 193.71 3835.75 759 029.46 
Q.36 London 5C3 City and Hackney Teach. 346.67 2 263 929.38 534 160.71 2 798 090.08 63 582.41 2 861 672.49 
Q.36 London 5C9 Haringey Teaching PCT 153.38 1 203 689.40 42 598.08 1 246 287.48 5895.77 1 252 183.26 
Q.36 London 5K5 Brent Teaching 102.71 816 513.50 12 279.81 828 793.31 14 464.82 843 258.13 
Q.36 London 5LF Lewisham 92.44 667 443.96 57 368.46 724 812.42 13 694.84 738 507.26 
Q.36 London 5LD Lambeth 78.54 701 592.68 67 198.84 768 791.52 10 316.11 779 107.63 
Q.36 London 5K9 Croydon 77.91 745 439.97 19 714.91 765 154.88 9894.25 775 049.14 
Q.36 London 5A8 Greenwich Teaching 70.42 419 118.03 26 249.18 445 367.22  445 367.22 
Q.36 London 5C2 Barking and Dagenham 68.56 364 400.50 64 994.92 429 395.42 8953.02 438 348.44 
Q.36 London 5C1 Enfield 68.49 592 207.17 29 422.94 621 630.11  621 630.11 
Q.36 London 5NA Redbridge 67.95 602 773.58 32 508.31 635 281.89 23 964.23 659 246.12 
Q.36 London 5C5 Newham 62.55 498 489.48 51 103.68 549 593.16 10 189.18 559 782.34 
Q.36 London 5LE Southwark 60.62 461 880.46 61 307.34 523 187.80  523 187.80 
Q.36 London 5NC Waltham Forest 51.25 315 550.09 97 761.35 413 311.44 5391.55 418 702.99 
Q.36 London 5H1 Hammersmith and Fulh. 48.24 238 238.83  238 238.83 4193.96 242 432.79 
Q.36 London 5LG Wandsworth 35.78 309 506.58 35 640.86 345 147.45 17 807.38 362 954.83 
Q.36 London 5HX Ealing 34.82 303 962.39 20 635.42 324 597.81 2557.92 327 155.73 
Q.36 London 5LA Kensington and Chelsea 34.38 193 403.20 34 192.20 227 595.40 532.01 228 127.41 
Q.36 London 5K6 Harrow 33.19 196 649.77 3700.03 200 349.81  200 349.81 
Q.36 London 5LC Westminster 32.25 263 911.91 23 190.68 287 102.59 19 475.12 306 577.70 
Q.36 London 5K8 Islington 31.8 165 137.17 50 453.93 215 591.10 14 279.81 229 870.91 
Q.36 London TAK Bexley Care Trust 30.65 163 582.69 14 821.25 178 403.94 570.66 178 974.61 
Q.36 London 5M7 Sutton and Merton 28.74 252 620.20 57 982.86 310 603.05 2548.21 313 151.26 
        Continued 
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Table 2 Continued  
SHA Code PCT SCD adm./ Cost non-elective Cost elective Cost admiss. Cost extra Total cost 
   100 000 pop.a (A) (£) (B) (£) (A þ B) (£) LOS (c) (£) (A þ B þ C) (£) 
 
Q.36 London 
 
5A9 
 
Barnet 
 
23.06 
 
230 222.55 
 
12 512.72 
 
242 735.27 
 
2977.07 
 
245 712.35 
Q.36 London 5K7 Camden 18.2 132 341.63 28 954.52 161 296.15 6676.22 167 972.36 
Q.36 London 5A7 Bromley 17 112 356.40 15 740.26 128 096.66 290.3 128 386.95 
Q.36 London 5A5 Kingston 14.89 65 249.58 7280.35 72 529.93  72 529.93 
Q.36 London 5AT Hillingdon 14.02 89 094.73  89 094.73  89 094.73 
Q.36 London 5A4 Havering 10.94 92 387.46 1437.84 93 825.30  93 825.30 
Q.36 London 5C4 Tower Hamlets 8.9 69 996.30 7816.12 77 812.42  77 812.42 
Q.36 London 5HY Hounslow 5.06 36 578.71 3670.89 40 249.60  40 249.60 
Q.36 London 5M6 Richmond and Twicken. 0.53 1918.17  1918.17  1918.17 
Q.36 London Total  55.28 12 570 186 1 414 698 13 984 884 238 254 1 422 313 
Q.37 South East Coast 5LQ Brighton and Hove City 11.73 91 234.47 6851.82 98 086.29  98 086.29 
Q.37 South East Coast 5L3 Medway 9.93 62 161.74 1333.59 63 495.33  63 495.33 
Q.37 South East Coast 5P9 West Kent 5.69 71 170.18 4035.28 75 205.46 580.59 75 786.05 
Q.37 South East Coast 5P6 West Sussex 2.36 47 060.35 7816.12 54 876.47 251.55 55 128.02 
Q.37 South East Coast 5P5 Surrey 2.35 88 227.56  8227.56  88 227.56 
Q.37 South East Coast 5P8 Hastings and Rother 1.71 7808.30  7808.30  7808.30 
Q.37 South East Coast 5P7 East Sussex Downs W. 0.6 3214.69  3214.69  3214.69 
Q.37 South East Coast 5QA Eastern and Coastal Kent 0.54 50 565.20 6932.11 57 497.31  57 497.31 
Q.37 South East Coa. Total  3.81 421 442.49 26 968.92 368 411.41 832.14 449 243.55 
Q.38 South Central 5L1 Southampton City 9.71 66 712.88 6326.39 73 039.27  73 039.27 
Q.38 South Central 5QF Berkshire West 6.85 94 427.94  94 427.94 1082.14 95 510.08 
Q.38 South Central 5QE Oxfordshire 4.73 67 009.44 8047.49 75 056.93  75 056.93 
Q.38 South Central 5QD Buckinghamshire 3.72 49 435.48 7051.63 56 487.11  56 487.11 
Q.38 South Central 5FE Portsmouth City Teaching 3.27 20 859.09  20 859.09  20 859.09 
Q.38 South Central 5QG Berkshire East 1.98 19 666.46 3196.18 22 862.64  22 862.64 
Q.38 South Central 5QT Isle of Wight NHS 0.7 3075.99  3075.99  3075.99 
Q.38 South Central 5QC Hampshire 0.47 14 625.91  14 625.91 2800.32 17 426.23 
Q.38 South Central 5CQ Milton Keynes 0.41 3279.96  3279.96  3279.96 
Q.38 South Central Total  3.11 339 093.15 24 621.69 363 714.84 3882.46 367 597.30 
Q.39 South West 5QJ Bristol 17.02 180 505.09 33 917.74 214 422.84 8768.54 223 191.38 
Q.39 South West 5FL Bath and North East Som. 7.36 36 330.77 9567.15 45 897.92  45 897.92 
Q.39 South West 5F1 Plymouth Teaching 4.44 20 585.88 2608.15 23 194.02 4306.24 27 500.27 
Q.39 South West 5QH Gloucestershire 2.85 38 148.60 3189.05 41 337.65 10 624.99 51 962.64 
Q.39 South West 5A3 South Gloucestershire 2.34 15 945.25 1304.07 17 249.32  17 249.32 
Q.39 South West 5QQ Devon 0.53 12 038.89  12 038.89  12 038.89 
Q.39 South West 5K3 Swindon 0.48 1594.40  1594.40  1594.40 
Q.39 South West 5M8 North Somerset 0.47 3189.05  3189.05  3189.05 
Q.39 South West 5QK Wiltshire 0.22 1589.00  1589.00  1589.00 
Q.39 South West Total  2.52 309 926.93 50 586.16 360 513.09 23 699.77 384 212.87 
aThe rate is given by the number of admissions in emergency and elective over the number of population in the PCT for 2011. 
(2) Source of population at PCT level: NHS 2011. https://www.gov.uk/government/publications/exposition-book-2011 – 2012. 
 
 
practice and lack of baseline data in several areas make it difﬁ- 
cult to assess the cost impact of implementing the guideline.11 
One  study  assessing  the  views  of  patients  with  SCD 
showed that patients and carers often bypass their general 
practitioner for acute problems and attend directly at accident 
and emergency (A&E) suggesting better primary care interven- 
tions could reduce emergency admissions.20,21 One study looked 
at 145 general practices in the East Midlands and showed that as 
the proportion of patients able to consult their primary care 
physician increased, emergency admission rates decreased.22 
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Table 3 Regression of total costs of admission on age and sex at national level and London level only 
 
 National    London 
 
Geometric mean 
 
Comparison (as % of 
 
P value  
 
Geometric 
 
Comparison (as % of 
 
P value  
cost (£) reference group costs)   mean cost (£) reference group costs)   
  Age         
 ,1 1758 50.26 ,0.001  1828 50.27 ,0.001  
 1 – 9 1732 49.53 ,0.001  1804 49.61 ,0.001  
 10 – 19 1812 51.83 ,0.001  1881 51.71 ,0.001  
 20 – 29 3499 Ref. Ref.  3636 Ref. Ref.  
 30 – 39 3564 101.87 ,0.001  3640 100.11 ,0.001  
 40 – 49 3565 101.94 ,0.001  3638 100.03 ,0.001  
 50þ 3535 101.10 0.194  3622 99.55 0.605  
 Sex         
Men 3021 Ref. Ref.  3182 Ref. Ref. 
Women 2854 99.59 0.195  3052 100.36 0.278 
 
Source: our elaboration. 
 
 
Table 4 Logistic regression of the association between age and gender on incurring extra bed days at national level and London level 
 
 
 
 
 
 
 
 
1 – 9 1.31 1.26 0.576 0.82 0.54 0.316 
10 – 19 8.08 8.38 ,0.001 8.1 5.65 ,0.001 
20 – 29 1.04 Ref. Ref. 1.47 Ref. Ref. 
30 – 39 1.11 1.07 0.834 1.26 0.84 0.616 
40 – 49 0.93 0.90 0.8 0.85 0.56 0.24 
50þ 1.27 1.22 0.745 1.7 1.09 0.895 
Sex       
Men 1.98 Ref. Ref. 1.78 Ref. Ref. 
Women 2.47 1.00 0.985 2.73 1.35 0.162 
 
Source: our elaboration. 
 
 
A study conducted in London has shown that overnight 
admissions decreased as a result of betterpain management, 
use of analgesia, transfusions, community support and 
improved education at home.23 – 26 Moving treatments from 
hospital to community or ambulatory setting could contribute 
to avoid patients being admitted to hospital to be treated, with 
savings in terms of resources. Elective transfusions for 
example are an essential treatment in SCD and can now be 
provided in ambulatory setting instead of admitting the 
patients in hospital to receive the treatment.23 – 25  There is 
evidence that admissions are increasing as an effect of read- 
missions of patients with SCD and that effective discharge 
planning with a link between hospitals, primary and commu- 
nity care might help prevent readmissions.22,27 
 
 
What this study adds 
This study is the ﬁrst in England to use HES data to assess 
the cost of admissions for SCD, applying the HRGs tariffs to 
those admissions presenting SCD as primary diagnosis only. 
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We adopted a conservative approach to ensure the costs are 
linked to SCD with crisis to provide an accurate estimate of 
the costs for hospitalization linked to SCD. 
According to a report published by the Audit Commission, 
clinical coding errors continue to affect Healthcare Resource 
Conclusions 
According to our study, in 2010 – 11, the cost of emergency 
admissions in England due to SCD was £17.1 million which 
compares  with  the  £16.2  million  estimated  in  the  NICE 
11 
Coding (HRG) assignment in England.20  Nevertheless, this report. In this study we did not take into account all of the 
study relies on good quality coding (in 2009 primary diagno- 
ses codes were validated as accurate the 87% of the time).20 
 
Limitations of this study 
The analysis underestimates the real costs of admissions asso- 
ciated with SCD, as it takes into account only the cases of SCD 
with crisis as primary diagnosis, but there are many episodes in 
which SCD appears as a secondary, tertiary or further under- 
lying diagnosis. Even if the main cause of admission is not an 
SCD crisis, the disease’s underlying characteristics may have 
predisposed the patient to be admitted to hospital or increased 
the risk of comorbidity or complications. 
In our study, the admissions having SCD with crisis as a 
primary diagnosis represent 92.5% of all the admissions for 
SCD with crisis (including also secondary, third, fourth and 
ﬁfth diagnosis) and so almost 7.5% of admissions are not 
included here. Assuming we can apply the same HRG tariffs 
for the excluded admissions (those after the primary diagno- 
sis), the total cost for admissions linked to SCD with crisis 
will increase to £20 376 822, a difference of £1 578 567. 
The other 13 589 admissions are linked to SCD without 
crisis (ICD-10 codes D57.1 – 8) as primary or further diagno- 
sis, but the cost for these admissions has not been taken into 
account in this study. It is very difﬁcult to estimate the cost of 
these admissions without knowing the HRG tariff applied 
when the patient is discharged. However, the primary diagno- 
sis of these admissions is mainly for SCD without complica- 
tions, anaemia, respiratory infections and asthma. Considered 
that 25% of these admissions are in emergency, the cost of 
admissions for SCD is even higher. Further research can help 
gain a more detailed estimate of the costs borne by the NHS 
and also for unaccounted expenditures such as those spent by 
patients and their families to treat and manage this condition 
at home or for other sectors, providing a closer estimate of 
the entire societal cost. 
Finally, we used the episode as unit of analysis instead of 
spells or continuous inpatient stay as we excluded from the 
analysis patients who have been transferred. We are aware that 
this might have an impact on excess payments for extra LOS 
and might underestimate or overestimate the cost for some 
providers. However, it would have been difﬁcult to attribute 
in a reliable way the cost of extra LOS to each Trust. We there- 
fore decided to adopt a conservative approach. 
day-case activities or admissions that have SCD with crisis as 
a secondary, tertiary or further diagnosis which explains the 
cost discrepancy between our study and the NICE report. 
London accounts for 75.7% of all of England’s costs for 
admissions associated with SCD. 
The results show that emergency admissions represent 
90.9% of the entire admissions cost. Shifting the balance of 
care from A&E to primary care is possible28 and better clinic- 
al management of patients with SCD may positively impact 
emergency admissions. 
Management of SCD needs to take a more modern ap- 
proach.29 Proper management is essential in reducing crises 
and episodes that require hospital admissions. In order to 
provide effective and safe care, primary care physicians, com- 
munity nurse specialists and community paediatricians should 
have a better awareness of warning symptoms and signs 
which require assessment in hospital.
30
 
This study shows that patients 10 – 19 years old are much 
more likely to incur extra bed days and that the cost of an 
extra day for them is higher than for adults. Therefore, a 
better management of SCD in children to prevent hospital 
admissions or at least reduce the LOS could be cost saving. 
A recent study emphasizes the need for ‘a preventative and 
comprehensive model of care in addition to care manage- 
ment’.
31 Adults with SCD need coordinated care led by a 
primary care physician in coordination with a provider experi- 
enced in SCD. Patients and parents of children affected by 
SCD should also have a good awareness of symptoms and 
when and how to seek help.32 
Recently, SCD has achieved specialized commissioning 
status but the current speciﬁcations focus mainly on provision 
of acute care.33 Links between primary care and community 
care could be improved through proper discharge planning, 
multi-disciplinary teams and better communication with 
primary care.34 The ‘community hub model’ was ﬁrst intro- 
duced by the Sickle Cell Society’s Comprehensive Care 
Project and in contrast shows that the patients and patient 
groups prioritize social determinants of health. The model 
advocates a patient-centred approach where an integrated 
sickle care pathway encompassing all public health-care needs 
are addressed speciﬁcally mental, social (employment and 
schooling), acute and primary. This in turn may increase user 
satisfaction and could assist in reducing unnecessary admis- 
sions to hospitals.34 – 36 
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Further research which better understands hospital utiliza- 
tion of patients with SCD could also explain allocation of 
health-care costs due to SCD. HRG tariffs could also be revis- 
ited to link disease severity with scalable HRGs which could 
give a clearer picture as to whom the majority of the SCD 
patients consuming resources are. 
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